










The handle http://hdl.handle.net/1887/26945 holds various files of this Leiden University 
dissertation 
 
Author: Snelder, Nelleke 
Title: Towards predictive cardiovascular safety : a systems pharmacology approach 
Issue Date: 2014-06-25 
Towards predictive cardiovascular safety - 
a systems pharmacology approach
Nelleke Snelder
The publication of this thesis was financially supported by LAP&P Consultants BV, Leiden, 
The Netherlands
Lay-out and printing by Ridderprint BV, Ridderkerk
© 2014. Copyright by N. Snelder
Towards predictive cardiovascular safety - 
a systems pharmacology approach
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties








Prof. Dr. M. Danhof 




Prof. Dr. A.H.J. Danser, Erasmus Universiteit Rotterdam
Prof. Dr. P.H. van der Graaf
Prof. Dr. J. Burggraaf
Prof. Dr. T. Hankemeier
Prof. Dr. B. van de Water
… The End is in the Beginning, and now we go on …
    A. van der Veen according to S. Becket

Table of contents
Section I General introduction
1. A systems pharmacology approach for predicting drug-induced 
changes in hemodynamic variables
11
2. Scope and outline of the investigations 31
Section II Development of a systems pharmacology model to 
characterize drug effects on the CVS
3. PKPD modeling of the interrelationship between mean arterial 
blood pressure, cardiac output and total peripheral resistance 
in conscious rats
39
4. Drug effects on the cardiovascular system in conscious rats – 
separating cardiac output into heart rate and stroke volume 
using PKPD modeling 
69
Section III Application of the developed systems pharmacology model to 
S1P receptor agonists
5. Translational pharmacokinetic modeling of fingolimod as a 
paradigm compound subject to sphingosine kinase-mediated 
phosphorylation
105
6. Characterization and prediction of cardiovascular effects of 
fingolimod and siponimod using a systems pharmacology 
modeling approach
131
Section IV Summary, conclusions & perspectives
7. A systems pharmacology approach to the prediction of 
cardiovascular side effects in man - Summary, conclusions & 
perspectives
169




























C h a p t e r 1
A systems pharmacology approach for 





Persistent elevation of blood pressure (BP) is a risk factor for heart failure and is a leading 
cause of cardiovascular disease (Graham et al., 2007). Clinically, hypertension is defined 
as BP higher than 140/90 mmHg, (i.e. a systolic pressure higher than 140 mmHg and a 
diastolic pressure higher than 90 mmHg), and affects 44.2 and 27.6 % of the European and 
American population in the age range of 35 to 64 years, respectively (Wolf-maier et al., 
2003). The most common form of hypertension is primary hypertension (also called es-
sential hypertension), of which by definition, the cause is unknown. This complicates the 
treatment and has led to a “trial and error” treatment strategy based on predefined first-, 
second- and third-line therapy (Royal College of Physicians, Management of hypertension 
in adults in primary care. NICE Clinical Guideline 18, 2006). The prevalence of second-
ary hypertension, i.e. hypertension with an identifiable underlying cause, is much lower. 
Although in only 5% of the hypertensive patients the cause of hypertension is known, the 
absolute number of patients affected by secondary hypertension is still high. Secondary 
hypertension can be caused by various diseases including endocrine and kidney diseases 
and cancer (Grossman and Messerli, 2012). However, it can also be caused as a side ef-
fect of drugs that are prescribed for non-cardiovascular indications, (Sager et al., 2013). 
This is still an unappreciated cause of secondary hypertension even though a myriad of 
drugs have been reported to induce a transient or sustained increase in BP, including 
non-steroidal anti-inflammatory drugs and analgesics, anti-anginogenic therapies that 
inhibit vascular endothelial growth factor signaling, antidepressant agents, steroids and 
sex hormones (Grossman and Messerli, 2012). For these specific drug classes the mecha-
nisms of action (MoA) underlying the undesired effects on BP have been elucidated. 
However, in drug development cardiovascular safety issues occur frequently with novel 
compounds (Sager et al., 2013). The MoA underlying these undesired BP effects is often 
not fully understood. This is a major drawback since a quantitative understanding of the 
pharmacological effects of (novel) drugs on BP control is pivotal from a drug safety point 
of view. In addition, although clinically hypertension is defined by a clear cut-off value, i.e. 
BP higher than 140/90 mmHg, it should be noted that the risk of cardiovascular events 
continuously increases with increased BP levels. Even changes in BP as small as 3 mmHg 
can have a relatively large influence in certain patient populations (Sager et al., 2013; 
EMEA, 2004). This underscores the importance of detecting and understanding undesired 
BP effects of novel compounds.
This thesis focuses on identification of the MoA of drugs with an undesired effect on BP. 
Moreover, it describes how the magnitude and dynamics of drug effects on the cardio-
vascular system (CVS) in man can be predicted from pre-clinical investigations, which is 
important as this determines the benefit-risk ratio of novel drugs. In this chapter, the 
physiology of the CVS is described first. Thereafter, it is discussed how the parameters of 
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Chapter 1 Introduction
the CVS can be monitored. Subsequently, the current status with regard to the assessment 
of drug-induced changes in BP during drug development is reviewed. Finally, the use of 
systems pharmacology modeling to provide a quantitative understanding of the pharma-
cological effects of (novel) drugs on the CVS to improve the prediction of the magnitude 
of the hemodynamic effects in humans is discussed. Although this chapter focuses on 
undesired effects of drug on BP it should be realized that many of the principles that are 
discussed are also relevant for drugs with desired effects on BP. However, this is beyond 
the scope of this chapter.
Physiology of the CVS
The primary function of the CVS, which consists of the heart, blood, and blood vessels 
and includes the pulmonary and systemic circulation, is the rapid convective transport of 
oxygen, glucose, amino acids, fatty acids, vitamins and water to the tissues and the rapid 
washout of metabolic waste products such as carbon dioxide, urea and creatinine (Levick, 
2003). 
Hemodynamics
The blood flow through the systemic circulation (hemodynamics) is governed by physical 
laws. Under steady flow conditions, the flow is proportional to the pressure difference 
between the inlet and outlet pressure (Equation 1) (Levick, 2003).
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It indicates that resistance equals the difference in pressure needed to drive one unit of flow in 
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In conclusion, the hemodynamics of the CVS are characterized by two equations (Figure 1). 
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In this equation, Q represents the flow, K represents the hydraulic conductance, and P1 
and P2 represent the inlet and outlet pressure, respectively. As resistance (R) is the reverse 
of conductance, i.e. 1/K, the basic law of flow can be re-written into Darcy’s law of flow, 
which is similar to Ohm’s law for fluid flow (Equation 2).
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It indicates that resistance equals the difference in pressure needed to drive one unit of 
flow in steady state, i.e. mmHg per mL/min. In the CVS, flow through the entire systemic 
circulation equals the cardiac output (CO). The pressure difference is mean arterial pres-
sure (MAP) minus central venous pressure (CVP) and resistance is called total peripheral 
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resistance (TPR). Therefore, when applying Darcy’s law to the CVS, equation 2 translates 
into Equation 3.
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In conclusion, the hemodynamics of the CVS are characterized by two equations (Figure 
1).
It should be noted that arterial pressure is pulsatile, because the heart ejects blood inter-
mittently. Between successive ejections the systemic arterial pressure decays from a peak 
of ~120 mmHg to a trough of ~80 mmHg. The pulsatile character of arterial pressure is not 
captured by these equations. However, this is deemed irrelevant as this thesis focuses on 
drug effects on MAP.




The mechanisms of BP regulation by the CVS have been carefully characterized, and the 
homeostatic principles of the CVS are thoroughly understood. Briefly, MAP is maintained 
within narrow limits by various regulatory feedback systems which control BP on different 
time scales (Figure 2). The baroreceptor reflex system is primarily responsible for short 
term BP regulation at the time scale of seconds. Other systems that regulate BP within 
seconds include the chemoreceptor reflex and the ischemic response. In addition, several 
hormonal systems including the renin-angiotensin-aldosterone system (RAAS) (indicated 
by “Capillary” in Figure 2), and some minor systems, control blood pressure within at 
a time scale of minutes. Finally, the kidney-fluid volume system is responsible for long 
term BP regulation and affects blood pressure within hours or days (Okumura and Cheng, 
Figure 2: Blood pressure control. Degree of activation, expressed in terms of feedback gain at optimal pressure, 
of different pressure control mechanisms after a sudden change in arterial pressure. CNS, central nervous system 
(Okumura and Cheng, 2012)
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2012).  In this chapter, first, the baroreflex system and, subsequently, the RAAS will be 
discussed in more detail.
The baroreceptor reflex system regulates HR and TPR and, thereby, MAP through the 
sympathetic and parasympathetic nervous system. Baroreceptors are stretch-sensitive 
mechanoreceptors, which are present in the vena cavae, carotid sinuses and aortic arch. 
When MAP rises, the carotid and aortic sinuses are distended resulting in stretch and, 
subsequently, activation of the baroreceptors. Active baroreceptors fire action potentials 
more frequently than inactive baroreceptors. The greater the stretch the more rapidly 
baroreceptors fire action potentials. These action potentials are relayed to the brainstem. 
Baroreceptor activation results in inhibition of the sympathetic nervous system and ac-
tivation of the parasympathetic nervous system. The sympathetic and parasympathetic 
branches of the autonomic nervous system have opposing effects on MAP. Sympathetic 
activation leads to an elevation of TPR and CO via increased contractility of the heart and 
increased heart rate and, thus, to increased MAP. Conversely, parasympathetic activation 
leads to decreased CO via a decrease in HR and, thus, to decreased MAP. By coupling 
sympathetic inhibition and parasympathetic activation, the baroreflex maximizes MAP re-
duction (Levick, 2003). In a similar manner, sympathetic activation with parasympathetic 
inhibition allows the baroreflex to elevate MAP. 
The RAAS regulates blood volume. If blood volume increases the venous return of blood to 
the heart increases, resulting in increased SV, CO and MAP. The blood volume is regulated 
through changes in MAP. Briefly, a decrease in MAP promotes the release of the hormone 
renin from the kidney into the blood. Renin promotes the production of angiotensin I 
from angiotensinogen. Subsequently, angiotensin I is converted into angiotensin II by 
angiotensin converting enzyme (ACE). Angiotensin II constricts blood vessels and pro-
motes renal salt and water retention by direct intrarenal actions and by stimulating and 
by stimulating the release of aldosterone (Cleophas, 1998). Aldosterone acts on the distal 
tubules and collecting ducts of the nephron, increasing reabsorption of ions and water in 
the kidney. This causes the conservation of sodium, secretion of potassium, increase in 
water retention, and increase in MAP. 
Drug effects on the cardiovascular system
The cardiovascular system can be influenced by drugs through a variety of different, and 
often complex, mechanisms. However, basically, most compounds directly influence HR, 
SV and/or TPR as elucidated for a selection of commonly applied cardiovascular drugs in 
Table 1. Due to the different feedback mechanisms that regulate the CVS the direct effect 
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of compounds are translated into differential effects on the other variables of the CVS, i.e. 
MAP, CO, HR, SV and TPR (this thesis). For example, fasudil is a calcium channel blocker, 
which decreases TPR through smooth muscle cell contraction (direct effect). Since MAP 
equals the product of TPR and CO, MAP is also decreased. As a result of the different 
Table 1: A selection of commonly applied cardiovascular drugs and their mechanism of action (this thesis).
Compound Class Mechanism of action effect 
amiloride diuretic
Diuretics cause blood volume contraction and lower venous pres-
sure, which decreases cardiac filling and, by the Frank-Starling 






Amlodipine is a dihydropyridine that blocks voltage gated 
calcium channels and selectively inhibits Ca2+ influx into vascular 
smooth muscle cells. Calcium antagonists act by decreasing total 
peripheral resistance to lower arterial pressure. As a consequence, 
reflex tachycardia, increased cardiac output, and increased 
plasma catecholamine and plasma renin activity are commonly 
seen, particularly with the initial dose and with short-acting 
dihydropyridines (Michalewicz et al., 1997; Perez-Reyes et al., 2009). 
TPR
atropine M2 receptor antagonist
Muscarinic (M2) receptor antagonist (MRA) is an agent that blocks 
the activity of the muscarinic acetylcholine receptor. It causes 
tachycardia by blocking vagal effects on the sinoatrial node. 
Acetylcholine hyperpolarizes the sinoatrial node which is overcome 







ACE inhibitors competitively inhibit angiotensin I-converting 
enzyme, preventing the conversion of angiotensin I to angiotensin II, 
a potent vasoconstrictor that also stimulates release of aldosterone. 
Decreased levels of angiotensin II lead to decreased total peripheral 
resistance that is unassociated with reflex stimulation of the heart 
(Frohlich, 1989). In addition, aldosterone acts on the distal tubules 
and collecting ducts of the nephron, the functional unit of the 
kidney. Decreased levels of aldosterone, cause the depletion of 





Rho-kinase inhibits myosin light chain phosphatase activity and 
plays a key role in Ca2+ sensitization and hypercontraction of vascular 
smooth muscle cells. Rho-kinase inhibitors decrease total peripheral 
resistance (Masumoto et al., 2001).
TPR






Prazosin is a quinazoline derivative that is a specific and selective 
competitive antagonist of α1 adrenoceptors on vascular smooth 
muscle cells. Prazosin reduces BP by reducing elevated peripheral 






Propranolol is a non-selective beta blocker. It antagonizes the action 
of norepinephrine and epinephrine at all β-adrenergic receptors. 
Propranolol decreases cardiac output and heart rate with a reflex 




feedback mechanisms regulating the CVS HR, SV and CO are increased after administra-
tion of fasudil (indirect effect).
Monitoring the variables of the cardiovascular system
Detection of drug-induced changes in the hemodynamics may be influenced by the fre-
quency and type of cardiovascular measurements during a study (Sager et al., 2013). As 
mentioned in the section “Physiology”, the hemodynamics of the CVS are characterized by 
five basic variables, i.e. MAP, HR, CO, SV and TPR. In experimental and clinical pharmacol-
ogy measuring MAP and HR is common practice. However, measuring CO, SV and TPR is 
not due to a lack of a perfect ‘gold’ standard measuring technique as detailed further in 
this section. Moreover, most measurement techniques require invasive instrumentation 
procedures, which limits the applicability of these techniques. Nevertheless measuring 
CO is important, because when MAP, HR and CO are measured SV and TPR can be derived 
using Equations 4 and 5. This provides a full understanding of drug effects on all variables 
of the CVS instead of on only two, i.e. MAP and HR. Moreover, since drug effects on CO and 
TPR may be much larger than anticipated from the observed responses on MAP and HR, 
measuring CO provides powerful information to detect patho-physiological conditions. In 
this section, it is first discussed how MAP and HR can be measured in conscious animals 
and in humans. Subsequently, it is discussed how CO can be measured.
Despite the fact that MAP is one of the most commonly measured hemodynamic param-
eters throughout drug development, there is no uniformly agreed methodology for how 
MAP should be measured (Sager et al., 2013). Typically, in preclinical research, dedicated 
telemetry studies are performed to evaluate acute effects of drugs in conscious rats, dogs 
or nonhuman primates. In these studies, MAP and HR are usually continuously recorded 
using indwelling catheters (Sager et al., 2013). Since MAP and HR are continuously re-
corded over several days this provides information for detecting 1) the diurnal profile, 
2) direct and delayed drug effects and 3) short and long term effects on MAP and HR. In 
addition, another noninvasive technique to measure MAP is available, i.e. oscillometric 
tail cuff with jackets, but this technique requires further refinement to improve system 
sensitivity to detect smaller changes in MAP (Ward et al., 2012, Sager et al., 2013). In 
human, MAP is measured noninvasively using manual or digital sphygmomanometers 
(blood pressure meters) or by ambulatory blood pressure monitoring (ABPM) and HR can 
be measured by ABPM, electrocardiograph (ECG) or pulse oximeters. The information 
obtained on changes in MAP and HR by ABPM is comparable to the information obtained 
from telemetry studies in conscious animal. Therefore, ABPM measurements are uniquely 
suited to detect the dynamics of drug effects on MAP and HR. In addition, the variability 
in measurements is much smaller with ABPM as compared to measurements from sphyg-
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momanometers. Especially when MAP and HR are measured in the clinic the variation in 
MAP and HR measurements can be very large, e.g. because of the white-coat effect (i.e. 
a transient elevation in MAP that does not appear to be linked to target organ damage or 
prognosis, but to the anxiety or stress that can be experienced during a visit to a physi-
cian). This should be taken into account when assessing drug-induced changes in the CVS.
Although measuring CO could provide a better understanding of underlying patho-
physiological processes, this has not been integrated into daily practice due to difficulties 
associated with invasive instrumentation procedures in both animal and human (Vincent 
et al., 2011; Doursout et al., 2001). In conscious and freely moving rats, CO can be mea-
sured with a variety of techniques (Doursout et al., 2001), including the Fick method, 
thermodilution, microsphere detection, impedance cardiography, transit ultrasound and 
electromagnetic flowmetry (Tsuchiya et al., 1978; Gotshall et al., 1987). Only the last 
method allows immediate observation of phasic aortic flow patterns and has been used 
to estimate cardiac function indirectly by means of derivatives of phasic aortic signals 
(deWildt and Sangster, 1983). Another method of interest for measurement of blood flow 
is the use of pulsed Doppler flow probes. This method is based on the direct relationship 
between blood velocity and volume flow. This method of measuring CO has not been used 
in many species. However, it has been claimed that these measurements are accurate in 
rats (Gardiner et al., 1990). In human, the pulmonary artery catheter, also called Swan-
Ganzkatheter, has long been considered optimal for hemodynamic monitoring, allowing 
for the almost continuous, simultaneous recording of pulmonary artery and cardiac filling 
pressures, cardiac output and oxygen saturation. However, the technique is invasive. 
Moreover, there is increasing evidence that this method is neither accurate nor effective 
in guiding therapy (Vincent et al., 2011). There are many different monitoring systems 
available ranging from the highly invasive pulmonary artery catheter to the completely 
non-invasive bioimpedance/bioreactance, CO2 rebreathing and echocardiography and 
echo-Doppler techniques. In general, variability in CO measurements is large. Classifying 
them according to how accurate or precise they are is difficult, in part because of the lack 
of a perfect ‘gold’ standard for comparison (Vincent et al., 2011). Most devices have been 
evaluated by comparing their results with those obtained by intermittent thermodilution 
from the pulmonary artery catheter as the reference, although this technique has its own 
limitations and may not represent the gold standard best. The bioimpedance/bioreac-
tance technique has been used for physiological studies in healthy individuals (Marque 
et al., 2009). This technique has the advantage that it allows continuous recording of CO. 
However, further investigation is required to investigate if this technique is reliable in 
critically ill patients (Vincent et al., 2011).
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Assessment of drug effects on the CVS in drug-development
In general, drug effects on MAP are assessed in all phases of the drug-development pro-
cess (Figure 3). In preclinical development, safety studies are performed ranging from in 
vitro assays to fully integrated in vivo animal models (Sager et al., 2013). The translation of 
these effects from preclinical to clinical development is often not fully understood and it is 
under debate whether preclinical studies are predictive for clinical studies. A recent meta-
analysis comparing the effects of small molecules on diastolic BP measured in conscious 
dog telemetry studies and the single-ascending dose phase of first-in-human studies 
suggest that a 5% change in diastolic BP in dog telemetry studies would provide for 37% 
sensitivity (probability of dog correctly identifying a positive phase I outcome) and 60% 
specificity (probability of correctly identifying negative phase I outcome) (Sager et al., 
2013). As the physiology of the CVS is comparable between species (Schmidt-Nielsen, 
1995) it is plausible that drug effects on the CVS are comparable between species too, 
albeit that there may be quantitative differences resulting from differences in size and 
function. Therefore, in cases where at first site the drug effect observed in animals seems 
to be not predictive for human, this may be explained by an incomprehensive under-
standing of the translation (the system differences). Another explanation may be that 
the interpretation of the results is not adequate, e.g. because of the lack of uniformity 
in the nonclinical approaches and the variability in the MAP measurements in clinical 
development (section “Monitoring the parameters of the CVS”). Therefore, an integrative 
Figure 3: MAP Assessment Development process (Sager et al., 2013)
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approach to data interpretation would appear most desirable (section “Modelling the 
CVS”).
Although undesired cardiovascular drug effects are usually detected in preclinical stud-
ies, the clinical relevance of these effects often only becomes apparent in the clinical 
development when drug effects are evaluated in healthy volunteers and/or in the target 
population. The clinical relevance of drug-induced cardiovascular effects is determined 
by many factors, such as the benefit-risk profile, treatment indication and duration of 
treatment and the cardiovascular risk of the target population. The clinical evaluation 
of drug effects on MAP involves multiple considerations, which are usually based on the 
presumed MoA underlying the undesired effects on MAP (Figure 3). However, in contrast 
to the detailed understanding of the physiologic regulation of MAP, the mechanisms 
underlying the effects on MAP of compounds with a novel MoA are often less clear. This 
is a major drawback since a quantitative understanding of the pharmacological effects of 
(novel) drugs on MAP control is pivotal with regard to safety, the prediction of the mag-
nitude of hemodynamic effects in human and the adequate assessment during clinical 
development. For example, if intensified MAP monitoring in phase III studies is required 
to investigate possible risk mitigation with antihypertensive therapy it is pivotal to under-
stand the MoA of the compound in order to adequately reverse an adverse effect on MAP 
(Sager et al., 2013). This underscores the importance of understanding these effects early 
in preclinical development since this could improve the anticipation of the magnitude of 
hemodynamic effects in humans. 
Modelling the CVS
Pharmacometrics is the scientific discipline that uses mathematical models based on 
biology, pharmacology, physiology, and disease for in vivo quantification of drugs effects. 
Models in pharmacometrics can be differentiated by their area of application, for example 
“pharmacokinetic-pharmacodynamic (PKPD) models”, “disease models”, “trial execution 
model” or any combination of these (Zhang et al., 2008). In this section, the focus is on 
PKPD modeling. The primary objective of PKPD modeling is to identify key properties of a 
drug in vivo, which allows the characterization and prediction of the time course of drug 
effects under physiological and pathological conditions. A pharmacokinetic (PK) model 
characterizes the time-course of the drug concentration and a pharmacodynamic (PD) 
model characterizes the relationship between exposure and pharmacological effect. PKPD 
modeling is applied in all stages of drug development and has proven to be a useful tool 
to support decision making in the key steps of drug development process (Breimer and 
Danhof, 1997). Within this context, PKPD modeling constitutes the theoretical basis for 
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Figure 4: Processes in the causal chain between drug administration and the change in response over time, includ-
ing the pharmacokinetics of a drug (process A), target site distribution and receptor (target) binding kinetics (pro-
cess B), receptor activation (process C) and transduction (process D).These processes are characterized by receptor 
theory models incorporated in mechanism-based PK-PD models (Ploeger et al., 2009). 
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the selection of drug candidates, lead optimization, and the optimization of early proof-
of-concept clinical trials on the basis of information from preclinical studies (Danhof et al., 
2007; Danhof et al., 2008). PKPD modeling has developed from an empirical and descrip-
tive approach into a scientific discipline based on the (patho-) physiological mechanisms 
behind PKPD relationships. As a result PKPD models range from purely empirical models, 
i.e. descriptive models to mechanism-based and systems pharmacology models with an 
increasing level of complexity an increasing level of predictive power. Mechanism-based 
models differ from empirical models in that they quantitatively characterize specific 
processes in the causal chain between drug administration and effect. A key element of 
mechanism-based modelling is the explicit distinction between parameters to describe 
drug-specific properties and biological system-specific properties. Drug-specific pa-
rameters (i.e., receptor affinity, intrinsic efficacy) describe the interaction between the 
drug and the biological system in terms of target affinity and target activation, whereas 
system-specific parameters describe the functioning of the biological system (Figure 4). 
The explicit distinction between drug-specific parameters and biological system-specific 
parameters is crucial to the prediction of in vivo drug effects (Danhof et al., 2007; Ploeger 
et al., 2009). Therefore, mechanism-based PKPD models have much improved properties 
for extrapolation and prediction as compared to empirical models. Systems pharmacology 
models attempt to inject biological realism to bring molecular or cellular detail closer to 
high-level, functional behavior (Vicini and van der Graaf, 2013). Where mechanism-based 
models focus on pathways, the level of complexity in systems pharmacology is increased 
further by focusing on networks and the interaction between different components of the 
network. This can be on different levels in the biological system ranging the organ level 
to the cellular level. Focusing on networks instead of pathways has the advantage that 
drug effects on interrelationships between the components of a network, i.e. different 
pathways, can be characterized and predicted. 
Systems biology is an approach to understanding biological processes as integrated sys-
tems instead of as isolated parts. The influence of systems biology has often been at a 
very fundamental (cellular or subcellular) biological scale, difficult to mechanistically link 
to higher-order tissue or organ systems. The Guyton and Coleman, which describes the 
physiology of the CVS in great detail model (Guyton et al., 1972), represents an example 
of a systems biology model (Figure 5). This model is a systems model of the human circula-
tory physiology, capable of simulating a variety of experimental conditions and contains 
a number of linked subsystems related to the circulation and its neuroendocrine control. 
The complete model consists of separate modules, each of which characterizes a sepa-
rate part of the physiological subsystem. The “Circulation Dynamics” part is the primary 
system, to which other modules/blocks are connected. The other modules characterize 
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the dynamics of the kidney, electrolytes and cellular water, thirst and drinking, hormone 
regulation, autonomic regulation, cardiovascular system etc., and these feed back on 
the central circulation model. The Guyton model has provided the scientific basis for the 
understanding of long-term BP control (Montani and Van Vliet, 2009).
Typically, systems biology is not concerned about therapeutic intervention; rather, deep 
study of targets and pathways is its focus. In that respect systems biology models differ 
from PKPD models, which aim to characterize drug effects. Next to this obvious difference, 
these models also differ in the level of detail included in the model and in the model 
selection criteria and the criteria for parameter identification. In PKPD modelling a data 
driven, top-down approach is followed starting at a parsimonious descriptive level and 
subsequently adding more complexity to better understand the system. These models 
are developed and selected by finding a middle ground between the model’s complexity 
and its descriptive power. Such middle ground can be based on statistical principles (e.g., 
balancing number of parameters and goodness of data fitting). The driver is invariably 
parsimony — in other words, selection of a model whose complexity is “just right” (least 
complex with the fewest parameters), given the data. On the other hand, systems biol-
ogy models are inherently complete and fully mechanistic and one follows a bottom-up 
approach, starting from the level of molecular pathways (Ploeger et al., 2009). In systems 
Figure 5: A systems analysis diagram for the full Guyton model describing circulation regulation (CellML, 2008)
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biology, model selection is rarely performed. Systems pharmacology provides a middle-
out approach. As discussed earlier the level of detail in the model is increased further as 
compared to mechanistic models as networks instead of pathways are characterized in a 
quantitative manner on different levels in the biological system ranging the organ level to 
the cellular level. Thereby, the level of detail included in these models middles the level 
of detail in systems biology models and empirical models. Next to the statistical criteria 
for model selection, systems pharmacology models are selected based on their function 
(Figure 6). 
Although in many therapeutic areas PKPD modeling has evolved from empirical model-
ling to mechanistic or systems pharmacology modeling, with examples in diverse areas 
such as central nervous system disease (Geerts et al., 2013), osteoporosis (Post et al., 
2013; Peterson and Riggs, 2012), endometriosis (Riggs et al., 2012) and safety (Lippert 
et al., 2012), PKPD modeling did not exceed the stage of empirical modeling in the area 
of cardiovascular disease. For several antihypertensive drugs, no clear relationship be-
Figure 6: A graphical summary of bottom-up, middle-out, and top-down approaches to model development and 
their relationship to various model types currently applied in drug discovery and development. In bottom-up 
approaches, low-level information determines the model, and this often remains conceptual. In top-down ap-
proaches, high-level organization and information determine interpretative models. In middle-out approaches, 
the driving force is available information, and models are selected and built on the basis of functional behavior. In 
this framework, systems pharmacology can be regarded as an approach to integrate the desirable features of the 




tween drug concentration and its effect on MAP has been reported (Gomez et al., 1989; 
MacGregor et al., 1983; Hansson et al., 1974). This is probably the result of initial studies 
in which relatively high doses were administered with exposures in the upper part of 
the sigmoid concentration–response curve, resulting in effects all close to the maximum 
response (van Rijn-Bikker et al., 2013). Furthermore, the description of the concentra-
tion–effect relationship for antihypertensive drugs is often confounded by a failure to 
collect sufficient pharmacodynamic data, a failure to identify and account for the fact that 
the MAP-lowering effect develops over a number of weeks, and a failure to account for 
circadian variability in the diurnal MAP profile (Meredith, 1997). On the other hand, the 
concentration–effect relationship for angiotensin converting enzyme inhibitors, calcium 
antagonists and alpha blockers have been successfully established (Bellissant and Giudi-
celli, 1998; Bellissant and Giudicelli, 2001; Donnellyv, 1989; Donnelly et al., 1988; Donnelly 
et al., 1993). These models may be classified as empirical models. To date no mechanism-
based, mechanistic or systems pharmacology models exist that provide an integrated 
description of the effects of drugs on the CVS except for a model that was postulated by 
Francheteau et al. (Francheteau et al., 1993). This model provides a description of the ef-
fect of dihydropyridine drugs on the relationship between MAP, CO and TPR. However, as 
several key model parameters of the Francheteau model were not identifiable this is not a 
truly mechanism-based model in the sense that drug- and system-specific properties were 
distinguished. The fact that no systems pharmacology models are available to character-
ize drug effects on the CVS is a major drawback since these models are uniquely suited 
to provide a quantitative understanding of the pharmacological effects of (novel) drugs 
on the CVS, which is pivotal with regard to drug safety. Moreover, understanding these 
effects early in preclinical development could improve the anticipation of the magnitude 
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In general, cardiovascular safety issues in drug development occur often (Sager et al., 
2013). In this context, an adequate understanding of the cadiovascular system (CVS) 
which regulates blood pressure in both preclinical species and human is pivotal to ef-
ficiently anticipate clinical effects of drugs on blood pressure in man. The development 
of such a translational PKPD model for the cardiovascular system requires a mechanistic 
understanding of blood pressure regulation (Ploeger et al., 2009; Danhof et al., 2007). 
The physiological principles of the CVS including BP regulation are well established and 
the homeostatic principles of the CVS are thoroughly understood. Briefly, mean arterial 
pressure (MAP) equals the product of cardiac output (CO) and total peripheral resistance 
(TPR) and CO equals the product of heart rate (HR) and stroke volume (SV) (Levick, 2003). 
However, drug effects on this interrelationship have not been analyzed in a mechanism-
based and quantitative manner. 
The objectives of the investigations described in this thesis were 1) to establish a systems 
pharmacology model to characterize the effects of drugs with different MoA’s on the inter-
relationship between BP, TPR, CO, HR and SV in a quantitative manner and 2) to apply the 
model to the quantification of the cardiovascular effect of the sphingosine 1-phosphate 
(S1P) receptor modulator fingolimod on the CVS. 
Outline
In section I an overview is presented of the analysis on drug effects on CVS (Chapter 1). 
First, the physiology of the CVS is described. Thereafter, it is discussed how the variables of 
the CVS can be monitored and, the assessment of drug-induced changes in BP during drug 
development is reviewed. Finally, the use of systems pharmacology modeling to provide 
a quantitative understanding of the pharmacological effects of (novel) drugs on the CVS 
early in preclinical development for the prediction of drug effects in humans is discussed.
In section II, a systems pharmacology model is proposed to characterize the CVS in 
normotensive and hypertensive rats. As a first step a systems pharmacology model was 
developed that describes in a strictly quantitative manner the interrelationship between 
BP, CO and TPR (Snelder et al., 2013). It is shown that this model can describe the phar-
macological effects of cardiovascular drugs in hypertensive rats and can be can be applied 
to elucidate that MoA of novel compounds using MAP and CO measurements (Chapter 3). 
Subsequently, this model was extended by parsing CO into HR and SV (Chapter 4). This ex-
tension was deemed important as it facilitates the elucidation of the MoA of cardiovascular 
drug effects using MAP and HR measurements only. In other words no CO measurements 
are required, which is beneficial as measuring CO is invasive and technically demanding. 
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Moreover, differences in BP regulation between normotensive and hypertensive rats were 
quantified, which is important since it is anticipated that effects observed in normotensive 
rats may be more representative for hemodynamic side effects in normotensive persons. 
To develop these system pharmacology models, rigorous preclinical experiments were 
designed measuring, MAP, HR and CO during the on- and offset phases of the drug effects 
when challenging the hemodynamic system with a training set of cardiovascular drugs 
with well described, but different mechanisms of action.
In Section III, the system-specific model to characterize drug effects on the interrela-
tionship between MAP, CO, HR, SV and TPR (Chapter 4) was applied to characterize the 
cardiovascular effects of S1P receptor agonists (Kappos et al., 2006; Kappos et al., 2010; 
Selmaj et al., 2013; Gergely et al., 2012) using fingolimod as a paradigm compound, as 
a basis for the prediction of its effects in humans. Fingolimod exerts its pharmacological 
effect through its active metabolite fingolimod-phosphate (fingolimod-P), which is formed 
by the enzyme sphingosine kinase (S1PHK) (Billich et al., 2003; Kihara and Igarashi, 2008; 
Kharel et al., 2005). First, a semi-mechanistic population PK model for the inter-conversion 
of S1PHK substrates and their respective phosphates in rats and humans was presented. 
Specific aim of this study was to investigate whether the rate of phosphorylation in blood 
platelets constitutes a basis for interspecies scaling using fingolimod as a paradigm com-
pound (Chapter 5). In this model, differences in the rate of phosphorylation in blood, 
estimated from ex vivo inter-conversion measurements in platelets, partly explain the 
differences in exposure between rats and humans. It is demonstrated that in addition, 
differences in pre-systemic phosphorylation should also be taken into account. Subse-
quently, the in Chapter 4 developed systems pharmacology model and the in Chapter 
5 developed PK model for fingolimod and fingolimod-P in rat was applied to obtain a 
quantitative understanding of the mechanisms leading to cardiovascular effects following 
the administration of fingolimod in normotensive and hypertensive rats (Chapter 6). To 
this end, the systems pharmacology model (Chapter 4) was integrated with expressions 
to describe S1P receptor binding kinetics, internalization and sensitization. This enabled 
the application of the model to the prediction of the effect of siponimod, a S1P receptor 
agonist with different receptor subtype selectivity, on MAP and HR in rat.
In Section IV, the next steps towards characterization and prediction of cardiovascular drug 
effects in human are discussed (Chapter 7). In this chapter, the results of the presented 
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research are summarized. In addition, the future perspectives are presented. An ultimate 
application of the developed systems pharmacology model would be the anticipation of 
the clinical response based on preclinical data for newly developed compounds and, more 
specifically, for S1P receptor agonists, i.e. follow-up compounds of fingolimod. First, the 
translation of the systems pharmacology model is discussed. Thereafter, the translation of 
the effect of S1P receptor agonists is addressed.
 Chapter 2
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Chapter 3 Basic CVS model
Summary
Background and purpose | The homeostatic control of arterial blood pressure is well 
understood with changes in blood pressure (BP) resulting from changes in cardiac output 
(CO) and/or total peripheral resistance (TPR). Drug effects on this interrelationship have 
not been analyzed in a mechanism-based and quantitative manner. This is important since 
it may constitute a basis for the prediction of drug effects on BP. This investigation aimed 
to describe, in a mechanism-based and quantitative manner, the effects of drugs with 
different mechanisms of action (MoA) on the interrelationship between BP, CO and TPR.
experimental approach | The cardiovascular effects of 6 drugs with diverse MoA’s, (am-
lodipine, fasudil, enalapril, propranolol, hydrochlorothiazide and prazosin) were charac-
terized in spontaneously hypertensive rats. The rats were chronically instrumented with 
ascending aortic flow probes and/or aortic catheters/radiotransmitters for continuous 
recording of CO and/or BP. Data were analyzed in conjunction with independent informa-
tion on the time course of drug concentration using a mechanism-based PKPD modeling 
approach.
Key results | By simultaneous analysis of the effects of 6 different compounds, the dy-
namics of the interrelationship between BP, CO and TPR, were quantified. System-specific 
parameters could be distinguished from drug-specific parameters indicating that the de-
veloped model is drug-independent.
Conclusions and Implications | A system-specific model characterizing the interrelation-
ship between BP, CO and TPR has been obtained, which can be used to quantify and 
predict cardiovascular drug effects and to elucidate the MoA for novel compounds. Ulti-





Persistent elevation of blood pressure (BP) is a risk factor for heart failure and is a leading 
cause of cardiovascular disease (Graham et al., 2007). This risk continuously increases 
with the level of BP. Even small changes in BP, i.e. 10-20 mmHg, can have a relatively 
large influence (EMEA, 2004). BP regulation by the cardiovascular system (CVS) is well 
characterized, and the homeostatic principles of the CVS are thoroughly understood. 
Briefly, mean arterial pressure (MAP) equals the product of cardiac output (CO) and total 
peripheral resistance (TPR). This relationship has been well established for many years 
and is based on Ohm’s Law, when applied to fluid flow. MAP is maintained within narrow 
limits by various regulatory feedback systems such as the renin-angiotensin-aldosterone 
system (RAAS) and the baroreflex system (Cleophas, 1998). In contrast to the detailed 
understanding of the physiologic regulation of BP, the mechanisms underlying the desired 
or undesired drug effects on BP are often less clear. This is a major drawback since a 
quantitative understanding of the pharmacological effects of (novel) drugs on BP control 
is pivotal with regard to drug efficacy and safety. Moreover, understanding these effects 
early in preclinical development could improve the anticipation of the magnitude of he-
modynamic effects in humans.
To date no models exist that provide an integrated description of the effects of drugs on 
the interrelationship between MAP, CO and TPR. A mechanism-based pharmacokinetic-
pharmacodynamic (PKPD) modeling approach is uniquely suited to provide quantitative 
insights in drug effects on the CVS since it clearly distinguishes drug-specific properties 
from system-specific properties (Danhof et al., 2007; Ploeger et al., 2009). This separation 
enables prediction and extrapolation of treatment effects to later stages of development 
using a translational modeling approach and, thereby, facilitating the drug development 
process and supporting compound selection (Danhof et al., 2007).
Following the concepts proposed by Van Der Graaf et al. (1999) and Van Schaick et al. 
(1997), we hypothesize that by challenging the CVS with a variety of compounds the rate 
and feedback parameters of the CVS can be quantified and a clear distinction can be made 
between drug- and system- specific parameters that govern the pharmacological effect. A 
crucial factor is that the ’training set’ of selected compounds acts on the same system, but 
with different target sites and time courses of effect. We have selected a training set of 
six antihypertensive compounds with different, but well described, effects on CO and/or 
TPR: enalapril, fasudil, amlodipine, prazosin, propranolol and hydrochlorothiazide (HCTZ) 
to challenge the CVS. The first four compounds have their primary effect on TPR; whereas 
the last two compounds have their primary effect on CO (Cleophas, 1998; Masumoto et 
al., 2001; Ram et al., 1981). An overview of the MoA of these compounds can be found 
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in Table 1. Besides an adequate selection of compounds, another important aspect of 
the experimental design is the selection of endpoints to monitor the drug effects on the 
CVS. Measuring BP is common practice, but it represents a ‘secondary’ pharmacodynamic 
parameter, as BP depends on both CO and TPR. At present, measuring CO has not been 
integrated into daily practice due to difficulties associated with invasive instrumentation 
procedures (Doursout et al., 2001). Still, from a mechanistic point of view these data are 
pivotal for a quantitative understanding of the dynamics of the system, especially since, 
due to the homeostatic feedback mechanisms, the effects on the underlying parameters 
CO and TPR may be much larger than the effects on BP (Brands et al., 2000). Finally, 
monitoring BP during the onset and offset of the drug effects provides the information 
Table 1: Selected compounds to challenge the CVS with the aim of distinguishing system- from drug-specific param-
eters and their mechanism of action.







ACE inhibitors competitively inhibit angiotensin I-converting 
enzyme, preventing the conversion of angiotensin I to angiotensin II, 
a potent vasoconstrictor that also stimulates release of aldosterone. 
Decreased levels of angiotensin II lead to decreased total peripheral 




Rho-kinase inhibits myosin light chain phosphatase activity and 
plays a key role in Ca2+ sensitization and hypercontraction of vascular 
smooth muscle cells. Rho-kinase inhibitors decrease total peripheral 






Amlodipine is a dihydropyridine that blocks voltage gated 
calcium channels and selectively inhibits Ca2+ influx into vascular 
smooth muscle cells. Calcium antagonists act by decreasing total 
peripheral resistance to lower arterial pressure. As a consequence, 
reflex tachycardia, increased cardiac output, and increased 
plasma catecholamine and plasma renin activity are commonly 
seen, particularly with the initial dose and with short-acting 








Prazosin is a quinazoline derivative that is a specific and selective 
competitive antagonist of α1 adrenoceptors on vascular smooth 
muscle cells. Prazosin reduces BP by reducing elevated peripheral 






Propranolol is a non-selective beta blocker. It antagonizes the action 
of norepinephrine and epinephrine at all β-adrenergic receptors. 
Propranolol decreases cardiac output and heart rate with a reflex 
rise in total peripheral resistance (Ebadi, 2008).
CO
HCTZ diuretic
Diuretics cause blood volume contraction and lower venous pres-
sure, which decreases cardiac filling and, by the Frank-Starling 




needed to quantify the parameters of a dynamical system as this information can only be 
derived when the system is not in equilibrium. The offset phase can be especially informa-
tive as it provides information on the question if, and how fast, the system returns to its 
initial state.
In this investigation, we describe the development of a mechanism-based PKPD model 
that integrates a quantitative description of the physiology of the interrelationship be-
tween BP, CO and TPR and the pharmacological effects of cardiovascular drugs using data 
from preclinical experiments with a training set of six antihypertensive drugs. Ultimately, 




Experiments were conducted on male, spontaneously hypertensive rats (SHR) (Taconic 
Farms,Germantown, NY) in accordance with approved Novartis Animal Care and Use Com-
mittee protocols and the Guide for the Care and Use of Laboratory Animals. At the time of 
study, rats’ ages ranged from 21-45 wk and body weights ranged from 269-490 gram.  Rats 
were housed on a 12-h light/dark cycle (light:  6 am to 6 pm) and were provided normal 
chow (Harlan Teklad 8604; Indianapolis, IN) and water ad libitum. The total number of rats 
used was 12 (10 in Study 1 and 2 in Study 2). All studies involving animals are reported in 
accordance with the ARRIVE guidelines for the reporting of experiments involving animals 
(Kilkenny et al., 2010; McGrath et al., 2010).
Experimental Procedures
The effects of a training set of compounds were obtained in two studies. In Study 1, 
detailed profiles of the time-course of the effects on MAP and HR were obtained after 
repeated dosing. In Study 2, information on the effect on MAP and CO was obtained fol-
lowing a single administration of a range of different doses. The combined information 
from both studies was crucial to the identification of the system-specific model character-
izing the interrelationship between MAP, CO and TPR.
For the recording of BP (Study 1), a sterile gel-filled catheter/radiotransmitter (PA-C40, 
Data Sciences International, St. Paul, MN) was surgically implanted under isoflurane an-
esthesia into a femoral artery (catheter tip residing in the lower abdominal aorta) and a 
44
Chapter 3 Basic CVS model
subcutaneous pocket or directly into the abdominal aorta. Arterial BP was for recorded for 
15 sec every 10 min as detailed previously (Bazil et al., 1993).
For BP and CO measurement (Study 2), rats were surgically instrumented with both an 
ascending aortic flow probe and a femoral arterial catheter/radiotransmitter (Figure 1). 
Rats were anesthetized with isoflurane, tracheally intubated, and artificially ventilated. 
A pre-calibrated 2.5 mm or 3.0 mm transit-time volumetric flow probe (2.5PS or 3PS, 
Transonic Systems Inc., Ithaca, NY) was placed around the ascending aorta via an incision 
at the right second intercostal space. The flow probe connector was tunneled subcutane-
ously to the mid-scapular region, where it was attached to the skin by a cutaneous button. 
The ribs were approximated with sutures, the chest was evacuated of air, and the chest 
wound closed in layers. Ketoprofen and penicillin G were administered for analgesia and 
infection prophylaxis. The rat was extubated and allowed to recover for approximately 
two weeks. Thereafter, the catheter/radiotransmitter was implanted as described above.
Figure 1: Experimental animal instrumentation. Rats in Study 2 were surgically instrumented with both an ascend-
ing aortic flow probe (A) and a femoral arterial catheter/radiotransmitter (B). CO was measured by connecting 
the flow probe to the flow meter via a cable and electrical swivel (C), which allowed the animal to remain fully 





































































































































































































































































































Chapter 3 Basic CVS model
In Study 2, rats were used repeatedly for up to 6 months with sufficient washout between 
consecutive experiments. For continuously recording of cardiac output, a tether cable was 
attached to the flow probe connector and a flow meter (Model T402, Transonic Systems) 
via an electrical swivel (Dragonfly Research & Development, Ridgeley, WV). The digitized 
flow and telemetered pressure signals were analyzed by a Ponemah data acquisition 
system (Data Sciences International).  MAP, heart rate, stroke volume, CO, and TPR were 
derived for all beats averaged over consecutive 2-min intervals.
Experimental design
Two different studies were conducted (Table 2). In Study 1, rats were treated once daily 
for 6 days with a single dose of drug (enalapril, fasudil, amlodipine or propranolol); SHR, 
n=5/drug. In Study 2, rats received single administrations of 4 different doses of each drug 
(amlodipine, prazosin or HCTZ) on 4 separate days.
In Study 1, rats were telemetered and after 2 weeks recovery, received 1 week of daily, 
oral dosing of saline (dosing training), then baseline data were collected during 3 days 
of no treatment. Subsequently, rats were treated with vehicle for 2 days prior to active 
treatment with active drug, which was administered once daily for 6 days at 11.00 am. 
Thereafter, washout data were collected during 6 days.
In Study 2, flow cables were connected to the flow probes by 7:00 am and disconnected 
after 5:00 pm. Baseline data were collected between 8:00 am and 10:00 am each day. 
Rats were dosed at 10:00 am and all data were continued to be collected until 5:00 pm. 
Thereafter, only MAP and HR data were captured until the flow probes were reconnected 
the next morning.
Compounds
In Study 1, enalapril maleate (Sigma-Aldrich, St. Louis, MO, USA, E6888), fasudil mono 
HCl (LC Laboratories, Woburn, MAF-4660), and amlodipine besylate (Lek pharmaceuticals 
d.d., Verovskova, Ljubljana, Slovenia) were formulated for administration at 5 ml/kg by 
oral gavage.  (±)-Propranolol HCl (Sigma-Aldrich, P0884) was dissolved in drinking water 
at 1 mg/mL. Enalapril maleate, fasudil and amlodipine were homogenized in 0.5% meth-
ylcellulose (MC) (Fisher Scientific, Pittsburgh, PA).
In Study 2, prazosin HCl (Sigma-Aldrich, P7791), amlodipine besylate, and HCTZ (H2910, 
Sigma-Aldrich) were formulated for administration at 2 ml/kg by oral gavage.  Prazosin 
and amlodipine were homogenized in 0.5% MC whereas HCTZ was dissolved in NaOH and 




The interrelationship between MAP, CO and TPR is expressed in the formula: MAP=CO*TPR 
(Levick, 2003). On the basis of this relationship a model was developed to describe the 
time course of the effects on MAP, CO and TPR (Figure 2). The model was defined by two 
linked turnover equations involving CO and TPR (Equation 1). Turnover models are also 
called indirect response models and can be used to describe hysteresis, i.e. the delay 
between a perturbation and a response (Dayneka et al., 1993). Examples of applications 
of this type of model can be found in the modeling of the homeostatic features of the 
release of endogenous compounds such as hormones or proteins (Gabrielsson and 
Weiner, 2000), or in the modeling of pharmacological responses such as drug-induced 
hypothermia (Zuideveld et al., 2001).
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In Study 1, enalapril maleate (Sigma-Aldrich, St. Louis, MO, USA, E6888), fasudil mono HCl (LC 
Laboratories, Woburn, MAF-4660), and amlodipine besylate (Lek pharmaceuticals d.d., 
Verovskova, Ljubljana, Slovenia) were formulated for administration at 5 ml/kg by oral gavage.  
(±)-Propranolol HCl (Sigma-Aldrich, P0884) was dissolved in drinking water at 1 mg/mL. Enalapril 
maleate, fasudil and amlodipine were homogenized in 0.5% methylcellulose (MC) (Fisher 
Scientific, Pittsburgh, PA). 
In Study 2, prazosin HCl (Sigma-Aldrich, P7791), amlodipine besylate, and HCTZ (H2910, 
Sigma-Aldrich) were formulated for administration at 2 ml/kg by oral gavage.  Prazosin and 
amlodipine were homogenized in 0.5% MC whereas HCTZ was dissolved in NaOH and diluted 
with filtered water (vehicle was water adjusted to pH 11). 
 
Data analysis 
The interrelationship between MAP, CO and TPR is expressed in the formula: MAP=CO*TPR 
(Levick, 2003). On the basis of this relationship a model was developed to describe the time 
course of the effects on MAP, CO and TPR (Figure 2). The model was defined by two linked 
turnover equations involving CO and TPR (Equation 1). Turnover models are also called indirect 
response models and can be used to describe hysteresis, i.e. the delay between a perturbation 
and a response (Dayneka et al., 1993). Examples of applications of this typ  of model can be 
found in the modeling of the homeostatic features of the release of endogenous compounds such 
as hormones or proteins (Gabrielsson and Weiner, 2000), or in the modeling of pharmacological 
responses such as drug-induced hypothermia (Zuideveld et al., 2001). 
 

















In these equations, Kin_CO and Kin_TPR represent the zero-order production rate constants 
and kout_CO and kout_TPR represent the first-order dissipation rate constants of CO and TPR 
respectively. These hypothetical production and dissipation rate constants reflect the rate 
of change in CO and TPR. FB1 and FB2 are constants representing the magnitude of the 
Kin_TPR






Figure 2: Cardiovascular model to describe the change in mean arterial BP after administration of different com-
pounds acting on cardiac output (CO) and total peripheral resistance (TPR). MAP equals the product of CO and TPR 
(MAP=CO*TPR). Effects on CO and TPR are described by two linked turnover equations. When MAP increases as a 
result of a stimulating effect on CO or TPR, the values of CO and TPR will decrease as a result of the action of the 
different feedback mechanisms regulating the CVS. The magnitude of feedback on CO and TPR is represented by 
FB1 and FB2.  Kin_CO and Kin_TPR represent the zero-order production rate constants of CO and TPR and kout_CO and 
kout_TPR represent the first-order dissipation rate constants of CO and TPR.
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negative feedback of MAP on CO and TPR. Following the criteria for statistical significance 
as specified in the section “Computation”, linear relationships between MAP and the 
production rate constants of CO and TPR were the most parsimonious relationships that 
captured the feedback mechanism adequately.
Initially, the circadian rhythm in BP was described as the sum of a maximum of 10 harmon-
ics with different periods (Equation 2). The number of cosine functions was systematically 
reduced following the criteria for statistical significance (section “Computation”).
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In these equations, Kin_CO and Kin_TPR represent the zero-order production rate constants and 
kout_CO and kout_TPR represent the first-order dissipation rate constants of CO and TPR respectively. 
These hypothetical production and dissipation rate constants reflect the rate of change in CO and 
TPR. FB1 and FB2 are constants representing the magnitude of the negative feedback of MAP 
on CO and TPR. Following the criteria for statistical significance as specified in the section 
“Computation”, linear relationships between MAP and the production rate constants of CO and 
TPR were the most parsimonious relationships that captured the feedback mechanism 
adequately. 
 
Initially, the circadian rhythm in BP was described as the sum of a maximum of 10 harmonics with 
different periods (Equation 2). The number of cosine functions was systematically reduced 





In this equation, amp represents the amplitude, t the time and hor the horizontal displacement 
over time. From a mechanistic point of view it is expected that the circadian rhythm in BP is a 
result of a circadian rhythm in CO and/or TPR as these are the primary drivers of MAP. However, 
as no 24 h measurements could be obtained for CO and TPR, the circadian rhythm was included 
in the model on MAP. Before pharmacological intervention (at baseline), MAP oscillates around 
its baseline value, which equals the product of the baseline values of CO and TPR (BSL_CO and 
BSL_TPR). 
 
Before pharmacological intervention, the system is in steady state, or dynamic equilibrium in 
mathematical terminology, denoting that MAP, CO and TPR do not change over time and are 
equal to their baseline values. As is common practice for turnover models (Dayneka et al., 1993) 
steady state conditions are described by the following equations (Equation 3) in which Kin is 














In this equation, amp represents the amplitude, t the time and hor the horizontal dis-
placement over time. From a mechanistic point of view it is expected that the circadian 
rhythm in BP is a result of a circadian rhythm in CO and/or TPR as these are the primary 
drivers of MAP. However, as no 24 h measurements could be obtained for CO and TPR, the 
circadian rhythm wa  includ d in the model on MAP. Before pharmacological intervention 
(at baseline), AP oscillates around its baseline value, which equals the product of the 
baseline values of CO and TPR (BSL_CO and BSL_TPR).
Before pharmacological intervention, the system is in steady state, or dynamic equilib-
rium in mathematical terminology, denoting that MAP, CO and TPR do not change over 
time and are equal to th ir baseline values. As is common practi e for turnover models 
(Dayneka et al., 1993) steady state conditions are described by the following equations 
(Equation 3) in which Kin is expressed in terms of BSL and kout. 
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    (3) 
 
 
In the experiments, TPR was derived (Equation 1) from the directly measured MAP and CO. In 
contrast, in the modeling, the baseline values of MAP (BSL_MAP) and BSL_TPR were estimated 
and BSL_CO was derived from these parameters for reasons of model stability. 
 
The system was functionally characterized by challenging the CVS with six different drugs with 
different mechanisms of action. Drug effects (EFF) were assumed to influence the production 
rates of either CO or TPR according to Equation 4. 
             
(4) 
 
During pharmacological intervention TPR and CO can be calculated using Equation 5, where 
TPRss and COss represent TPR and CO at steady state. 
 





Linear, Emax and Sigmoid Emax models were evaluated to describe the drug effects on CO or TPR. 
The effects of all compounds were best described by Emax models (Equation 6): 
 







































































In the experiments, TPR was derived (Equation 1) from the directly measured MAP and 
CO. In contrast, in the modeling, the baseline values of MAP (BSL_MAP) and BSL_TPR were 
estimated and BSL_CO was derived from these parameters for reasons of model stability.
The system was functionally characterized by challenging the CVS with six different drugs 
with different mechanisms of action. Drug effects (EFF) were assumed to influence the 
production rates of either CO or TPR according to Equation 4.
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During pharmacological intervention TPR and CO can be calculated using Equation 5, 
where TPRss and COss represent TPR and CO at steady state.
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Linear, Emax and Sigmoid Emax odels were evaluated to describe the drug effects on CO or 
TPR. The effects of all compounds were best described by Emax models (Equation 6):
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In this equation, Emax and EC50 represent the maximum effect and the concentration result-
ing in a half-maximal effect, respectively, and C equals the drug concentration in plasma, 
which varies with time. Using the time course of the drug plasma concentrations, i.e., the 
pharmacokinetics (PK), rather than the dose or exposure, as a predictor for the pharma-
codynamics (PD) has the advantage that it enables a better description of the time course 
of the drug effect. As the PK was not measured in these experiments, predicted plasma 
concentration versus time profiles were derived from the literature (Table 3). However, 
experimental conditions and formulations were different in these literature studies as 
compared to the experiments described in this paper. Therefore, for some compounds, 
PK parameters, e.g. the absorption rate, were estimated based on the known other PK 
parameters and the effect on BP (Table 3). In that case, PK and PD parameters were esti-
mated simultaneously.
50




















































































































































































































































































































































































































































































































































































































































































































































































































































The PK and PD models were based on the assumptions described in Table 4.
Influence of the selection of compounds on the system-parameters
An adequate selection of compounds to challenge the functioning of the CVS was thought 
to be pivotal to successfully quantify the parameters of the CVS model. The compounds 
were selected to have different mechanisms and durations of action as this provides the 
maximum power to identify the model i.e. to distinguish system- and drug-specific param-
eters. Furthermore, we expected that a combined analysis of data from the six compounds 
would enable accurate and precise quantification of all system-parameters. To determine 
whether the obtained model is truly system specific, the influence of selectively omitting 
the data of one of the six compounds on the values of the system parameters was exam-
ined. If omission of these data does not lead to significant changes in these parameter 
estimates, this indicates that the model is truly drug-independent. In this analysis, the 
estimates of the system parameters obtained with these six sub-models were compared 
with those of the model based on all compounds.
Table 4: Model assumptions
no. Assumption Clarification
1 Compounds selectively influence either CO or TPR.
Although some compounds may have a combined 
mechanism of action, i.e., have an effect on both 
CO and TPR, it was assumed that only including 
the direct/primary effect was sufficient for 
identifying the system. Therefore, any changes 
observed in the other parameters were assumed 
to be a result of the feedback (indirect/secondary 
effect).
2 All compounds influence the production rates of CO or TPR rather than the dissipation rates.
This assumption is based on the MoA of the 
selected compounds (Table 1).
3
For compounds for which the maximum effect was 
not observed, complete inhibition (i.e., Emax = 1) 
was assumed at infinite concentrations to ensure 
identification of the EC50 parameter.
To evaluate the validity of this assumption, the 
influence of different values of the Emax (i.e. Emax 
=0.8) on the estimates of the system parameters 
was tested. This was done for one of the 
compounds (amlodipine).
4
The PK do not differ between rat strains and can 
be scaled between rabbit and rat on the basis of 
an allometric function (West et al. 1999; Anderson 
and Holford, 2009).
Although published information on the PK of all 
selected compounds was available, the PK was 
often evaluated in different rat strains and, for 
prazosin, even in a different species (rabbit).
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System properties
Simulations were performed to investigate if the profiles of the time-course of the drug 
effect on MAP, CO and TPR are different for compounds with an influence on either CO 
or TPR. The typical profiles of MAP, CO and TPR versus time and of CO versus TPR are 
referred to as signature profiles. Pertinent differences in signature profiles for compounds 
with either an effect on CO or TPR indicate whether the drug-independent model can be 
applied to investigate the site of action (CO or TPR) of new compounds with an unknown 
MoA on BP. The responses on CO, TPR and MAP were simulated after triggering the model 
by enhancing TPR or inhibiting CO. The stimulation and inhibition functions were analyzed 
for a hypothetical constant rate infusion during 100 h to ensure that the drug effect is in 
steady state.
Computation
The data from Studies 1 and 2 were simultaneously analyzed using the non-linear mixed-
effects modeling approach implemented in NONMEM (version 7.1.0; Icon Development 
Solutions, Ellicott City, Maryland, USA). The models were compiled using Digital Fortran 
(version 6.6C3, Compaq Computer Corporation, Houston, Texas) and executed on a PC 
equipped with an AMD Athlon 64 processor 3200+ under Windows XP. The results from 
the NONMEM analysis were subsequently analyzed using the statistical software package 
S-Plus for Windows (version 6.2 Professional, Insightful Corp., Seattle, USA). The simula-
tions were carried out using Berkeley Madonna (version 8.3.5, Berkeley Madonna Inc., 
University of California). Parameters were estimated using the first order conditional 
estimation method with interaction between the two levels of stochastic effects (FOCE 
interaction). Random effects were included as exponential terms reflecting lognormal 
distributions of model parameters. The residual variability was explored with proportional 
and additive error models. Goodness-of-fit was determined using the minimum value of 
the objective function defined as minus twice the log-likelihood. For nested models, a 
decrease of 10.8 points in the objective function (MVOF) (corresponding to p<0.001 in a 
chi-squared distribution) by adding an additional parameter was considered significant. 
The goodness-of fit was also investigated by visual inspection of the plots of individual 
predictions and the diagnostic plots of (weighted) residuals. In addition, a visual predic-
tive check was performed in which the median and the 90% inter-quantile range of data 





The CVS model as expressed by Equations 1 - 6 and graphically represented in Figure 2 
was used to simultaneously analyze the data from Studies 1 and 2. To characterize the 
circadian variation in the baseline, the amplitudes of 5 harmonics of the circadian rhythm 
could be quantified. Amp1, amp3, amp4, amp5 and amp7 were estimated to be 3.17, -2.03, 
1.15, 1.63 and 1.28 mmHg, respectively. Amp2, amp6, amp8, amp9 and amp10 were fixed 
to 0 implying that these harmonics did not contribute to the circadian rhythm. In Study 
1, BSL_MAP was allowed to vary between individual rats (inter-individual variability (IIV)). 
Study 2 provided information to estimate IIV on both BSL_MAP and BSL_TPR. The residual 
errors of MAP and TPR were best described by additive residual error models, whereas 
the residual error of CO was best described by a proportional error model. The dissipa-
tion rate of CO (kout_CO) was found to be very high and could not be estimated with good 
precision. Therefore, this parameter was fixed to a high value (99 1/h) prior to estimating 
the other model parameters. The effects of all compounds were best described by Emax 
models. However, for amlodipine, fasudil, enalapril and HCTZ it was not possible to iden-
tify both drug effect parameters, Emax and EC50, independently and with good precision. 
This was due to the fact that the maximum effect was not observed. Therefore, Emax was 
fixed to 1 for these compounds assuming that complete inhibition of Kin can be reached 
for infinite concentrations. For these compounds the drug effects could have also been 
described with a linear concentration-effect relationship. However, these models were 
not applicable as the inhibition of Kin exceeded 100% during parameter optimization. In 
addition, adding a sigmoidicity parameter to the Emax models did not result in an improve-
ment in the goodness of fit for all compounds.
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In general, the model adequately described the data (Figures 3 and 4). However, for HCTZ 
the effect of a dose of 1 mg/kg was under-predicted, but the effects of the higher and 
lower doses of HCTZ were adequately described (Figure 4b). This could indicate that the 
selected pharmacodynamic model, an Emax model with the value of Emax fixed to 1, was not 
optimal. However, this effect model could not be further optimized as the selected dose 
range was not sufficiently large to cover the complete range from no effect to maximal 
effect.
All system parameters could be estimated with good precision as all standard errors 
were less than 50% of the parameter estimates (Table 5). Fixing Emax to 1 for amlodipine, 
fasudil, enalapril and HCTZ did not have a significant influence on the estimates of the 
system parameters (results shown for amlodipine after fixing the Emax of amlodipine to 
Figure 3: Visual predictive check of the description of the data from the repeated dosing Study 1 by the developed 
drug-independent CVS model. A) Full time scale; B) Expansion of the first two administrations of each drug. The 
grey dots represent the observations in SHR after administration of enalapril (30 mg/kg po) and amlodipine (10 
mg/kg p.o.), fasudil (30 mg/kg p.o.) and propranolol (1 mg/mL in drinking water); N=5 SHR/drug. The continuous 
lines represent the predicted median and the dashed lines represent the predicted lower and upper limit of the 90% 
prediction interval. The arrows indicate the six daily administrations of each drug.
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Figure 4: Description of the effects of amlodip-
ine (plot A), HCTZ (plot B) and prazosin (plot C) 
on cardiac output (CO), total peripheral resis-
tance (TPR) and mean arterial pressure (MAP) 
by the developed drug-independent CVS model. 
Data are from Study 2, in which vehicle and a 
different dose of amlodipine (0.3, 1, 3 and 10 
mg/kg p.o.), HCTZ (0.1, 0.3, 1 and 3 mg/kg p.o.) 
or prazosin (0.04, 0.2, 1 and 5 mg/kg p.o.) was 
administered on separate days. The grey and 
black dots represent the observations of two 
different rats. The continuous lines represent 
the individual prediction by the developed drug-
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Table 5: The system parameter values from the drug-independent model to describe the CVS.
Parameter Value Se CV LLCI ULCI
Value when Emax of 
amlodipine was fixed 
to 0.8 instead of 1
BSL_TPR (mmHG/(mL/min) 2.32 0.132 5.69 2.06 2.58 2.32
BSL_MAP (mmHG) 147 1.38 0.939 144 150 147
kout_CO (1/h) 99 FIXED  
kout_TPR (1/h) 0.260 0.129 49.6 0.00716 0.513 0.308
SL1 (1/mmHG) 0.00378 0.000148 3.92 0.00349 0.00407 0.00382
SL2 (1/mmHG) 0.00492 0.00101 20.5 0.00294 0.00690 0.00468
SE: Standard error of parameter estimate
CV: Coefficient of variation
LLCI: Lower limit of 95 % confidence interval
ULCI: Upper limit of 95 % confidence interval
Table 6: The drug-dependent parameter values estimated by the drug-independent model to describe the CVS
Parameter Value Se CV LLCI ULCI
Amlodipine
Emax 1 fixed
IC50 (ng/mL) 185 26.2 14.2 134 236
Fasudil
Emax 1 fixed
IC50 (ng/mL) 321 60.3 18.8 203 439
Propanolol
Emax 0.335 0.0624 18.6 0.213 0.457
IC50 (ng/mL) 9.82 3.8 38.7 2.37 17.3
enalapril
Emax 1 fixed
IC50 (ng/mL) 2410 373 15.5 1679 3141
HCTZ
Emax 1 fixed
IC50 (ng/mL) 12300 780 6.34 10771 13829
Prazosin
Emax 0.213 0.0158 7.42 0.182 0.244
IC50 (ng/mL) 0.133 0.146 109.8 -0.15 0.4
SE: Standard error of parameter estimate
CV: Coefficient of variation
LLCI: Lower limit of 95 % confidence interval
ULCI: Upper limit of 95 % confidence interval
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the arbitrarily selected value of 0.8 (instead of 1) in Table 5). In addition, all drug-specific 
parameters could be estimated with good precision, except for the EC50 of prazosin (CV: 
110%) (Table 6). For this compound EC50 and Emax were estimated simultaneously. Fixing 
Emax to 1, as was done for four other compounds, resulted in a more precise estimate of 
the EC50, but the goodness of fit was less good as indicated by a significant increase in the 
MVOF. All correlations between system-specific parameters were less that 0.95, except for 
the correlation between kout_TPR and FB2 (-0.984).
Influence of the selection of compounds on the system-parameters
None of the parameters changed significantly when data of one of the six compounds 
were selectively omitted with the exception of the value of the parameter FB1, which was 
Figure 5: Evaluation of drug-independency of the developed CVS model
Six different compounds, prazosin, HCTZ, propranolol, fasudil, enalapril and amlodipine, were used to estimate 
the system parameters of the developed CVS model. To determine if the system parameters were truly drug-
independent the model was re-evaluated omitting the different compounds one by one. The continuous black lines 
represent the parameter estimates of the model including all compounds and the dashed lines represent the 90% 
confidence intervals around these parameter estimates. The black lines with a black dot and the grey boxes repre-
sent the parameter estimates and the 90% confidence intervals around these parameter estimates after omitting 
one of the compounds. When the grey boxes overlap with the area between the dotted lines, parameters are not 
significantly different and the model is independent of that compound.  Therefore, the parameter estimate of FB1 
is dependent on the presence of the amlodipine data.
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found to be dependent on the presence of the amlodipine data (Figure 5). FB1 changed 
from 0.00379 (CI: 0.00348-0.00410) to 0.00454 (CI: 0.00418-0.00490) 1/mmHg.
System properties
Clear differences were found between the signature profiles of MAP, CO and TPR after 
simulating drug effects on CO and TPR. It was found that an increase in MAP can only be 
obtained by stimulating CO or TPR, and not by an overshoot of the feedback. Specifically, 
the simulation showed that inhibiting CO or TPR always results in a decrease in MAP, 
which demonstrates that feedback cannot be stronger than the primary effect (Figure 6). 
Figure 6: System properties of the CVS
The system properties of the CVS were investigated by simulating the response on CO, TPR and MAP after stimulat-
ing TPR (upper panel) or inhibiting CO (lower panel). Both perturbations result in visually comparable effects on 
CO and TPR (plot A). However, the response on MAP is in the opposite direction (plot B) indicating that the model 
can be used to identify the site of action. In addition, the hysteresis plot shows that an effect on TPR results in an 
immediate response on CO as a result of feedback, whereas, an effect on CO results in a delayed response on TPR 
as a result of feedback (plot C).
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In addition, the delay in response was longer when the drug effect was on CO as compared 
to on TPR (Figure 6c).
Discussion
A mechanism-based PKPD model was developed to describe drug effects on the inter-
relationship between MAP, CO and TPR using data from preclinical experiments with a 
training set of six compounds with diverse effects on BP. Several models that describe 
the physiology of the CVS in great detail have been published, such as the Guyton and 
Coleman model (Guyton et al., 1972), which has provided the basis for the understanding 
of long-term BP control (Montani and Van Vliet, 2009). However, to date no models exist 
that integrate a quantitative description of the physiology of the CVS and the effect of 
cardiovascular drugs on the relationship between MAP, CO and TPR except for a model 
that was postulated by Francheteau et al. (Francheteau et al., 1993). This model pro-
vides a description of the effect of dihydropyridine drugs on the relationship between 
MAP, CO and TPR. As several key model parameters of the Francheteau model were not 
identifiable this is not a truly mechanism-based model in the sense that drug- and system-
specific properties were indistinguishable. An important feature of a mechanism-based 
PKPD model is that both the drug-specific and the system-specific model parameters are 
identifiable and quantifiable on datasets from preclinical or clinical studies (Danhof et 
al., 2007). This enables an adequate prediction of cardiovascular drug effects and be-
comes especially relevant when the interest is to also understand the variation between 
biological systems (i.e., between species) or between individuals (Danhof et al., 2007). 
Therefore, the developed model is the first mechanism-based model that can be applied 
to describe the effect of cardiovascular drugs with different MoA’s on the interrelationship 
between MAP, CO and TPR.
The developed model was based on a number of assumptions. One assumption was that 
only taking the primary/direct effects of the compounds on either CO or TPR into con-
sideration was sufficient for identifying the system. For compounds like amlodipine and 
fasudil this assumption can be justified, since these compounds primarily influence TPR. 
The change in CO, which is observed after administration of these compounds, is thought 
to be a secondary effect, which is triggered by the feedback mechanisms of the CVS. For 
compounds like enalapril and propranolol, the MoA is less clear as these compounds influ-
ence both CO and TPR albeit with different magnitudes and on different timescales (Table 
1). Since the aim of this research was to develop a drug-independent model to describe 
the functioning of CVS, an adequate description of the system, based on all drug effects, 
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was considered more important than the best possible description of the individual drug 
effects of the different compounds.
Another assumption was that all compounds influence the production rates rather than 
the dissipation rates of CO or TPR. This assumption was based on the MoA of the differ-
ent compounds. The compounds that have a primary effect on TPR all influence smooth 
muscle cell contraction rather than causing relaxation. Therefore, assuming that contrac-
tion is equivalent to production, modeling of the drug effect on the production rather than 
the dissipation rate makes mechanistically sense. The two compounds that influence CO, 
HCTZ and propranolol, have quite different MoA’s (Table 1). HCTZ, a diuretic, decreases 
ventricular stroke volume by decreasing cardiac filling. On the other hand, propranolol 
reduces sympathetically mediated stimulation of left ventricular contractility and heart 
rate. Therefore, from a mechanistic point of view, both compounds are thought to also 
influence the production rather than the dissipation rates. As the MoA of HCTZ and pro-
pranolol are quite different, it might be expected that the delay in response, as reflected 
by kout_CO, would be different for these compounds. However, for both compounds, this 
delay was too short to quantify with good precision. Therefore, both the effects of HCTZ 
and propranolol could be adequately described by the model with kout_CO fixed to a high 
value of 99 1/h. Although kout_CO could not be quantified, the data did contain informa-
tion about the rate of change in CO being high as fixing this parameter to a lower value 
resulted in bias in the description of the HCTZ and propranolol data (results not shown). 
The exact value of kout_CO is only relevant when the interest is in the effect on shorter time 
scales than investigated in the current studies, i.e. seconds instead of minutes or hours. 
In addition, in theory, adding one or more compounds with an effect on the dissipation 
rate would provide additional information for identification of the system parameters. 
However, from a mechanistic point of view it is difficult to find compounds with an effect 
on the kout of CO or TPR. For example, enalapril influences the kout of angiotensin I as it 
inhibits angiotensin-I-converting enzyme. This effect however translates into an inhibition 
of the kin of angiotensin II which in turn leads to vasodilation. The current model there-
fore describes the effect of enalapril on the Kin of TPR. Moreover, from a data driven point 
of view including compounds with an effect on kout will only add additional information 
for quantification of the system parameters when the selected dose range is large enough 
to reach the maximum effect (Sharma and Jusko, 1996; 1998). In in vivo investigations 
however attainment of the maximum drug effect is not always feasible for safety reasons. 
Moreover, in situations where rapid adaptation occurs, it may be impossible experimen-
tally to reach the Emax (Porchet et al., 1988). An interesting feature of the developed model 
is that it can be extended to more detailed levels without having to change the structure 
of the model. For example, the system can be described in more detail by parsing CO into 
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heart rate and stroke volume. In addition, including more information on the different 
feedback mechanisms could lead to a model that distinguishes the effects of different 
classes of antihypertensive drugs in more detail. The feedback mechanisms currently 
included in the model are likely to reflect the acute compensatory mechanisms (such 
as the baroreceptor reflex) better than the long term compensatory mechanisms (such 
as the renin-angiotensin-aldosterone system (RAAS)) as the baroreflex system is active 
within minutes to hours to days whereas the RAAS is active within hours to days/weeks. 
To evaluate if the model is predictive for long-term effects on the CVS long-term studies of 
days or weeks with CO measurements are required.
The assumptions made regarding the use of PK models derived from published results 
may have a large impact on the PK profiles. Therefore, the PK models were descriptive and 
the PK and drug-specific PD parameters may not represent “true” values. Therefore, these 
estimates should only be interpreted in the context of this model. This was considered 
acceptable as system-specific parameters, which are of primary interest in this research, 
are considerably less sensitive to changes in PK compared to drug-specific parameters. 
This is explained by the fact that drug-specific parameters are directly dependent on the 
PK of a specific drug, whereas the values of system-specific parameters are determined 
by the data of all compounds.
Beforehand it was hypothesized that two aspects of the experimental design were pivotal 
to successfully quantify the parameters of the CVS model: i) the selection of the training 
set of compounds to challenge the functioning of the CVS and ii) measuring both MAP 
and CO during the on- and offset phases of the drug effects. The correlations between 
some drug- and system-specific parameters were high (results not shown). However, 
evaluating if the model was indeed drug independent has demonstrated that the selected 
combination of compounds was adequate to develop a drug-independent model as only 
the parameter FB1, i.e. 1 of the 5 system-specific parameters, changed when the data of 
1 of the 6 compounds (amlodipine) were omitted (Figure 5). To evaluate the importance 
of measuring both MAP and CO during the on- and offset phases of the drug effects, a 
retrospective sensitivity analysis was performed, using the parameter estimates of the 
developed model (Appendix). This sensitivity analysis demonstrated that measuring both 
MAP and CO during the on- and offset phase provided the pertinent information to quan-
tify the system parameters. This is in agreement with the good precision of the estimates 
of all system-specific parameters. However, the values of kout_TPR and FB2 were strongly 
correlated (-0.984) indicating that there was not enough information to estimate both 
parameters independently. This was confirmed by the sensitivity analysis, which showed 
that both parameters are most sensitive to the data collected during approximately the 
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same period after drug administration and during the offset phase of the drug effects for 
compounds influencing TPR (Appendix: Figure A). For compounds that influence CO these 
peaks are more distinct (results not shown), which indicates that the information to es-
timate these parameters independently was mainly provided by the compounds with an 
effect on CO. In the current research, only two compounds were included with a primary 
effect on CO, i.e., propranolol and HCTZ, and CO was measured only after administra-
tion of HCTZ. To distinguish these parameters, detailed MAP and CO measurements from 
more compounds with an influence on CO would be required. This should be taken into 
consideration when the model is applied for simulation purposes. Measuring CO provided 
insight into the magnitude of the counteracting effects on TPR and CO underlying the ef-
fect on BP. Since MAP is the primary regulated hemodynamic variable, drug effects on TPR 
and CO were disproportionately greater than those reflected by MAP alone. This indicates 
that a small observed pharmacologic effect on MAP may mask much larger therapeutic 
benefits or, conversely, an increased risk of cardiovascular disease. Based on estimates 
of the residual error, the model is qualified to distinguish changes in MAP, CO and TPR 
larger than 7.6 mmHg, 4.3 ml/min and 0.5 mmHg/(ml/min), respectively, from noise. This 
indicates that the model can be used to identify clinically relevant changes in BP. In con-
clusion, the rigorous experimental design was adequate to provide the data to describe 
the interrelationship between MAP, CO and TPR in a quantitative and mechanism-based 
manner.
The developed CVS model can be applied to estimate drug-specific parameters for new 
compounds, but this requires accurate and precise description of the pharmacokinetics. 
Recently, novel approaches have been proposed to accurately characterize pharmaco-
kinetics without influencing the pharmacodynamics in pre-clinical PKPD investigations, 
e.g. the PK can be measured after completion of the pharmacodynamic part of the study 
(Bender et al., 2009) or the PK and PD can be measured on different days during the study 
(Viberg et al., 2012). In addition, the developed model can be applied to identify the site 
of action of new compounds influencing MAP through an unknown MoA, as it was shown 
in a simulation experiment that distinct differences exist between the signature profiles of 
compounds with an effect on CO or TPR (Figure 6). In this context, the developed model 
provides key insights to support drug development, i.e. to learn about the underlying 
MoA of compounds with desired or undesired effects on BP. The model can also be ap-
plied to test hypotheses, e.g., hypotheses on multiple sites of action can be evaluated by 
including drug-effects on multiple parameters in the model. It should be noted that the 
identified set of system parameters is specific for spontaneously hypertensive rats. Drug 
effects on MAP, CO and TPR may vary considerably in other (normotensive) rat strains 
due to physiological differences (Pinto et al., 1998). Consequently, applications of the 
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developed model, using the identified set of system parameters, are limited to this rat 
strain. However, an advantage of a mechanism-based model is that it allows accurate 
extrapolation between different rat strains and from one species to another (Danhof et 
al., 2008; Ploeger, 2009) as the structure of the model is expected to be the same in 
all species. Therefore, an ultimate application of the developed drug-independent model 
would be to facilitate the anticipation of the clinical response based on preclinical data for 
newly developed compounds. Before our model can be applied for that purpose, the pre-
dictability of long-term blood pressure effect should be evaluated and the model should 
be scaled to human and validated on human MAP and CO measurements.
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BSL_CO Baseline value of cardiac output
BSL_MAP Baseline value of mean arterial pressure
BSL_TPR Baseline value of total peripheral resistance
C drug concentration in plasma
CO Cardiac output
CVS Cardiovascular system
Emax  Maximum effect
EC50 Concentration resulting in a half-maximal effect
FB1 negative feedback of mean arterial pressure on cardiac output




Kin_CO  Zero-order production rate constant of cardiac output
Kin_TPR Zero-order production rate constant of total peripheral resistance
kout_CO First-order dissipation rate constant of cardiac output
kout_TPR First-order dissipation rate constant of total peripheral resistance
MAP Mean arterial pressure
MC Methylcellulose
MoA Mechanisms of action





SHR Spontaneously hypertensive rats
T Time
TPR Total peripheral resistance
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Appendix: Sensitivity analysis, evaluation of the experimental 
design
An adequate experimental design was thought to be pivotal to distinguish drug- from 
system-specific parameters in this investigation. By showing how the dynamic behavior of 
the system responds to changes in parameter values, a sensitivity analysis enables identi-
fication of the part of the experimental protocol that provides the pertinent information 
to quantify the parameters and to distinguish one parameter from another. Using the pa-
rameter estimates of the developed model, a retrospective parameter sensitivity analysis 
was performed in Berkeley Madonna (version 8.3.5, Berkeley Madonna Inc., University of 
California) to determine how “sensitive” the developed model is to changes in the values 
of the parameters of the model.
First a simulation was performed with all system parameters fixed at their estimated 
values (S(t,x0)), while assuming an inhibiting drug effect on TPR during a constant drug in-
fusion of 100 h to ensure that the drug effect is in steady state. Subsequently, simulations 
were performed after 0.1% increments in the system parameters (0.1% is the standard in 
Berkeley Madonna) (S(t,x)). Finally, for each parameter, the sensitivity (S(t)) was calculated 
according to Equation A.1.
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The sensitivity (S(t)) in change from baseline for MAP, CO and TPR was evaluated for all system 
parameters (Figure A.1). This figure shows that the on- and offset phases of the drug effect 
contained complementary information as in both phases the peaks of the values of the different 
parameters of the pharmacodynamic system (BSL_TPR, BSL_MAP, kout_TPR, FB1 and FB2) 
occurred at different time points relative to each other. In addition, the three biomarkers of the 
CVS, MAP, CO and TPR also contained complementary information regarding the dynamics of 
the system. For example, the peaks of the two feedback parameters FB1 and FB2 occurred 
almost simultaneously when examining the sensitivity in MAP, whereas when looking at the 
sensitivity in CO and TPR the peaks occurred relatively later. Therefore, measuring CO provided 
the pertinent information to distinguish these parameters. 
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The sensitivity (S(t)) in change from baseline for MAP, CO and TPR was evaluated for all 
system parameters (Figure A.1). This figure shows that the on- and offset phases of the 
drug effect contained complementary information as in both phases the peaks of the 
values of the different parameters of the pharmacodynamic system (BSL_TPR, BSL_MAP, 
kout_TPR, FB1 and FB2) occurred at different time points relative to each other. In addition, 
the three biomarkers of the CVS, MAP, CO and TPR also contained complementary infor-
mation regarding the dynamics of the system. For example, the peaks of the two feedback 
param ters FB1 and FB2 occurred almost simult neously when examining the sensitivity 
in MAP, whereas when looking at the sensitivity in CO and TPR the peaks occurred rela-
tively later. Therefore, measuring CO provided the pertinent information to distinguish 
these parameters.
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Figure A: Sensitivity analysis
Influence of a 0.1% increase in the values of the system parameters of the drug-independent model (BSL_TPR, 
BSL_MAP, kout_TPR, FB1 and FB2) on the dynamic behavior of the CVS parameters MAP, CO and TPR. In this sensitiv-
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Chapter 4 Extended CVS model
Summary 
Background and purpose | Previously, a systems pharmacology model was developed 
characterizing drug effects on the interrelationship between mean arterial pressure (MAP), 
cardiac output (CO) and total peripheral resistance (TPR). The present investigation aims 
to 1) extend the previously developed model by parsing CO into heart rate (HR) and stroke 
volume (SV) and 2) to evaluate if the mechanism of action (MoA) of new compounds can 
be elucidated using HR and MAP measurements only.
experimental approach | The cardiovascular effects of 8 drugs with diverse MoA’s 
(amiloride, amlodipine, atropine, enalapril, fasudil, hydrochlorothiazide, prazosin and 
propranolol) were characterized in spontaneously hypertensive rats (SHR) and in normo-
tensive Wistar-Kyoto (WKY) rats following single administrations of a range of different 
doses. The rats were instrumented with ascending aortic flow probes and aortic catheters/
radiotransmitters for continuous recording of MAP, HR and CO for the full duration of the 
experiments. Data were analyzed in conjunction with independent information on the 
time course of the drug concentration following a mechanism-based pharmacokinetic-
pharmacodynamic modeling approach. 
Key results | The extended model, which quantifies the changes in TPR, HR and SV with 
negative feedback through MAP, adequately described the cardiovascular effects of the 
drugs while accounting for circadian variation and the influence of handling. 
Conclusions and Implications | A systems pharmacology model characterizing the inter-
relationship between MAP, CO, HR, SV and TPR has been obtained in hypertensive and 
normotensive rats. The extended model can be used to quantify the dynamic changes in 
the CVS and elucidate the MoA for novel compounds, with one site of action, using HR 
and MAP measurements only. The questions whether the model can also be applied for 




Blood pressure (BP) and heart rate (HR) are important parameters in the safety evaluation 
of novel drugs for a wide variety of disorders (Sudano, 2012, Gasparyan, 2012; Cardinale, 
2013; Guth, 2007). Although BP and HR are usually measured simultaneously, it is common 
practice to quantify drug effects on these hemodynamic parameters independently result-
ing in two separate dose/concentration-effect relationships. However, this approach dis-
regards the interrelationship between BP and HR. As this interrelationship is complex due 
to the feedback mechanisms regulating the cardiovascular system (CVS), interpretation of 
the separate relationships can be challenging and ambiguous. With the physiology of the 
CVS being well understood, an integrated analysis could result in improved understanding 
of cardiovascular effects and the underlying mechanism of action (MoA). Moreover, it 
has the advantage that a single dose/concentration-effect relationship can be established. 
Previously, it has been demonstrated that drug effects on the interrelationship between 
mean arterial pressure (MAP), cardiac output (CO) and total peripheral resistance (TPR) 
can be quantified using a systems pharmacology model (Snelder et al., 2013a). As CO 
equals the product of HR and stroke volume (SV) it is anticipated that this model can be 
extended to a more detailed level by parsing CO into HR and SV with the advantage that 
drug effects on MAP, CO, HR, SV and TPR can be characterized simultaneously. It has been 
demonstrated that the previously developed CVS model (basic CVS model) can be applied 
to elucidate the MoA of novel compounds (Snelder et al., 2013a). This requires continu-
ous recording of CO. However, measuring CO has not been integrated into daily practice 
due to the challenges associated with invasive instrumentation procedures (Doursout et 
al., 2001). Therefore, it is of interest to investigate if the proposed extended CVS model 
can be applied to elucidate the MoA of new compounds using HR and MAP measurements 
only. 
The basic CVS model is specific for spontaneously hypertensive rats (SHR). Thus modeling 
of the hemodynamic effects in normotensive rats has not been achieved. This is of inter-
est since the prediction of hemodynamic side effects is also important for normotensive 
subjects. The normotensive Wistar-Kyoto (WKY) rat strain is generally accepted as the 
most appropriate control strain for SHR (Louis et al., 1990). As there are pronounced dif-
ferences in MAP regulation between hypertensive and normotensive rats (Pinto et al., 
1998) the magnitude of the effect of cardiovascular drugs on the different hemodynamic 
endpoints may vary considerably between strains. Therefore, the basic CVS model might 
not be directly applicable to data from normotensive rats. This is a major drawback espe-
cially for drug safety evaluations, which are usually conducted in normotensive rats. As 
the ultimate aim of the proposed quantitative pharmacology model is to predict clinical 
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responses to novel pharmacologic agents, it is pivotal that the CVS model is applicable to 
both normotensive and hypertensive rats.
In this investigation, we describe the extension of the basic CVS model to a more detailed 
level by 1) parsing CO into HR and SV and 2) quantifying differences in BP regulation be-
tween normotensive and hypertensive rats, with the aim to evaluate if the MoA of new 
compounds can be elucidated using HR and MAP measurements only. To this end, data 
from preclinical experiments in hypertensive and normotensive rats with a training set 
of eight cardiovascular drugs with diverse MoA’s are used. Ultimately, this quantitative 




For the investigations male, SHR (Taconic Farms,Germantown, NY, USA) and WKY rats 
(Taconic Farms,Germantown, NY, USA) were used. All experiments were conducted in 
accordance with Novartis Animal Care and Use Committee protocols. These protocols 
have been accredited and conform to international animal welfare standards and to the 
Guide for the Care and Use of Laboratory Animals. The ages of the rats ranged from 41-54 
wk and 35-38 wk for SHR and WKY rats, respectively. The body weights were between 
367-504 gram and between 499-600 gram for SHR and WKY rats, respectively. Rats were 
housed on a 12-h light/dark cycle (light: 0600–1800 h), kept at room temperature, 22°C, 
and were provided normal chow (Harlan Teklad 8604; Indianapolis, IN, USA) and water 
ad libitum. The studies were reported in accordance with the ARRIVE guidelines for the 
reporting of experiments involving animals (Kilkenny et al., 2010; McGrath et al., 2010). 
Experimental Procedures
For continuous recording of BP, HR and CO rats were surgically instrumented with both an 
ascending aortic flow probe and a femoral arterial catheter/radiotransmitter as described 
by Snelder et al. (Snelder et al., 2013a). 
Experimental design
The effects of a training set of compounds were obtained in two studies. In Study 1, in-
formation on the effect on MAP, CO, HR, SV and TPR was obtained following a single oral 
administration of different doses of each drug (amiloride, amlodipine, enalapril, fasudil, 
HCTZ or prazosin) on separate days (Table 2a). The number of dose strenghts investigated 
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Table 1: Selected compounds to challenge the CVS with the aim of distinguishing system- from drug-specific param-
eters and their mechanism of action. 
Compound Class Mechanism of action effect 
amiloride diuretic
Diuretics cause blood volume contraction and lower venous 
pressure, which decreases cardiac filling and, by the Frank-







Amlodipine is a dihydropyridine that blocks voltage gated 
calcium channels and selectively inhibits Ca2+ influx into 
vascular smooth muscle cells. Calcium antagonists act by 
decreasing total peripheral resistance to lower arterial 
pressure. As a consequence, reflex tachycardia, increased 
cardiac output, and increased plasma catecholamine and 
plasma renin activity are commonly seen, particularly with the 
initial dose and with short-acting dihydropyridines (Michalewicz 
et al., 1997; Perez-Reyes et al., 2009). 
TPR
atropine M2 receptor antagonist
Muscarinic (M2) receptor antagonist (MRA) is an agent that 
blocks the activity of the muscarinic acetylcholine receptor. It 
causes tachycardia by blocking vagal effects on the sinoatrial 
node. Acetylcholine hyperpolarizes the sinoatrial node which is 







ACE inhibitors competitively inhibit angiotensin I-converting 
enzyme, preventing the conversion of angiotensin I to 
angiotensin II, a potent vasoconstrictor that also stimulates 
release of aldosterone. Decreased levels of angiotensin II lead 
to decreased total peripheral resistance that is unassociated 
with reflex stimulation of the heart (Frohlich, 1989). In addition, 
aldosterone acts on the distal tubules and collecting ducts of 
the nephron, the functional unit of the kidney. Decreased levels 
of aldosterone, cause the depletion of sodium, conservation of 




Rho-kinase inhibits myosin light chain phosphatase activity and 
plays a key role in Ca2+ sensitization and hypercontraction of 
vascular smooth muscle cells. Rho-kinase inhibitors decrease 
total peripheral resistance (Masumoto et al., 2001).
TPR






Prazosin is a quinazoline derivative that is a specific and 
selective competitive antagonist of α1 adrenoceptors on 
vascular smooth muscle cells. Prazosin reduces BP by reducing 
elevated peripheral resistance and has little effect on cardiac 






Propranolol is a non-selective beta blocker. It antagonizes the 
action of norepinephrine and epinephrine at all β-adrenergic 
receptors. Propranolol decreases cardiac output and heart rate 
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varied per drug in order to find an appropriate dose showing a clear effect, and therefore, 
the duration of the study also varied per drug. The MAP and CO measurements following 
the administration of amlodipine, prazosin and HCTZ (first occasion) in SHR were also used 
for the development of the previous CVS model (Snelder et al., 2013a). As these data are 
also informative for the proposed extended CVS model they are included in this investiga-
tion as well. However, in the previous investigation, the maximum effect of HCTZ was not 
observed at the investigated dose range. Therefore, information on the influence of higher 
doses of HCTZ on the hemodynamic parameters was obtained in this study (second oc-
casion) (Table 2a). In Study 2, the effects of atropine (10 mg/kg) and propranolol (30 mg/
kg) on MAP,CO,HR, SV and TPR were measured following a single, sequential or combined 
oral administration of propranolol and/or atropine in 8 SHR (Table 2b). No WKY rats were 
included in this Study. In the rats repeated experiments were conducted over periods of 
up to 6 months. Sufficient washout between consecutive experiments was allowed. In 
Studies 1 and 2 together, 10 SHR and 2 WKY rats were used. Data from 1 SHR (Study 2) 
were omitted for model development as this rat learned how to disconnect its flow cable 
and responded much stronger than all other rats (Table 2). For practical reasons, the flow 
cables were disconnected from the flow probes between 5:00 pm and 7:00 am the follow-
ing morning. On the experiment days baseline data were collected between 7:00 am and 
10:00 am. Drug administration took place at 10:00 am and 13:00 am (Study 2 only). Data 
collection was continued until 5:00 pm. In the period between 5:00 pm and 7:00 am the 
following morning, only MAP and HR data were captured. 
Compounds
Amiloride HCl hydrate (Sigma-Aldrich, St. Louis, MO, USA, A7410), enalapril maleate 
(Sigma-Aldrich, E6888), fasudil mono HCl (LC Laboratories, Woburn, MA, F-4660), atropine 
sulfate (Sigma-Aldrich, A0257) and propranolol HCl (Sigma-Aldrich, P0884) were dissolved 
in water. Amlodipine besylate (Lek Pharmaceuticals, Ljubljana, Slovenia) and prazosin HCl 
(Sigma-Aldrich, P7791) were homogenized in 0.5% methylcellulose (MC) (Fisher Scientific, 
Pittsburgh, PA). Hydrochlorothiazide (HCTZ, Sigma-Aldrich, H2910) was dissolved in NaOH 
and diluted with filtered water (vehicle was water adjusted to pH 11). All compounds were 
formulated for administration at 2 ml/kg by oral gavage.
Data analysis 
The interrelationship between MAP, TPR, CO, HR and SV is expressed by the formulas 
1) MAP=CO*TPR and 2) CO=HR*SV (Levick, 2003). Previously, we have developed a 
mechanism-based linked turnover model to describe the inter-relationship between MAP, 
CO and TPR (Snelder et al., 2013a). This model consisted of two turnover equations, one 
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ing homeostatic feedback mechanisms such as the baroreflex system (Cleophas, 1998) 
(Equation 1).







in which , Kin_CO and Kin_TPR are the zero-order production rate constants and kout_CO and kout_TPR 
the first-order dissipation rate constants of CO and TPR respectively. These rate constants 
describe the time course of the effect onCO and TPR. FB1 and FB2 are constants characterizing 
the negative feedback of MAP on CO and TPR.  
 
In the present study, this model was extended by parsing CO into HR and SV. More precisely, the 
turnover equation for CO was replaced by two turnover equations for HR and SV (Figure 1). 
Therefore, the extended CVS model consisted of three linked turnover equations involving TPR, 
HR and SV all linked by negative feedback through MAP (Equation 2). In addition, a direct 
inverse relationship between HR and SV was included in the model representing the relationship 
between the cardiac interval and left ventricular filling time (LVFT), i.e. when HR increases, the 
cardiac interval decreases, and therefore, LVFT decreases and SV decreases (Equation 2).  
 








In these equations, SV* represents the SV influenced by the negative feedback of MAP, Kin_HR 






































In these equations, Kin_CO and Kin_TPR are the zero-order production rate constants and kout_CO 
and kout_TPR the first-order dissipation rate constants of CO and TPR respectively. These rate 
constants describe the time course of the effect onCO and TPR. FB1 and FB2 are constants 
characterizing the negative feedback of MAP on CO and TPR. 
In the present study, thi  model was exte ded by parsing CO into HR and SV. More pre-
cisely, the turnover equation for CO was replaced by two turnover equations for HR and 
SV (Figure 1). Therefore, the extended CVS model consisted of three linked turnover equa-
Figure 1: Comparison between the basic CVS model to characterize drug effects on the interrelationship between 
MAP, CO and TPR and the extend d CVS model to cha acterize drug ffects on the interrelationship between MAP, 
CO, HR, SV and TPR. 
Extended CVS model: Cardiac output (CO) equals the product of HR and SV (CO=HR*SV) and MAP equals the prod-
uct of CO and TPR (MAP=CO*TPR). SV is influenced by indirect feedback through MAP (SVT) and by HR through a 
direct inverse log-linear relationship, where HR_SV represents the magnitude of this direct effect. Effects on HR, SV 
and TPR are described by three linked turnover equations. In these equations Kin_HR, Kin_SV and Kin_TPR represent the 
zero-order production rate constants and kout_HR, kout_SV and kout_TPR represent the first-order dissipation rate constants. 
When MAP increases as a result of a stimulating effect on HR, SV or TPR, the values of HR, SV and TPR will decrease 
as a result of the action of the different feedback mechanisms regulating the CVS. In this model the magnitude 
of feedback on HR, SV and TPR is represented by FB. System-specific parameters are indicated in black and drug-
specific parameters are indicated in dark grey.
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tions involving TPR, HR and SV all linked by negative feedback through MAP (Equation 2). 
In addition, a direct inverse relationship between HR and SV was included in the model 
representing the relationship between the cardiac interval and left ventricular filling time 
(LVFT), i.e. when HR increases, the cardiac interval decreases, and therefore, LVFT de-
creases and SV decreases (Equation 2). 







in which , Kin_CO and Kin_TPR are the zero-order production rate constants and kout_CO and kout_TPR 
the first-order dissipation rate constants of CO and TPR respectively. These rate constants 
describe the time course of the effect onCO and TPR. FB1 and FB2 are constants characterizing 
the negative feedback of MAP on CO and TPR.  
 
In the present study, this model was extended by parsing CO into HR and SV. More precisely, the 
turnover equation for CO was replaced by two turnover equations for HR and SV (Figure 1). 
Therefore, the extended CVS model consisted of three linked turnover equations involving TPR, 
HR and SV all linked by negative feedback through MAP (Equation 2). In addition, a direct 
inverse relationship between HR and SV was included in the model representing the relationship 
between the cardiac interval and left ventricular filling time (LVFT), i.e. when HR increases, the 
cardiac interval decreases, and therefore, LVFT decreases and SV decreases (Equation 2).  
 








In these equations, SV* represents the SV influenced by the negative feedback of MAP, Kin_HR 






































In these equations, SV* represents the SV influenced by the negative feedback of MAP, 
Kin_HR and Kin_SV represent the z ro-order production rat  constants and kout_HR and kout_SV 
and represent the first-order dissipation rate constants of HR, SV and TPR, respectively. 
These hypothetical production and dissipation rate constants reflect the rate of change 
in HR, SV and TPR. FB is a constant representing the magnitude of the negative feedback 
of MAP on HR, SV and TPR and HR_SV is a constant that represents the magnitude of the 
direct effect of HR and SV. Following the criteria for statistical significance as specified in 
the section “Computation”, a linear relationship between MAP and the production rate 
constants of HR, SV and TPR and a log-linear relationship between HR and SV were the 
most parsimonious relationships that adequately captured the feedback mechanism and 
the direct inverse relationship between HR and SV, respectively.  
The circadian rhythm, which was observed in all 5 parameters of the CVS, was described 
by two cosine functions, one influencing Kin_HR and one influencing Kin_TPR (Equation 3). As a 
result of the feedback through MAP this model also describes the circadian rhythm in SV, 
CO and MAP in addition to that of HR and TPR.
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the first-order dissipation rate constants of HR, SV and TPR, respectively. These hypothetical 
production and dissipation rate constants reflect the rate of change in HR, SV and TPR. FB is a 
constant representing the magnitude of the negative feedback of MAP on HR, SV and TPR and 
HR_SV is a constant that represents the magnitude of the direct effect of HR and SV. Following 
the criteria for statistical significance as specified in the section “Computation”, a linear 
relationship between MAP and the production rate constants of HR, SV and TPR and a log-linear 
relationship between HR and SV were the most parsimonious relationships that adequately 
captured the feedback mechanism and the direct inverse relationship between HR and SV, 
respectively.   
 
The circadian rhythm, which was observed in all 5 parameters of the CVS, was described by two 
cosine functions, one influencing Kin_HR and one influencing Kin_TPR (Equation 3). As a result of the 
feedback through MAP this model also describes the circadian rhythm in SV, CO and MAP in 












In these equations, the parameter amp is the amplitude, t is the time and hor is the horizontal 
displacement of the physiological variable over time.  
 
Brief manual restraint and oral dose administration either directly or indirectly (i.e., sensed by a 








































In these equations, the parameter amp is the amplitude, t is the time and hor is the 
horizontal displacement of the physiological variable over time. 
Brief manual restraint and oral dose administration either directly or indirectly (i.e., 
sensed by a bystander rat in the same room) caused a temporary increase in HR, TPR, CO 
and MAP and decrease in SV that was independent of drug exposure. This handling effect 
was described by an empirical function HD (Visser et al., 2006) influencing the Kin_HR and 
Kin_TPR (Equation 4).
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decrease in SV th t was independe t of drug expos re. Thi  handl ng effect was described by an 
empirical function HD (Visser et al., 2006) influencing the Kin_HR and Kin_TPR (Equation 4). 







In this equation, PHR and PTPR determine the magnitudes of the handling effect on HR and TPR 
respectively, kHD determines the rate of disappearance of the handling effect and tHD equals the 
time of handling. 
 
At baseline, before drug administration, the system is in oscillating steady state. This means that 
the values of the parameters oscillate around their baseline values. For turnover models it is 
common practice to derive the steady-state conditions and to express Kin in terms of BSL and kout 
(Dayneka et al., 1993). For this system the steady-state conditions for the oscillating steady state 
cannot be derived analytically. Therefore, Kin was expressed in terms of BSL and kout without 
accounting for the circadian rhythm (Equation 5). To ensure that the system is in oscillating 
steady state at start of pharmacological intervention the observations where shifted two weeks 
(determined empirically), i.e. the system was initialized at time=0 h and the pharmacological 
interventions started at time=336 h.  
   























































In this equation, PHR and PTPR determine the magnitudes of the handling effect on HR and 
TPR respectively, kHD determines the rate of disappearance of the handling effect and tHD 
equals the time of handling.
At baseline, before drug administration, the system is in oscillating steady state. This 
means that the values of the parameters oscillate around their baseline values. For turn-
over models it is common practice to derive the steady-state conditions and to express Kin 
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in terms of BSL and kout (Dayneka et al., 1993). For this system the steady-state conditions 
for the oscillating steady state cannot be derived analytically. Therefore, Kin was expressed 
in terms of BSL and kout without accounting for the circadian rhythm (Equation 5). To en-
sure that the system is in oscillating steady state at start of pharmacological intervention 
the observations where shifted two weeks (determined empirically), i.e. the system was 
initialized at time=0 h and the pharmacological interventions started at time=336 h. 
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decrease in SV that was independent of drug exposure. This handling effect was described by an 
empirical function HD (Visser et al., 2006) influencing the Kin_HR and Kin_TPR (Equation 4). 
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In this equation, BSL_HR, BSL_SV and BSL_TPR represent the baseline values of HR, SV 
and TPR, respectively. In the experiments, SV and TPR were derived from the directly 
measured MAP, CO and HR. Therefore, in the modeling, the BSL_MAP and BSL_CO and 
BSL_HR were estimated and BSL_SV and BSL_TPR were derived from these parameters.
To functionally characterize the system, eight different drugs with different mechanisms 
of action were administered. In the analysis of the data, it was assumed that the drugs 
(EFF) influence the production rates of HR, SV or TPR according to Equation 6.
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In this equation, BSL_HR, BSL_SV and BSL_TPR represent the baseline values of HR, SV and 
TPR, respectively. In the experiments, SV and TPR were derived from the directly measured 
MAP, CO and HR. Therefore, in the modeling, the BSL_MAP and BSL_CO and BSL_HR were 
es imated and BSL SV and BSL_TPR were d rived from the  parameters.
 
To functionally characterize the system, eight different drugs with different mechanisms of action 
were administered. In th  analysis of the data, it was assumed that the drugs (EFF) influence the 
production rates of HR, SV or TPR according to Equation 6. 
      
  (6) 
 
 
The time course of the drug plasma concentrations, i.e., the pharmacokinetics (PK), rather than 
the dose, was used as a predictor for the pharmacodynamics (PD). This enables an accurate 
description of the time course of the drug effect. For that purpose predicted plasma concentration 
versus time profiles were used, which were derived from the literature (Table 3). However, for 
atropine and prazosin the administration route was different in these literature studies 
(intravenous administration) as compared to the experiments described in this paper (oral 
administration). Therefore, for these compounds the absorption rate was estimated based on the 
time course of the effect on BP in conjunction with the relevant information on the 
pharmacokinetics from the literature (Table 3). For atropine and prazosin, PK and PD parameters 
were estimated simultaneously.  
 
The concentration-effect relations for the drug effects on HR, SV and TPR were evaluated using 


















The time course of the drug plasma concentrations, i.e., the pharmacokinetics (PK), rather 
than the dose, was used as a predictor for the pharmacodynamics (PD). This enables an 
accurate description of the time course of the drug effect. For that purpose predicted 
pla ma concentration versus time profiles were used, which were derived from the itera-
ture (Table 3). However, for atropine and prazosin the administration route was different 
in these literature studies (intravenous administration) as compared to the experiments 
described in this paper (oral administration). Therefore, for these compounds the ab-
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Table 3: Specification of the PK models to describe the pharmacokinetics of the six selected compounds, enalapril, 
fasudil, amlodipine, prazosin, propranolol and HCTZ to challenge the CVS. The PK models were based on literature 
models. The adjustments required to account for the differences in experimental conditions and formulations in 
these literature studies as compared to the experiments described in this paper are described in the “Comments” 
column.
Compound PK model Literature model Comments Species
amiloride 2-compartmental 
model with liver 
compartment






(Stopher et al., 1988): Non-
compartmental analysis
Ka was derived from 
the reported half-life, 






(Perlstein et al., 2002) 
2-compartmental model







(Lin et al., 1988)
and (Li et al., 2007)
Data read out from 
the manuscripts and 
a 2- compartmental 
model with Michaelis-
Menten elimination 






(Ikegaki et al., 2001): 
Non-compartmental 
analysis
Ka and lag-time were 
derived from the 
reported half-life, 





(Asdaq and Inamdar, 2009): 
1-compartmental model
Reported: Ke, Ka, 
Vd, AUC -> F was 





(Hamilton et al., 1985): 
1-compartmental model
CL, Vd; scaled to 
rat using allometric 






(van Steeg et al., 2010) and 




parameters were fixed 
to van Steeg et al.. 
Ka was estimated in 
NONMEM using data 










sorption rate was estimated based on the time course of the effect on BP in conjunction 
with the relevant information on the pharmacokinetics from the literature (Table 3). For 
atropine and prazosin, PK and PD parameters were estimated simultaneously. 
The concentration-effect relations for the drug effects on HR, SV and TPR were evaluated 
using linear, power, Emax or Sigmoid Emax pharmacodynamic models (Equation 7).
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In this equation, EFF represents the effect at concentration C. SL, Emax, EC50 and γ represent the 
slope of the linear relationship, the maximum effect, the concentration at which half of the 
maximum effect is achieved and the Hill coefficient (sigmoidicity parameter), respectively. 
 
For the basic CVS model we have presented an equation to calculate TPR and CO at steady 
state during pharmacological intervention. For the extended CVS model there is no analytical 
solution for the steady-state values during pharmacological intervention. However, these values 
can be simulated from the final model by using the steady-state concentration Css.
  
The proposed model assumes that the time delay between concentration and effect (hysteresis) 
is the same for all classes of compounds influencing a certain effect site, i.e. HR, SV or TPR. To 
evaluate this assumption, for each compound it was investigated if there was an additional delay 
between concentration and effect by re-evaluating the proposed model with an extra hypothetical 
effect compartment (Equation 8). 
        
      (8) 
 
In this equation, C and Ce represent the plasma concentration and the concentration in the 
hypothetical effect compartment, respectively, and ke0 represents the first order rate constant 
describing drug transport. This approach implies that at equilibrium C equals Ce. A significant 
improvement of the goodness of fit after the addition of an effect compartment indicates that there 
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e ⋅=  (8)
In this equation, C and Ce represent the plasma concentration and the concentration in 
the hypothetical effect compartment, respectively, and ke0 represents the first order rate 
constant describing drug tr nsport. This approach implies that at quilibrium C equals Ce.
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A significant improvement of the goodness of fit after the addition of an effect compart-
ment indicates that there is a difference in temporal delay between plasma concentration 
and effect between different classes of drugs influencing the same parameter (HR, SV or 
TPR).
The PK and PD models were based on the assumptions described in Table 4 and discussed 
by Snelder et al. (Snelder et al., 2013a). 
SHR versus WKY rats
The difference in BP regulation between hypertensive SHR and normotensive WKY rats 
was investigated by evaluating the system parameters per strain under the assumption 
that the structural model was the same for SHR and WKY rats. In addition, as the level 
of baseline BP, which is known to differ between and within strains (Louis et al., 1990), is 
continuously and proportionally related to cardiovascular risk (Pinto et al., 1998), it was 
investigated if continuous relationships between BSL_MAP and the system parameters 
could be identified. Linear and power relationships were investigated.
System properties
To investigate if the profiles of the time-course of the drug effect on MAP, CO, HR, SV and 
TPR are different for compounds with a direct effect on HR, SV or TPR respectively, simula-
tions were performed. The obtained simulated profiles of the time course of the change 
in MAP, CO, HR, SV and TPR are referred to as signature profiles. Distinct differences in 
the signature profiles for compounds with an effect on HR, SV or TPR indicate that the 
extended CVS model can be applied to identify the site of action (HR, SV or TPR) of novel 
compounds with an unknown MoA on BP. The time courses of the effects on MAP, CO, HR, 
Table 4: Model assumptions
no. Assumption Clarification
1 All compounds influence the production rates of HR, SV or TPR rather than the dissipation rates.
This assumption is based on the MoA of the se-
lected compounds (Table 1).
2
For compounds for which the maximum effect was 
not observed, complete inhibition (i.e., Emax = 1) 
was assumed at infinite concentrations to ensure 
identification of the EC50 parameter. 
The validity of this assumption was evaluated for 
amlodipine using the basic CVS model (Snelder et 
al., 2013a). The influence of different values of the 
Emax (i.e. Emax =0.8) on the estimates of the system 
parameters was tested. 
3
The PK do not differ between rat strains and can 
be scaled between rabbit and rat on the basis 
of an allometric function (West 1999; Anderson, 
2009).
Although published information on the PK of all 
selected compounds was available, the PK was 
often evaluated in different rat strains and, for 
prazosin, even in a different species (rabbit). 
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SV and TPR were simulated after triggering the model by inhibiting HR, SV or TPR with a 
hypothetical compound after a single oral dose.
HR and MAP measurements only
Previously, it was demonstrated that measuring CO is pivotal for characterizing the sys-
tem (Snelder et al., 2013a). However, at present, the measurement of CO is not common 
practice, due to the technical difficulties of these invasive instrumentation procedures 
(Doursout et al., 2001). Therefore, the question arises if the extended CVS model, which 
was developed using MAP, HR and CO measurements, can be used to quantify the dy-
namic changes in the CVS and elucidate the MoA for novel compounds using HR and 
MAP measurements only. This was investigated using the data from the compounds from 
Table 2. These data were also used for model development and, therefore, for estimation 
of the system specific parameters. Hence it seems obvious that the drug effects of these 
compounds can be quantified using the extended CVS model. However, for model devel-
opment, the site of action was assumed to be known (Table 1). Moreover, MAP, CO, HR, 
SV and TPR measurements were used to quantify the drug effects. Therefore, the question 
remains if the site of action and the drug effect of each compound on HR and MAP can be 
quantified using a limited amount of data (i.e., only HR and MAP measurements). For each 
compound, a model-based hypothesis testing procedure was followed using the extended 
CVS model with the system-specific parameters fixed to values from Table 5.
1) Different hypotheses of the site of action (i.e. HR, SV and TPR) and direction of the 
effect (i.e., inhibiting or stimulating) were formulated, resulting in 6 possible combina-
tions of effects. 
2) For each hypothesis, the model was fitted to the HR and MAP measurements.
3) It was evaluated which hypothesis resulted in the best description of the data as judged 
by the agreement between the observed and predicted direction and magnitude of 
effect and the lowest minimum value of the objective function (MVOF) as specified in 
the section “Computation”.
Since not all compounds were investigated in WKY rat, only data from SHR were used.
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Table 5: The system- and drug-specific parameter values from the extended drug-independent model to describe 
the CVS.
Parameter Value RSE LLCI ULCI
System-specific parameters     
BSL_HR_SHR (beats/min) 310 1.12 303 317
BSL_MAP_SHR (mmHg) 155 0.684 153 157
BSL_CO_SHR (mL/min) 69.0 4.17 63.4 74.6
BSL_HR _WKY(beats/min) 323 1.61 313 333
BSL_MAP_WKY (mmHg) 102 0.884 100 104
BSL_CO_WKY (mL/min) 129 1.47 125 133
kout_HR (1/h) 11.6 19.1 7.27 15.9
kout_SV (1/h) 0.126 30.7 0.0501 0.202
kout_TPR (1/h) 3.58 29.1 1.54 5.62
FB0 (1/mmHg) 0.00290 5.93 0.00256 0.00324
FB0_MAP -1.98 10.6 -2.39 -1.57
HR_SV 0.312 15.6 0.216 0.408
kHD (1/h) 4.70 8.19 3.95 5.45
PHR 0.632 9.67 0.512 0.752
PTPR 0.331 12.9 0.247 0.415
horHR (h) 8.73 3.10 8.20 9.26
ampHR 0.0918 5.15 0.0825 0.101
horTPR (h) 19.3 1.92 18.6 20.0
ampTPR Fixed to ampHR
Drug-specific parameters     
amiloride: Emax model with Emax fixed to 1
EC50 (ng/mL) 245 25.1 125 365
amlodipine: Emax model with Emax fixed to 1
EC50 (ng/mL) 82.8 4.99 74.7 90.9
atropine: linear model
SL (1/(ng/mL)) 0.00149 32.3 0.000547 0.00243
Ka (1/h) 1.17 59.9 -0.204 2.54
enalapril: Emax model with Emax fixed to 1
EC50 (ng/mL) 1200 4.03 1110 1290
ke0 (1/h) 0.163 5.07 0.147 0.179
fasudil: Emax model with Emax fixed to 1
EC50 (ng/mL) 0.172 18.4 0.110 0.234
HCTZ: Emax model with Emax fixed to 1
EC50 (ng/mL) 28900 7.65 24600 33200
prazosin: power model
SL (1/(ng/mL)) 0.328 5.58 0.292 0.364
POW 0.0910 6.05 0.0802 0.102
     
Inter-Individual variability     
BSL_HR (CV%) 6.1 4.36 7.47
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The data from Studies 1 and 2 were simultaneously analyzed using a non-linear mixed-
effects modeling approach implemented in NONMEM (version 7.2.0; Icon Development 
Solutions, Ellicott City, Maryland, USA). The models were compiled using Digital Fortran 
(version 6.6C3, Compaq Computer Corporation, Houston, Texas) and executed on a PC 
equipped with an AMD Athlon 64 processor 3200+ under Windows XP. The results from 
the NONMEM analysis were subsequently analyzed using the statistical software package 
S-Plus for Windows (version 8.0 Professional, Insightful Corp., Seattle, USA). Modeling 
techniques were detailed by Snelder et al. (Snelder et al., 2013a). Goodness-of-fit was 
determined using the MVOF defined as minus twice the log-likelihood. For nested models, 
a decrease of 10.8 points in the MVOF (corresponding to p<0.001 in a chi-squared distri-
bution) by adding an additional parameter was considered significant. The goodness-of 
fit was also investigated by visual inspection of the plots of individual predictions and the 
diagnostic plots of (weighted) residuals (Snelder et al., 2013a). 
Results
The extended CVS model as expressed by Equations 2 - 8 and as shown graphically in 
Figure 1 was used to simultaneously analyze the data from Studies 1 and 2. In the analysis, 
inter-individual variation in the baseline values of the parameters, BSL_HR, BSL_MAP and 
BSL_CO, was allowed (inter-individual variability (IIV)). The residual errors of HR, MAP and 
CO were best described by proportional residual error models. The residual errors of TPR 
and SV were derived from these parameters. 
Table 5 Continued
Parameter Value RSE LLCI ULCI
BSL_MAP (CV%) 3.7 2.67 4.49
BSL_CO (CV%) 22.7 18.09 26.57
     
Residual variability     
Prop. Res.ErrorHR (CV%) 7.8 7.26 8.22
Prop. Res.ErrorMAP (CV%) 6.0 5.44 6.57
Prop. Res.ErrorCO (CV%) 6.9  5.72 7.83
RSE: Relative standard error of parameter estimate
CV: Coefficient of variation
LLCI: Lower limit of 95 % confidence interval
ULCI: Upper limit of 95 % confidence interval
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Figure 2: Description of the handling effect 
and circadian rhythm in MAP, HR, CO, SV 
and TPR in SHR (plot A) and WKY rats (plot 
B) after vehicle administration. Data are 
from Study 1 and Study 2 from all treatment 
groups. 
Handling of the rats caused a temporary in-
crease in HR, TPR, CO and MAP and decrease 
in SV that was independent of drug expo-
sure. The handling effect is visible at 10 AM, 
i.e. when the rats were dosed with vehicle 
as indicated by the arrows.2 SHR were also 
dosed at 1PM (not indicated in the plot). The 
grey dots represent the observations, which 
are connected by the continuous grey lines, 
the dashed black lines represent the mean 
of the observations and the continuous 
black lines represent the population predic-
tion by the developed extended CVS model. 
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SHR versus WKY rats
The baseline parameters were found to differ per strain with a higher BSL_MAP and a 
lower BSL_CO for SHR as compared to WKY rats, whereas BSL_HR did not significantly 
differ between the strains (Table 5). BSL_SV and BSL_TPR were derived from these param-
eters, resulting in a lower BSL_SV and a higher BSL_TPR for SHR as compared to WKY rats.
In addition, for both SHR and WKY rats FB was found to decrease with BSL_MAP according 
to the following relationship (Equation 9): 
Chapter 4 – Extended CVS model 
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               (9) 
 
In this equation, FB0, FB0_MAP, IBSL_ MAP and TVBSL_MAP_SHR represent the feedback for 
a typical SHR rat, the exponent of the power relationship, the individual baseline values of MAP 
and typical value of BSL_MAP in SHR, respectively. Overall, the feedback is about 2-fold higher 
in WKY rats as compared to SHR. Based on statistical grounds this model was preferred over a 
model with FB estimated per strain. 
 
Vehicle response 
The response in the p.o. vehicle groups is characterized by circadian variation and a handling 
effect. The handling effect, which is visible at 3 hours, was adequately described by Equation 4 
(Figure 2). The circadian rhythm, which was observed in all 5 parameters of the CVS, was 
adequately described by two cosine functions influencing Kin-HR and Kin-TPR in both SHR (Figure 
2A) and WKY rats (Figure 2B). However, on two out five occasions CO is under-predicted 
between 3 and 5 hours in WKY rats. In addition, in WKY rats CO is slightly under-predicted on a 
population level. As TPR is derived from MAP and CO, TPR is slightly over-predicted on a 
population level. The amplitudes of the 2 cosine functions, i.e. ampHR and ampTPR , could not be 
distinguished and were estimated to be 0.09 indicating that the variation in Kin_HR and Kin_TPR is 
maximally 9% during the day. The horizontal displacement parameters of the 2 cosine functions, 
i.e horHR and horTPR, were significantly different, even if one of the cosines would have been 
replaced by a sine (i.e. a shift of 12 hours) (Table 5). In addition, omitting one of the cosine 




For prazosin, the absorption rate parameter (Ka) was found to be very high and could not be 










In this equation, FB0, FB0_MAP, IBSL_ MAP and TVBSL_MAP_SHR represent the feedback 
for a typical SHR, the exponent of the power relationship, the individual baseline values 
of MAP and typical value of BSL_MAP in SHR, respectively. Overall, the feedback is about 
2-fold higher in WKY rats as compared to SHR. Based on statistical grounds this model was 
preferred over a model with FB estimated per strain.
Vehicle response
The response in the p.o. vehicle groups is characterized by circadian variation and a han-
dling effect. The handling effect, which is visible at 3 hours, was adequately described by 
Equation 4 (Figure 2). The circadian rhythm, which was observed in all 5 parameters of 
the CVS, was adequately described by two cosine functions influencing Kin-HR and Kin-TPR in 
both SHR (Figure 2A) and WKY rats (Figure 2B). However, on two out five occasions CO is 
under-predicted between 3 and 5 hours in WKY rats. In addition, in WKY rats CO is slightly 
under-predicted on a population level. As TPR is derived from MAP and CO, TPR i  slightly 
over-predicted on a population level. The amplitudes of the 2 cosine functions, i.e. ampHR 
and ampTPR , could not be distinguished and were estimated to be 0.09 indicating that the 
variation in Kin_HR and Kin_TPR is maximally 9% during the day. The horizontal displacement 
parameters of the 2 cosine functions, i.e horHR and horTPR, were significantly different, even 
if one of the cosines would have been replaced by a sine (i.e. a shift of 12 hours) (Table 5). 
In addition, omitting one of the cosine functions resulted in a decrease in the goodness of 
fit indicated by a significant increase in the MVOF.
Drug effects
For prazosin, the absorption rate parameter (Ka) was found to be very high and could 
not be estimated with good precision. Therefore, for this compound Ka was fixed to a 
high value (99 1/h) prior to estimating the other model parameters. Overall, fixing Ka re-
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Figure 3: Description of the effects of 
amlodipine in SHR (plot A) and WKY rats 
(plot B). Data are from Study 1, in which 
vehicle and a different dose of amlodip-
ine (0.3, 1, 3 and 10 mg/kg p.o.) were 
administered on separate days.
Amlodipine has an inhibiting effect on 
TPR. Therefore, TPR decreases after ad-
ministration of amlodipine. As a result 
of the indirect feedback HR, SV and CO 
increase. In addition, the initial decrease 
SV is related to the direct inverse relation-
ship between HR and SV. MAP changes 
in the same direction as the initial ef-
fect, i.e. MAP decreases. The grey and 
black dots represent the observations of 
two different rats. The continuous and 
dashed lines represent the individual and 
population prediction by the developed 




sulted in a reduction of runtimes as correlations between drug-specific parameters were 
removed. For atropine, Ka was estimated simultaneously with the PD. The poor precision 
of the estimate with a standard error of 59.9% (Table 5) was considered acceptable as 
system-specific parameters were not influenced by this parameter (results not shown). 
This was demonstrated by successively removing data from one of the compounds that 
were used for model development according to the methods as detailed by Snelder et al. 
(Snelder et al., 2013a). 
The concentration-effect relationships for amiloride, amlodipine, enalapril, fasudil and 
HCTZ were best described by Emax models. As described previously (Snelder et al., 2013a), 
Emax was fixed to 1 for these compounds and EC50 was estimated. Enalapril was found to in-
fluence both TPR and SV with the same EC50. Initially, different EC50 values were estimated. 
However, confidence intervals overlapped indicating that the EC50 values for the two ef-
fects could not be distinguished. In addition to the turnover equations (Equation 2), an 
effect compartment was used to describe the delay between change in enalapril plasma 
concentration and the effect on TPR and SV. The half-life of this additional delay was 4.3h. 
The effect of atropine was best described by a linear concentration-effect relationship. As 
atropine had a stimulating effect on Kin _HR applying a linear concentration-effect relation-
ship did not result in problems with parameter optimization. The effect of prazosin was 
best described by a power model. The exponent of this relationship was low (0.0910) 
indicating that the maximum effect is not reached for the highest dose evaluated. Finally, 
the effect of propranolol was too small to be quantified. 
In general, the data were adequately described by the model (Figure 3 and Supplemental 
Figures A and B). Except for the absorption rate of atropine, all system- and drug-specific 
parameters could be estimated with good precision as all standard errors were less than 
50% of the parameter estimates (Table 5). In addition, all parameter correlations were 
below 0.85. 
System properties
In the simulations, distinct differences between the signature profiles of MAP, CO, HR, SV 
and TPR were observed for direct drug effects on HR, SV and TPR, respectively. Specifi-
cally, in the simulations it was shown that inhibition of HR, SV or TPR always results in a 
decrease in MAP, demonstrating that homeostatic feedback cannot be stronger than the 
primary effect (Figure 4). Interestingly, the delay between the stimulus and the response 
on MAP was longer in case the drug effect was on SV as compared to TPR. 
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HR and MAP measurements only
For each compound, it was investigated if the developed extended CVS model could be 
used to quantify the dynamic changes in the CVS and indentify the site of action (HR, SV or 
TPR) using HR and MAP measurements only. Amlodipine was selected as a paradigm com-
pound to illustrate the results of this analysis. Assuming a stimulating effect of amlodipine 
on HR resulted in an adequate description of the effect on HR. However, the description of 
the effect on MAP was inadequate as the directions of the observed and predicted effects 
were opposite (Figure 5). Assuming an inhibiting effect of amlodipine on SV resulted in 
an adequate description of the effect on HR and a reasonable description of the effect on 
MAP (Figure 5). However, the delay in effect on MAP was over-predicted. Finally, assum-
ing an inhibiting effect of amlodipine on TPR resulted in an adequate description of the 
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Figure 4: System properties of the CVS
The system properties of the CVS were investigated by simulating the response on MAP, CO, HR and TPR after inhib-
iting HR (A), SV (B) or TPR (C). Inhibiting HR, SV or TPR always results in a decrease in MAP, which demonstrates that 
feedback cannot be stronger than the primary effect. In addition, the delay in response on MAP was longer when 
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Figure 5: Description of the effects of amlodipine on MAP and HR using the extended CVS model with the system-
specific parameters fixed to values from Table 5, while assuming a stimulating effect on HR (A), an inhibiting effect 
on SV (B) or an inhibiting effect on TPR (C). Data are from Study 1, in which vehicle and a different dose of amlodip-
ine (0.3, 1, 3 and 10 mg/kg p.o.) were administered on separate days. 
To evaluate if the site of action of amlodipine can be identified using MAP and HR measurements only, three hy-
potheses were evaluated. A) Hypothesizing a stimulating effect on HR resulted in an adequate description of the 
effect on HR. However, the description of the effect on MAP was inadequate as the directions of the observed and 
predicted effects were opposite. B) Hypothesizing an inhibiting effect of amlodipine on SV resulted in an adequate 
description of the effect on HR and a reasonable description of the effect on MAP. However, the delay in effect on 
MAP was over-predicted. C) Hypothesizing an inhibiting effect of amlodipine on TPR resulted in an adequate de-
scription of the effect on HR and MAP. In conclusion, model-based hypothesis testing indicated that it is most likely 
that the effect of amlodipine is on TPR, which is consistent with the available information from the literature. This 
indicated the MoA of a compound can be elucidated using MAP and HR measurements only. The grey and black 
dots represent the observations of two different rats. The continuous and dashed lines represent the individual and 
population prediction.
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described assuming an inhibiting effect on TPR, which was confirmed by a significantly 
lower MVOF for the model with an effect on TPR as compared to the models with an effect 
on HR or SV. The estimated EC50 (84.9 [confidence interval (CI): 75.4–94.4] ng/mL) did not 
differ significantly from the estimated EC50 from the final extended CVS model (82.8 [CI: 
74.7–90.9] ng/mL). 
The effects of fasudil and prazosin on HR and MAP were best described assuming inhibi-
tion of TPR (results not shown). For amiloride, HCTZ and enalapril the effect on HR and 
MAP were best described following inhibition of SV (results not shown). Finally, the effect 
of atropine was best described by stimulating HR (results not shown). As the effect of 
propranolol was too small to be quantified, propranolol was omitted from this analysis. 
For all compounds the estimated drug-specific parameters did not differ significantly from 
the drug-specific parameters estimated by the final extended CVS model.
Discussion
Previously, a systems pharmacology model was developed that integrated a quantitative 
description of the physiology of the interrelationship between MAP, CO and TPR and the 
pharmacological effects of cardiovascular drugs in SHR (Snelder et al., 2013a). This model 
can be applied for elucidation of the MoA of novel compounds, but this requires continu-
ous recording of MAP and CO. Measuring CO has not been integrated into daily practice 
due to the challenges associated with invasive instrumentation procedures (Doursout et 
al., 2001). Therefore, the aim of this research was to evaluate if the MoA of new com-
pounds can be elucidated using HR and MAP measurements only.
 
First, the basic CVS model was extended by parsing CO into HR and SV. This extension 
was successfully established since 1) all drug-effects of compounds with different MoA’s 
were adequately described, 2) all system-specific parameters were estimated with good 
precision and 3) drug- and system-specific parameters were not correlated. Distinguishing 
drug- from system-specific properties is essential for mechanism-based PKPD modeling 
(Danhof et al., 2007; Ploeger et al., 2009) and enables the prediction of treatment effects 
to later stages of development using a translational modeling approach (Danhof et al., 
2008), which is an ultimate application of the developed quantitative systems pharmacol-
ogy model. The system-specific parameters of the extended CVS model were comparable 
to the system-specific parameters of the basic CVS model (Snelder et al., 2013a) except for 
kout_TPR, which was about 10 fold higher in the extended CVS model. This may be explained 
by the fact that in the basic CVS model kout_TPR and FB2 (feedback of MAP on TPR) were 
highly correlated (-0.984) indicating that these parameters could not be distinguished. In 
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the current model, the feedback parameters representing the magnitude of the feedback 
of MAP on HR, SV and TPR could not be distinguished. Therefore, only one feedback pa-
rameter could be estimated. As FB2 was a little higher than FB this could well explain the 
difference in kout_TPR between the two models. 
SHR versus WKY rats
A secondary aim of this research was to quantify possible differences in BP regulation 
between hypertensive and normotensive rats. This is important as normotensive rats are 
often used for safety evaluation and are thought to be more predictive for the effects in 
human with normal BP than hypertensive rats. As expected, the baseline parameters were 
found to differ per strain with a higher BSL_MAP and a lower BSL_CO for SHR as compared 
to WKY rats (Table 5). In addition, FB decreased with higher BSL_MAP indicating impaired 
BP regulation in hypertensive rats. Similar findings were reported by Francheteau et al. 
regarding BP regulation in humans (Francheteau et al., 1993). They hypothesized that the 
effect of dihydropyridine drugs in hypertensive patients can be adequately predicted by 
assuming different baselines and lower feedback relative to normotensive subjects. 
The relationship between FB and BSL_MAP was described by a hyperbolic function. It 
should be noted that this function is purely descriptive and was based on data from only 
10 SHR and 2 WKY rats. Therefore, further research is required to establish the precise 
relationship between FB and BSL_MAP. 
Vehicle response 
The under-prediction of CO between 3 and 5 hours in WKY rats is a result of a large and 
highly variable handling effect. Since including inter-occasion variability, which describes 
the variability of a parameter within a rat from one occasion to another, in the model 
did improve the description of the data on an individual level, but did not influence the 
estimates of the structural parameters this bias was accepted. In addition, the under-
prediction of CO on a population level in WKY rats is a result of the fact that the population 
prediction is based on the observations from all rats, including the observations following 
active treatment, and the observed baselines of the rats following vehicle administration 
are in the tail of the overall baseline distribution, which is thought to be chance finding 
that is related to the low number of WKY rats included in the study.
Drug effects
As the PK was not measured in these experiments, predicted plasma concentration versus 
time profiles were derived from the literature (Table 3). As discussed previously (Snelder 
et al., 2013a), the assumptions made regarding the use of PK models derived from pub-
lished results may have a large impact on the PK profiles. Therefore, the PK models were 
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descriptive and the PK and drug-specific PD parameters should only be interpreted in the 
context of this model. The effects of all compounds were adequately described by the 
extended CVS model. However, the effect of propranolol was too small to be quantified. 
Therefore, propranolol did not contribute to the identification of the system-parameters. 
Enalapril was found to influence TPR and SV with the same EC50. In our previous research 
less detailed information on the effect of enalapril on the CVS was available as CO was 
not measured at that stage (Snelder et al., 2013a). Therefore, only the primary effect of 
enalapril on TPR was included in the model. Enalapril is an angiotensin-converting enzyme, 
which influences TPR and SV through the RAAS (see Table 1 for a description of the MoA). 
Therefore, the effect of this compound is delayed in comparison to the effect of calcium 
channel blockers or selective α1 adrenergic receptor blockers, which directly influence 
vascular smooth muscle cell contraction. This additional delay was described adequately 
by an effect compartment. From a mechanistic point of view a turnover model might be 
better as it has been demonstrated that the RAAS can be described by a set of turnover 
equations (Hong et al., 2008). However, as there was only one compound included in 
this research with an effect on the RAAS, the data did not contain enough information to 
characterize the RAAS in a mechanism-based manner. 
System properties
Clear differences were found between the signature profiles of MAP, CO, HR, SV and TPR 
after simulating drug effects on HR, SV and TPR (Figure 4). From these simulations it can 
be concluded that, even if CO is not measured, it is likely that the extended CVS model can 
be used to elucidate the site of action of novel compounds with a simple MoA (i.e., one 
site of action). In summary, when the direction of the effect on HR and MAP is the same, 
the primary effect is on HR. When the direction of the effect on HR and MAP is opposite, 
the primary effect of the drug is on SV or TPR. Effects on SV and TPR can be distinguished 
by the delay between the perturbation and the effect on MAP, i.e. a long delay indicates 
that the primary effect is on SV and a short delay indicates that the primary effect is on 
TPR. These conclusions are based on data from eight different cardiovascular drugs. To 
further support these conclusions data from more compounds is required.  
HR and MAP measurements only and system properties
To further evaluate if the extended CVS model can be applied to elucidate the MoA of 
novel compounds using HR and MAP measurements only, the effect of each compound 
was quantified using the extended CVS model, while assuming different sites of action 
and different directions of the effects. For all compounds, the identified site of action 
was consistent with the available information on the MoA of the compounds (Table 1). 
However, the effect of enalapril on HR and MAP was best described after inhibiting SV, 
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whereas according to information from the literature enalapril influences both TPR and 
SV (Table 1). Evaluating a model that is structurally comparable to the final extended CVS 
model, but with a combined delayed inhibiting effect on TPR and SV, improved the good-
ness of fit (results not shown). However, without any prior knowledge it is foreseen that 
it may be difficult to identify the site of action of novel compounds with unknown and 
more complex MoA’s. Nevertheless, since the site of action of 6 out of 7 compounds was 
adequately characterized, and there are pronounced differences in signature profiles, it is 
anticipated that the extended CVS models can be applied to elucidate the MoA for novel 
compounds using HR and MAP measurements only. Before our model can be applied for 
that purpose, this conclusion should be validated using data from new compounds, i.e. 
compounds that were not used for model development, but with a known mechanism 
of action. Recently, the extended CVS model was applied to provide insights into the 
site of action of fingolimod (Snelder et al., 2013b), which is effective in the treatment 
of multiple scelerosis (Cohen et al., 2010), but is associated with cardiovascular effects 
(Kappos et al., 2006; Kappos et al., 2010). Results indicated that the active metabolite of 
fingolimod, fingolimod-phosphate (fingolimod-P), has an effect on TPR in rats, and it is 
likely that fingolimod-P also influences HR. This is in line with the available information 
on the mechanisms underlying the cardiovascular effects of fingolimod-P, which indicates 
that the model can also be applied to provide insights into the site of action of compounds 
with a more complex MoA. In addition, for all compounds, the estimated drug-specific 
parameters did not differ significantly from the estimated drug-specific parameters from 
the final extended CVS model. This implies that the model also can be used to predict 
the dynamics of the effects on CO, SV and TPR for novel compounds using HR and MAP 
measurements only.
In conclusion, the extended CVS model can be applied to elucidate the MoA and to quan-
tify drug-specific parameters for new compounds with desired and undesired effects on 
the CVS using HR and MAP measurements only, Applications of the developed model, 
using the identified set of system parameters, are limited to SHR and WKY rats. However, 
since a mechanism-based modeling approach was applied, it is foreseen that accurate 
extrapolation between different rat strains and from one species to another is possible 
(Danhof et al., 2008; Ploeger et al., 2009). This requires the differences in the values of 
the systems specific parameters between the different species to be known. An ultimate 
application of the extended CVS model would be to predict the change in the hemody-
namic parameters in humans based on preclinical data for newly developed compounds. 
However, before our model can be applied for that purpose, it is necessary to predict 
long-term blood pressure effects (Snelder et al., 2013a). Moreover, the model should be 
scaled to humans and validated on human MAP, HR and CO measurements.
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BSL_CO Baseline value of cardiac output
BSL_HR Baseline value of heart rate
BSL_MAP Baseline value of mean arterial pressure
BSL_SV Baseline value of stroke volume
BSL_TPR Baseline value of total peripheral resistance
C drug concentration in plasma
CO Cardiac output
CVS Cardiovascular system
Emax  Maximum effect
EC50 Concentration resulting in a half-maximal effect
FB  Negative feedback of mean arterial pressure 
FB0 Feedback of a typical subject





Kin_HR  Zero-order production rate constant of heart rate
Kin_SV Zero-order production rate constant of stroke volume
Kin_TPR Zero-order production rate constant of total peripheral resistance
kout_HR First-order dissipation rate constant of heart rate
kout_SV First-order dissipation rate constant of stroke volume
kout_TPR First-order dissipation rate constant of total peripheral resistance
LVFT Left ventricular filling time
MAP Mean arterial pressure
MC Methylcellulose
MoA Mechanisms of action










TPR Total peripheral resistance
WKY Wistar Kyoto rats
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Appendix
Figure A: Description of the effects of amiloride in SHR (plot A), enalapril in SHR (plot B), fasudil in SHR (plot C), 
HCTZ part a in SHR (plot D), HCTZ part b in SHR (plot E), HCTZ part a in WKY rats (plot F), prazosin in SHR (plot G) 
and prazosin in WKY rats (plot H). Data are from Study 1, in which vehicle and a different dose of amiloride (10 mg/
kg p.o.), enalapril (3, 10 and 30 mg/kg p.o.), fasudil (3, 10 and 30 mg/kg p.o.), HCTZ (part a: 1, 3, 0.1 and 0.3 mg/kg 
p.o; part b: 10 and 30 mg/kg p.o.) or prazosin (0.04, 0.2, 1 and 5 mg/kg p.o.) were administered on separate days.
Fasudil and prazosin have an inhibiting effect on TPR. Therefore, TPR decreases after administration of these com-
pounds. As a result of the indirect feedback HR and CO increase. SV first decreases due to the direct inverse relation-



































































































































































































































































Therefore, the influence on the parameters of the CVS is similar to the influence of fasudil and prazosin. However, 
as enalapril also has and inhibiting effect on SV the initial decrease is SV is not reversed by the indirect feedback. 
Amiloride and HCTZ have an inhibiting effect on SV. Therefore, SV and, consequently, CO, decrease after administra-
tion of these compounds. As a result of the indirect feedback HR and TPR increase. MAP changes in the same direc-
tion as the initial effect for all compounds. The dots represent the observations of different rats (colored in different 
shades of grey by rat). The continuous and dashed lines represent the individual and population predictions by the 
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0 12 24 0 12 24 0 12 24 0 12 24 0 12 24 0 12 24 
Time (h)
      vehicle       propranolol      atropine   1st propranolol 1st atropine  combination 
                                                                2nd atropine   2nd propranolol
Figure B: Description of the effects of atropine and propranolol. Data are from Study 2, in which atropine (10 mg/
kg) and/or propranolol (30 mg/kg) were administered alone, sequentially with a 3 hour interval or simultaneously 
on separate days.
Atropine has a stimulating effect on HR. Therefore, HR and, consequently, CO, increase after administration of at-
ropine. As a result of the indirect feedback SV and TPR decrease. MAP changes in the same direction as the initial 
effect. The effect of propranolol was too small to be quantified. The dots represent the observations of different rats 
(colored in different shades of grey by rat). The continuous and dashed lines represent the individual and population 
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Chapter 5 Pharmacokinetics of sphingosine kinase substrates
Summary
A complicating factor in the translational pharmacology of sphingosine 1-phosphate 
(S1P) agonists is that they exert their pharmacological effect through their respective 
phosphate metabolites, which are formed by the enzyme sphingosine kinase (S1PHK). In 
this investigation, we present a semi-mechanistic pharmacokinetic model for the inter-
conversion of S1PHK substrates and their respective phosphates in rats and humans with 
the aim of investigating whether characterization of the rate of phosphorylation in blood 
platelets constitutes a basis for interspecies scaling using fingolimod as a paradigm com-
pound. Data on the time course of fingolimod and fingolimod-phosphate (fingolimod-P) 
blood concentrations following intravenous and oral administration of fingolimod and/or 
fingolimod-P in rats and following oral administration of fingolimod in doses of 0.5, 1.25 
and 5 mg once daily in healthy volunteers were analyzed in conjunction with data on the ex 
vivo inter-conversion and blood-plasma distribution in rat and human blood, respectively. 
Integrating the data from the ex vivo and in vivo studies enabled prediction of fingolimod 
and fingolimod-P concentrations in plasma rather than blood, which are more relevant 
for predicting drug effects. Large interspecies differences in the rate of phosphorylation 
between rats and humans were quantified. In human, phosphorylation of fingolimod in 
the platelets was 4 times slower compared to rat, whereas the de-phosphorylation rates 
were comparable in both species. This partly explained the 12-fold over-prediction of 
fingolimod-P exposure in human when applying an allometric scaling approach on the 
developed rat model. Additionally, differences in pre-systemic phosphorylation should 




Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator, which is effective in the 
treatment of multiple sclerosis (Cohen et al., 2010). The active metabolite of fingolimod, 
fingolimod-phosphate (fingolimod-P) binds to 4 of the 5 subtypes of the S1P receptor 
(S1P1 and S1P3-5) with high affinity (0.3-3.1nM) (Mandala et al., 2002; Brinkmann, 2007; 
Brinkmann et al., 2004; Chun and Hartung, 2010). In contrast, the affinity of fingolimod 
for all S1P receptors is low (Hale et al., 2004; Albert et al., 2005). The phosphorylation 
of fingolimod is therefore a critical step in its pharmacological effect. With the discovery 
of fingolimod and the elucidation of its mechanism of action, the search for other S1P 
agonists with different pharmacokinetic (PK)-pharmacodynamic (PD) properties has been 
propelled. Currently available S1P agonists can be categorized into two classes: amino 
alcohol pro-drugs and second-generation direct agonists (Cusack and Stoffel, 2010). The 
first class of compounds, to which fingolimod belongs, owes it biological activity to phos-
phorylation by the enzyme sphingosine kinase (S1PHK) (Billich et al., 2003; Kihara and 
Igarashi, 2008; Kharel et al., 2005). There are important inter-species differences in the 
expression and function of S1PHK. In the rat, S1PHK is predominately expressed in the kid-
ney, spleen and liver tissue (Olivera et al., 1998). In humans, S1PHK1, which is one of the 
two S1PHK isoforms, is mainly expressed in lung and spleen, whereas the other isoform, 
S1PHK2, is predominantly expressed in liver and heart tissue (Liu et al., 2000; Paugh et 
al., 2003). These large inter-species differences complicate the prediction of exposure to 
phosphorylated S1P pro-drugs in humans using in vivo animal data. Therefore, an allome-
tric scaling approach, which does not consider inter-species differences in enzyme tissue 
distribution or enzyme activity, will not be applicable to S1P pro-drugs. Since an adequate 
characterization of the exposure in rat and human may be important for translational 
modeling (Danhof et al., 2008) a qualitative and quantitative understanding of differences 
in the PK of S1PHK substrates between rat and human must be considered.
 
Fingolimod is an interesting paradigm compound to investigate the pharmacokinetics 
of S1PHK substrates since the inter-conversion between fingolimod and its phosphate 
has been well investigated in several in vitro, in vivo and ex vivo studies (Albert et al., 
2005; Billich et al., 2003; Kihara and Igarashi, 2008; Olivera et al., 1998; Liu et al., 2000; 
Kovarik et al., 2007). From ex vivo studies it is known that fingolimod is phosphorylated 
in the blood platelets (Albert et al., 2005; Kihara and Igarashi, 2008; Anada et al., 2007). 
We hypothesize that characterization of the inter-conversion between fingolimod and 
fingolimod-P in blood platelets may constitute a basis for the scaling of the PK between 
rats and humans. To date, no PK models have been published that describe the time 
course of the fingolimod and fingolimod-P concentrations simultaneously. Since the 
conversion between fingolimod and its phosphate is a reversible and dynamic process it 
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is anticipated that the PK of fingolimod-P is closely linked to the PK of fingolimod. There-
fore, a simultaneous analysis of the in vivo concentration-time course of fingolimod and 
fingolimod-P and the ex vivo inter-conversion, and blood-plasma distribution will yield 
an understanding of the dynamics of the overall inter-conversion and the relevance of 
the inter-conversion in blood platelets. Moreover, characterizing the blood to plasma 
distribution allows the prediction of the fingolimod-P plasma concentrations rather than 
whole blood concentrations, which are the relevant concentrations for the modeling of 
pharmacodynamic effects in future pharmacokinetic pharmacodynamic investigations. 
In this investigation, we present a semi-mechanistic population PK model for the inter-
conversion of S1PHK substrates and their respective phosphates using fingolimod as a 
paradigm compound with the aim a) to investigate whether characterization of the 
inter-conversion in blood (platelets) constitutes a basis for the scaling of the PK between 
rats and humans and b) to predict the time course of plasma (rather than whole blood) 
concentrations of phosphate metabolites. 
Materials and Methods
An overview of the studies used to characterize the PK of fingolimod(-P) in rat and human 
can be found in Table 1. 
Ex vivo studies
Three ex vivo experiments were performed in isolated blood from male albino rats of 
strain Hanover Wistar and human blood obtained from healthy male volunteers (Blut-
spendezentrum SRK, Basel, Switzerland). Experiment A was an inter-conversion experi-
ment in which (rat and human) blood samples (~ 6 mL) were spiked with a fingolimod 
or fingolimod-P spiking solution (20 µg/mL; solvent: ethanol abs: 1 M HCl (95:5, w:w) 
) to achieve final concentrations of 100 ng/mL fingolimod and fingolimod-P. In total, 11 
samples were incubated at 37°C with gentle agitation. 0.8 mL aliquots were taken after 0, 
1, 2, 4, 7, 24 and 48 h of incubation, immediately frozen on dry ice and stored at – 80°C. 
Fingolimod and fingolimod-P blood concentrations were determined by LC/MS/MS after 
liquid/liquid extraction. The lower limits of quantification (LOQ) were 1.08 and 2.5 ng/mL 
for fingolimod and fingolimod-P, respectively. Experiments B and C investigated the blood/
plasma distribution of fingolimod-P. In experiment B the time dependency of blood/
plasma distribution (time points: 0.25, 0.5, 1, 2 and 4 h) was studied for a concentration 
of 30 ng/mL [14C]fingolimod-P in rat blood and at 30 and 300 ng/mL [14C]fingolimod-P 
in human blood. Experiment C investigated the fingolimod-P blood/plasma distribution 
for the nominal concentrations of 3, 30, 300 and 3000 ng/mL [14C]fingolimod-P in trip-
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licate (in addition at 1 and 0.3 ng/mL for human). Samples were incubated for 120 min 
at 37°C with constant agitation on an orbital shaker. In experiments B and C separation 
of cells and plasma was achieved by centrifugation (1500 g, 10 min, 37°C). Samples for 
quantification of total radioactivity were taken before and after (plasma fraction only) 
centrifugation. The radioactivity in the biological samples was measured by LSC with Irga-
Safe Plus (Packard) as Scintillator. Radiometry was performed in TriCarb 2500 TR and 2700 
TR Liquid Scintillation Systems (Packard Instr. Co., Meriden, CT, USA). Concentrations of 
radiolabeled substances in plasma and blood were determined in weighed samples. Data 
were converted from dpm/g to ng/mL assuming a density of 1.00 g/mL for all samples and 
using the specific radioactivity.
Studies in rat
The studies in rats were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health. 
Study 1, was a single dose PK-PD study in which fingolimod and fingolimod-P concentra-
tions where measured following intravenous (iv) and oral administration of fingolimod, in 
male, Lewis rats. Rats were provided normal chow and water ad libitum. Study 2, was a 
study on the PK of fingolimod and fingolimod-P after single iv administration of fingolimod 
or fingolimod-P, in male Sprague Dawley rats (Charles River, France). At the time of study, 
body weights ranged from 296-318 gram. Rats were provided normal chow (NAFAG pel-
lets No. 890, ECOSAN Eberle NAFAG AG, Gossau, Switzerland) and tap water ad libitum. 
In these pharmacokinetic investigations the vena femoralis was cannulated for compound 
administration and the arteria femoralis for blood sample collection. Following cannula-
tion, a recovery period of 72 h was observed. Meloxicam was used for post-surgery anal-
gesia (1-2 mg/kg, subcutaneously). Cannulae were filled with aqueous heparin solution. 
During the recovery time, the functional capability of the cannulae was regularly tested.
Studies in healthy volunteers
The studies in healthy volunteer were conducted in accordance with the Declaration of 
Helsinki.  The protocols for studies 2105, 2213 and 2215 were approved by local medical 
ethics committees and written informed consent was obtained from all subjects. Sub-
jects were judged eligible for the studies if they were aged between 19 and 50 years or 
between 18 and 45 years for studies 2105 and 2213/2215, respectively. In addition, all 
subjects were in good health as determined by past medical history, physical examination, 
vital signs, electrocardiogram, and laboratory tests at screening. 
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Venous blood samples were collected according to the sampling schemes described in 
Table 1. Blood concentrations were determined by a validated liquid chromatography 
method with mass spectrometry detection. Samples were analyzed following liquid-liquid 
extraction (Kovarik et al., 2004). In the studies in rats, the LOQ’s were 0.250 and 1 ng/mL 
for fingolimod and fingolimod-P, respectively. In the clinical studies the LOQ was 0.080 
ng/mL for fingolimod. For fingolimod-P, the LOQ’s were and 0.1 and1 ng/mL in studies 
2105 and 2215, respectively. Assay accuracy ranged from 97.5% to 108.7% and precision 
coefficients of variation from -2.5% to 8.7%.
Population PK modeling strategy
Two PK models were developed, i.e. one model to characterize the PK of fingolimod en 
fingolimod-P in rat and one model to characterize the PK of fingolimod and fingolimod -P 
in human. The rat PK model was developed using data from studies 1 and 2 and the ex vivo 
studies in rat blood. The human PK model was developed using data from studies 2105 
and 2213 and the ex vivo studies in human blood. Data from study 2215 were used for 
(external) evaluation of the predictive value of the model.
Only physiologically plausible models were evaluated, i.e. all evaluated models were 
based on the knowledge from published in vitro, in vivo and ex vivo studies. Briefly, the 
following is known about the inter-conversion between fingolimod and its phosphate. 
i) Fingolimod is phosphorylated peripherally (Olivera et al., 1998; Liu et al., 2000), in 
the platelets in blood (Albert et al., 2005), and pre-systemically during first-pass in the 
liver upon oral administration (Kovarik et al., 2007).   
ii) Fingolimod-P is dephosphorylated back to fingolimod before it is eliminated from the 
body (Zollinger et al., 2011). 
iii) Dephosphorylation occurs only in the plasma. Fingolimod-P is dephosphorylated by the 
enzyme lipid phosphatase type 3 (LLP3)( Kihara and Igarashi, 2008), which is expressed 
in the plasma membrane on cells exposed to plasma such as vascular endothelial cells 
and blood cells (Kihara and Igarashi, 2008).
One-, two- and three-compartmental models were evaluated to describe the disposition 
of fingolimod and fingolimod-P. Furthermore, it was investigated if the absorption from 
the gastrointestinal-tract (dose compartment) to the blood (central compartment) could 
be described with first- or zero-order processes. In addition, an exploratory graphical 
analysis of the dose-normalized raw fingolimod and fingolimod-P blood concentrations 
indicated that absorption, distribution and/or inter-conversion might be non-linear with 
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dose/concentration. Therefore, it was evaluated if the description of the data could be 
improved by describing the absorption, distribution or inter-conversion by saturable 
processes, i.e. by Michaelis-Menten like processes (Equation 1) or by saturable binding to 
plasma proteins (Equation. 2).
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In this equation A(x) is the amount in compartment x, C(x) is the concentration in compartment x, 
Vm is the maximum rate of biotransformation and Km is the concentration at which the half 
maximal rate of biotransformation is reached. The term SPK is used to represent saturation of a 
certain mechanism, e.g. a saturable distribution or saturable inter-conversion. It results in a 
sigmoid relationship approaching a maximum at infinitely high concentration.  
                                                          (2) 
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In case of saturable binding, in this equation, phi is the free fraction, C is the total con-
centration in the plasma and Bmax and Kd are the binding capacity and binding affinity, 
respectively.
Allometric scaling
The PK of fingolimod and fingolimod-P in human was also predicted from the rat model 
using an allometric scaling approach (West et al., 1999). This approach describes how bio-
logical properties vary with body mass. As the fingolimod and fingolimod-P plasma protein 
binding is comparable for rat and human, predictions were not corrected for differences in 
the unbound fraction.  Mean body weights of human and rat were assumed to be 70 and 
0.3 kg, respectively. All rate constants were scaled with an allometric exponent of - 0.25 
and an exponent of 1 was used for scaling the volume of distribution. The absorption was 
not scaled, according to the assumption that the bioavailability (F1) and absorption rate 
constant (ka) equal the average F1 and ka of the values in different preclinical species as 
determined in compartmental PK models (Vuppugalla et al., 2011). As we described the 
PK of fingolimod and fingolimod-P only in rat, this yields the situation where the values of 




Data from the in vivo and ex vivo studies were analyzed simultaneously using the non-
linear mixed-effects modeling approach implemented in NONMEM (version 7.1.0; Icon 
Development Solutions, Ellicott City, Maryland, USA). The models were compiled using 
Digital Fortran (version 6.6C3, Compaq Computer Corporation, Houston, Texas) and ex-
ecuted on a PC equipped with an AMD Athlon 64 processor 3200+ under Windows XP. The 
results were analyzed using the statistical software package S-Plus for Windows (version 
6.2 Professional, Insightful Corp., Seattle, USA). Parameters were estimated using the first 
order conditional estimation method with interaction between the two levels of stochastic 
effects (FOCE interaction). Random effects were included as exponential terms reflect-
ing lognormal distributions of model parameters. The residual variability was explored 
with proportional and additive error models. Goodness-of-fit was determined using the 
minimum value of the objective function defined as minus twice the log-likelihood. For 
nested models, a decrease of 10.8 points in the minimum value of the objective function 
(MVOF) (corresponding to p<0.001 in a chi-squared distribution) by adding an additional 
parameter was considered significant. The goodness-of fit was also investigated by visual 
inspection of the plots of individual predictions and the diagnostic plots of (weighted) 
residuals. To evaluate the predictive value of the human pharmacokinetic model a visual 
predictive check (VPC) was performed in which the median and the 90% inter-quantile 
range of data simulated with the developed model were plotted together with the ob-
servations. In addition, the predictive value of the human pharmacokinetic model was 
externally validated with data from study 2215 using the same VPC technique.
Results
Rat PK model
The data from the rat ex and in vivo studies (studies 1 and 2) were described by the 
model depicted in Figure 1, (Rat). The phosphorylation of fingolimod was described by the 
combination of a first-order process in the platelets (k67) and a first-order phosphoryla-
tion process in plasma (k34), which is only relevant in vivo. In vivo dephosphorylation 
was found to be faster than the ex vivo dephosphorylation. This was accounted for by 
estimating an extra rate constant (k43b), which is only relevant in vivo. The disposition 
of fingolimod and fingolimod-P were characterized by three-compartmental models with 
saturable distribution from the plasma to one of the peripheral compartments for fingo-
limod and fingolimod-P. The absorption and elimination of fingolimod were described by 
first-order processes (ka and k30). Fingolimod was also pre-systemically phosphorylated. 
As calculated from the absorption rates, 82% of the total fingolimod dose was converted 
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Figure 1: Pharmacokinetic models to describe the time course of the fingolimod and fingolimod-P blood concentra-
tion in rat and human. 
The grey area describes the inter-conversion and blood/plasma distribution in isolated blood. Kxy represent the 
first-order distribution and elimination rate constants. Arrows with an equal number of slashes indicate that these 
rates are the same. In addition, the dashed lines represent saturable processes.  
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to fingolimod-P before entering the blood. The absorption of the pre-systemically formed 
fingolimod-P was characterized by two transit compartments to describe observed delay 
in absorption. In addition, the absorption from the last transit compartment to the central 
compartment was described by a saturable Michaelis-Menten like process. The bioavail-
ability was found to decrease from 1, for a dose of 0.1 mg/kg, to 0.36, for the highest 
orally administered dose, i.e. 3 mg/kg, according to a descriptive log-dose equation (Table 
2), which is only valid in the observed dose range between 0.1 and 3 mg/kg. The ex-vivo 
blood volume (Vex vivo) and in vivo central volume of distribution (Vin vivo) were allowed to 
vary between experiments and between individual rats (IIV). The residual errors for the 
ex and in vivo were best described by proportional residual error models with an extra 
additive residual error for ex vivo experiment A. 
The developed model adequately described the inter-conversion between fingolimod and 
fingolimod-P as well as the blood-plasma distribution as can be seen in the description 
Figure 2: Description of the data from the ex vivo inter-conversion (A) and blood/plasma distribution (B and C) stud-
ies in isolated blood from rat (upper half) and human (lower half). 
The dots represent the observations and the continuous lines (A and B) and squares (C) represent the individual 
predictions. The dashed lines represent the population predictions.
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of the data from the ex vivo experiments (Figure 2, Rat). The in vivo time course of the 
fingolimod(-P) blood concentrations was also adequately described after both iv and oral 
administration of fingolimod (Figure 3). All parameters could be estimated with good 
precision as all standard errors were less than 50% of the parameter estimates (Table 
2). The estimated clearance of 0.774 L/h/kg does not differ from the systemic clearance 
of 0.748 L/h/kg derived from a published physiologically based pharmacokinetic (PBPK) 
model (Meno-Tetang et al., 2006).
Allometric scaling
The predicted PK of fingolimod and figolimod-P in human after allometric scaling dem-
onstrated that the fingolimod exposure was adequately predicted, but the fingolimod-P 
exposure was 12-fold over-predicted (Figure 4). Hence, an allometric scaling approach 
seems not applicable for predicting fingolimod-P exposure in human.
Figure 3: Description of the fingolimod and fingolimod-P blood concentrations from studies 1 and 2 after oral fin-
golimod (dose: 0.1, 0.3, 1, or 3 mg/kg) or intravenous administration of fingolimod (dose: 1 mg/kg) or fingolimod-P 
(dose: 0.1 mg/kg)




The model to describe the data from the human ex and in vivo studies (studies 2213 and 
2105) was comparable to the model to describe the rat data (Figure 1, Human). However, 
several differences are noticeable between the rat and human models. i) Only one periph-
eral compartment could be quantified to describe the distribution of fingolimod-P. ii) The 
phosphorylation and dephosphorylation processes in plasma, which were identified in rat, 
could not be quantified in human. Instead, the dephosphorylation in plasma was described 
by a saturable, Michaelis-Menten like process (Equation 1). iii) In human, two peaks were 
observed during the absorption phase. This was described by two dose compartments 
with a lag time for the absorption from the second dose compartment. iv) The distribution 
of fingolimod into the red blood cells could be quantified in human, whereas this process 
could not be quantified in rat. v) The distribution of fingolimod-P into the platelets and 
the peripheral compartment was found to be faster for higher concentrations. This was 
described by a saturable binding process (Equation 2) resulting in a higher blood/plasma 
Figure 4: Prediction of the fingolimod and fingolimod-P blood concentrations from multiple dose studies 2105 in 
health volunteers using the allometrically scaled rat model
The grey dots represent the observations after administration of fingolimod (0.5 or 1.25 mg po) and the dashed 
lines represent the observed median. The continuous lines represent the predicted median.
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ratio for higher concentrations (Figure 2C, human). k30 and the Vin vivo were allowed to vary 
between individual subjects. The residual errors for the ex and in vivo studies were best 
described by proportional residual error models. 
In general, the developed model adequately described the data from the ex vivo studies 
(Figure 2, Human). In addition, the time course of the in vivo fingolimod and fingolimod-P 
blood concentrations was adequately described as the continuous lines, which represent 
the predicted median, closely resemble the observed median (dashed lines) (Figure 5). 
However, the observations from the 1.25 mg dose group in study 2105 were slightly over-
predicted. For study 2213, the variability was adequately predicted as about 90% of the 
observations are within the 90% prediction interval (grey area) (Figure 5). For study 2105, 
the variability was slightly over-predicted. All parameters could be estimated with good 
precision as all standard errors were less than 50% of the parameter estimates (Table 2). 
Figure 5: Visual predictive check of the description of the fingolimod and fingolimod-P blood concentrations from 
multiple dose studies 2105 and 2213 in health volunteers 
The grey dots represent the observations after administration of fingolimod (0.5, 1.25 or 5 mg po) and the dashed 
lines represent the observed median. The continuous lines represent the predicted median and the grey area rep-
resents the 90% prediction interval.
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About 69% of the total fingolimod dose was converted to fingolimod-P before entering the 
blood. A comparison of the time course of the predicted fingolimod-P blood and plasma 
concentrations demonstrates that for a dose of 0.5 mg/day the fingolimod-P blood/
plasma concentration ratio varies between 0.8 and 0.95 within a day at steady state. The 
difference between blood and plasma concentrations is the largest around tmax (Figure 6).
The developed model could, in general, adequately predict both the trend and the vari-
ability in the data from the external (i.e. study not used for model development) study 
2215 (Figure 7). However, fingolimod and fingolimod-P concentrations observed in the 
10 mg dose-group were slightly over-predicted. On the other hand the concentrations 
of 5 out of 6 subjects included in this treatment-group fall within the prediction interval. 
Therefore, this might be a chance observation, which is due to the low number of sub-
jects. The observed concentrations of the 6th subject of this treatment are much lower 
than predicted, but also much lower than the observed concentrations in the lowest dose 
group. In addition, the maximum fingolimod-P concentrations are slightly under-predicted 
for the higher dose groups. This indicates that there might be another non-linear process 
involved that becomes relevant after administration of doses higher than 10 mg. 
Figure 6: Predicted fingolimod-P blood and plasma concentrations and blood/plasma ratio after once daily admin-
istration of fingolimod during 14 days 
The grey line represents the predicted fingolimod-P plasma concentration and the dashed lines black represents the 
predicted fingolimod-P blood concentration after administration of fingolimod (0.5 mg po). The dashed grey line 
represents the predicted blood/plasma ratio.
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Figure 7: Prediction of the fingolimod and fingolimod-P blood concentrations from single dose study 2215 in health 
volunteers 
The grey dots represent the observations after administration of fingolimod (5-40 mg po) and the dashed lines 
represent the observed median. The continuous lines represent the predicted median and the grey area represents 
the 90% prediction interval.
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Comparison of exposure between rat and human
A comparison between the predicted steady-state fingolimod-P exposure in rat and hu-
man demonstrated that fingolimod-P exposure was about 10-12 fold lower in human as 
compared to rat for equivalent doses when following a dose-by-factor approach, which is 
commonly applied to scale the ‘no-observed adverse effect level’ (Figure 8)(Sharma and 
McNeill, 2009; FDA, 2010).  This approach uses allometric scaling on the basis of body sur-
face area. Generally, an exponent of 0.67 or 0.75 is used. For example, in rat a dose of 0.1 
mg/kg results in an exposure of 1005 ng*h/mL. The human-equivalent dose after applying 
the dose-by-factor approach with an exponent of 0.75 equals 1.8 mg (0.1*70*(70/0.3)-
0.25). The “observed” exposure as predicted by the developed PK model for human was 95 
ng*h/mL. As a result, there was an 11 (1005/95) fold difference in exposure between rat 
and human.
Discussion
With the aim of 1) of investigating whether characterization of the phosphorylation in 
blood platelets constitutes a basis for pharmacokinetic scaling and 2) predicting plasma 
rather than whole blood concentrations of fingolimod phosphate, PK models were de-
Figure 8: Comparison of the predicted steady state fingolimod-P exposures in blood after oral administration of 
fingolimod in doses of 0.1-5 mg/kg in rat and 0.1-5 mg in human. 
The dashed and continuous lines represent the exposure in rat and human, respectively.
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veloped to quantify the exposure of the prototypical S1PHK substrate fingolimod and its 
active metabolite, fingolimod-P, in rat and human. Previously, the time course of the blood 
concentrations of the parent compound but not the phosphorylated metabolite has been 
described by a physiologically-based pharmacokinetic model (Meno-Tetang et al., 2006). 
In addition, the time course of the fingolimod-P blood concentrations has been described 
by a descriptive population PK model (Wu et al., 2011). However, to date, no pharmaco-
kinetic models have been published that describe the time course of the fingolimod and 
fingolimod-P concentrations simultaneously. 
The developed models, i.e. the rat model and the human model, consisted of three parts 
to describe the phosphorylation and the dephosphorylation in blood, the distribution 
and elimination from the systemic circulations and the absorption, respectively. Although 
both models were structurally related, several differences are noticeable between the rat 
and human models. First of all, not all peripheral compartments that were identified in 
the rat model could be identified in the human model. This is explained by the fact that 
fingolimod(-P) concentrations were not measured following intravenous administration 
of fingolimod in human, and therefore, less detailed information was available about 
the distribution. Another important difference between the rat and human model is that 
saturable binding to a high affinity/low capacity binding site on a protein in the plasma 
was identified in humans, whereas this could not be identified in rats. As a result, the 
fingolimod-P blood/plasma exposure ratio was constant over the observed dose range 
(the ratio was about 1) in rats, whereas this ratio increased with higher doses from 0.95 
for a dose of 0.5 mg to 1.9 for a dose of 5 mg at steady state in human. Therefore, the 
human plasma concentrations may be a little higher than anticipated after administra-
tion of doses below 0.5 mg/day. In addition, for a dose of 0.5 mg/day the blood/plasma 
concentration ratio varied between 0.8 and 0.95 within a day at steady state (Figure 6). 
The difference between blood and plasma concentrations is the largest around tmax. This is 
relevant since the fingolimod-P plasma concentrations are likely to be more predictive for 
pharmacodynamic effects than blood concentrations. Finally, in both species, the in vivo 
dephosphorylation was found to be much faster than the dephosphorylation in isolated 
blood. Fingolimod-P is dephosphorylated by LLP3, which is expressed on cells exposed to 
plasma such as vascular endothelial cells, which are not present in the isolated blood used 
for the ex vivo studies. In humans, dephosphorylation is best described by a Michaelis-
Menten process, whereas in rats no capacity limited (Michelis-Menten) kinetics could be 
identified, due to the limited concentration range that has been studied. The developed 
models are valid in the evaluated dose range of 0.1 to 3 mg/kg following oral administra-
tion in rat and 0.5 to 5 mg following oral once daily administration to humans. In general, 
the data from the studies in rat and human were adequately described. However, in study 
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2105 the observations from the 1.25 mg dose group were slightly over-predicted. This 
is thought to be due to non-compliance for some subjects in this treatment group. In 
addition, for this study, the variability was slightly over-predicted. As there were only 
12 subjects per treatment-group included in this study the observed variability may not 
be representative for the variability in a larger population. An external validation of the 
human model using data from a single-dose study with doses between 5 and 40 mg dem-
onstrated that the model can also be used to predict fingolimod(-P) blood concentrations 
following doses up to 10 mg, which is a dose well above the therapeutic dose of 0.5 mg 
once daily. The developed models can be applied to evaluate possible covariate influences 
or to predict the time course of the fingolimod and fingolimod-P plasma concentrations. 
Moreover, the model can be applied to characterize the time course of pharmacodynamic 
effects of fingolimod-P by linking the time course of the fingolimod-P plasma or blood 
concentrations to pharmacodynamic observations.
Besides describing the PK of fingolimod and fingolimod-P in human by a compartmental 
model, the PK in human were predicted from rat data using an allometric scaling ap-
proach. Various dose extrapolation techniques have been described ranging from em-
pirical allometric scaling to semi-mechanistic methodologies, which attempt to account 
for species difference in physiology, and further to the mechanistic whole-body PBPK 
modeling approach, which relies on physicochemical properties of the drug and knowl-
edge of human physiology (tissue composition)(Jones et al, 2011). Allometric scaling of 
the PK parameters from rat resulted in an adequate prediction of the PK of fingolimod. 
However, the exposure of fingolimod-P was 12-fold over-predicted. When examining the 
inter-conversion rate parameters in both species it is noticeable that the phosphoryla-
tion of fingolimod in the platelets is 4-fold faster in rats as compared to humans after 
allometric scaling (Table 1, K67). As in rats, an extra phosphorylation rate was estimated in 
the plasma, the overall phosphorylation was 9-fold faster in rats as compared to humans. 
This extra phosphorylation could represent rapid phosphorylation in other tissues, but 
this rate was not quantifiable in human. This could possibly be due to differences in the 
S1PHK2 enzyme tissue distribution, which may also explain the inadequate allometric pre-
diction of the volume of distribution as inter-species differences in inter-conversion are 
not accounted for in a general allometric scaling approach. Overall, the 4-fold difference in 
phosphorylation rate quantified from the ex vivo experiments is indicative for differences 
in exposure between rat and human, but does not exclusively elucidate this difference. 
This is explained by the minor contribution of phosporylation in the platelets as compared 
to the 82% and 69% pre-systemic phosphorylation seen in rats and humans, respectively. 
More mechanistic approaches are required to integrate the differences in pre-systemic 
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phosphorylation and enzyme tissue distribution in the translational pharmacokinetics of 
fingolimod and fingolimod-P and other S1PHK substrates.
In conclusion, large interspecies differences in the rate of phosphorylation between 
rats and humans were demonstrated, using fingolimod as a paradigm compound, which 
cannot be accounted for by allometric scaling. A semi-mechanistic PK model is proposed 
that constitutes a basis for the prediction of the concentrations of S1PHK substrates and 
their phosphorylated metabolites in plasma. In this model, differences in the rate of phos-
phorylation in blood, estimated from ex vivo inter-conversion measurements in platelets, 
partly explain the differences in exposure between rats and humans. However, differences 
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Summary 
Background and purpose | Fingolimod and siponimod are sphingosine 1-phosphate (S1P) 
receptor agonists which are effective in treating multiple sclerosis, but are associated with 
cardiovascular effects in humans. This investigation aimed to characterize these effects, 
in a quantitative manner, using a recently developed systems cardiovascular pharmacol-
ogy (CVS) model for drug effects on the interrelationship between mean arterial pressure 
(MAP), cardiac output (CO), heart rate (HR), stroke volume (SV) and total peripheral 
resistance (TPR).
experimental approach | The cardiovascular effects of fingolimod-phosphate (fingolimod-
P), and siponimod were characterized in spontaneously hypertensive and Wistar-Kyoto 
rats following once daily administration of 0, 0.1, 0.3, 1, 3 and 10 mg/kg and 3 and 15 mg/
kg, respectively. The rats were chronically instrumented with ascending aortic flow probes 
and/or aortic catheters/radiotransmitters for continuous recording of CO, MAP and HR. 
Key results | The effect of fingolimod-P on MAP, CO, HR, SV and TPR was adequately 
characterized by the CVS model combined with a receptor binding model, a receptor 
down-regulation model and a sensitization model with direct inhibiting and stimulating 
drug effects on HR and TPR, respectively. The effect of siponimod on MAP and HR in rats 
was adequately predicted on the basis of constants derived from in vitro assays.
Conclusions and Implications | The proposed CVS model can be applied to predict the 
cardiovascular effects of S1P receptor agonists with different selectivity profiles in rats 
and, ultimately, it may constitute a basis for prediction of cardiovascular effects of S1P 




Fingolimod and siponimod are sphingosine 1-phosphate (S1P) receptor agonists with 
different subtype selectivity profiles, which are effective in the treatment of multiple 
sclerosis (Cohen et al., 2010; Gergely et al., 2012). Fingolimod, and more specifically, the 
active metabolite of fingolimod, fingolimod-phosphate (fingolimod-P) binds to 4 of the 5 
subtypes of the S1P receptor (S1P1 and S1P3-5) with high affinity (0.3-3.1 nM) (Mandala et 
al., 2002; Brinkmann, 2007; Brinkmann et al., 2004), whereas siponimod binds only to 2 
of the 5 subtypes (S1P1 and S1P5) with high affinity, while the affinity for the S1P3 recep-
tor is low (Gergely et al., 2012). In humans, S1P receptor ligands have been associated 
with cardiovascular side effects. Briefly, following the administration of fingolimod and 
siponimod a dose-dependent decrease in HR was observed on the first day of treatment 
with a gradual return to baseline with continued treatment (Kappos et al., 2006; Kappos 
et al., 2010; Selmaj et al., 2013; Gergely et al., 2012). In addition, after administration of 
fingolimod a small increase of 1 – 2 mm Hg in mean arterial pressure (MAP) was observed 
at a dose of 0.5 mg and MAP was mildly increased by 4-6 mmHg after 2 months at doses 
of 1.25 and 5 mg (Kappos et al., 2006; Kappos et al., 2010). No information has been 
published on potential effects of siponimod on MAP. The immunosuppressant, as well 
as the cardiovascular effects of fingolimod-P and siponimod are believed to be mediated 
through various S1P receptor subtypes, which complicates the search for novel S1P recep-
tor agonists that are devoid of cardiovascular side effects. A mechanistic and quantitative 
understanding of the hemodynamic effects of S1P receptor agonists is important as it may 
constitute a basis for 1) the prediction, in a strictly quantitative manner, of the cardio-
vascular effects of novel S1P receptor agonists with different receptor selectivity profiles 
and 2) the extrapolation of cardiovascular effects to humans based on information from 
preclinical investigations. 
Recently, a systems cardiovascular pharmacology (CVS) model was developed to charac-
terize drug effects on the interrelationship between mean arterial pressure (MAP), cardiac 
output (CO), heart rate (HR), stroke volume (SV) and total peripheral resistance (TPR) us-
ing hemodynamic data from rats (Snelder et al., 2013a; submitted (a)). The parameters of 
the CVS model were quantified by challenging the CVS with a prototype set of compounds 
with different, but well known, mechanisms of action (MoA). It was demonstrated that 
the CVS model is system-specific by showing that successively removing data from one 
of the compounds that were used for model development does not affect the estimates 
of the system parameters. Furthermore by the analysis of hemodynamic profiles, it was 
demonstrated that the site of action of new compounds can be identified by a model-
based analysis of the time course of the change in the hemodynamic variables. Therefore, 
this model is uniquely suited to provide a quantitative understanding of the mechanisms 
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underlying the cardiovascular effects of S1P receptor agonists. A potential application 
of this model is the prediction of the cardiovascular effects of novel compounds. This 
requires the interfacing of the CVS model with a receptor binding and activation model. 
Ultimately this quantitative pharmacology model could be a basis for the prediction of 
cardiovascular effects in man based on preclinical data (Danhof et al., 2008).
In this investigation, the recently proposed systems cardiovascular pharmacology model 
was combined with 1) a target binding-activation model and 2) a receptor down-regu-
lation and sensitization model, to describe the cardiovascular effects of fingolimod-P in 
rat. Subsequently, the developed model was used to predict the cardiovascular effects of 
siponimod in rats on the basis of dissociation constants derived from in vitro assays.
Methods
Animals 
Experiments were conducted on male, spontaneously hypertensive rats (SHR) (Taconic 
Farms, Germantown, NY, USA), Wistar-Kyoto (WKY) rats (Taconic Farms, Germantown, NY, 
USA) and Lewis rats in accordance with approved Novartis Animal Care and Use Commit-
tee protocols (which have been accredited and conform to international animal welfare 
standards) and the Guide for the Care and Use of Laboratory Animals (National Research 
Council, 2011). At the time of study, rats’ ages (body weights) ranged from 24-50 (331-
504), 24-36 (477-781) wk (g) for SHR, and WKY rats, respectively. Rats were housed on 
a 12-h light/dark cycle (light: 0600–1800 h), kept at room temperature, 22°C, and were 
provided normal chow (Harlan Teklad 8604; Indianapolis, IN, USA) and water ad libitum. 
All studies involving animals are reported in accordance with the ARRIVE guidelines for 
reporting experiments involving animals (Kilkenny et al., 2010; McGrath et al., 2010). 
Experimental Procedures
The effect of fingolimod-P on the CVS after repeated dosing was evaluated in two studies 
(Table 1). In Study 1, MAP, HR and CO were measured. In Study 2, only MAP and HR 
were measured. In the second study, in addition to the effect of fingolimod-P, the effects 
of the new ligand siponimod were studied. For continuous recording of CO and/or MAP 
and HR rats were surgically instrumented with an ascending aortic flow probe and/or a 
femoral arterial catheter/radiotransmitter as described by Snelder et al. (Snelder et al., 
2013a). After 5 weeks of washout in this study, carotid arterial catheters were implanted 
for conducting a single-dosing pharmacokinetics (PK) study one week later. In Study 3, the 
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with a femoral venous and arterial cannula for compound administration and for blood 
sample collection, respectively. 
Experimental design
In Study 1, baseline measurements were recorded during 5-7 days prior to active treat-
ment with fingolimod, which was administered once daily for 1, 2 or 4 weeks, at doses 
of 0, 0.1, 0.3, 1, 3 and 10 mg/kg p.o. Thereafter, washout data were collected during at 
least 9 days. In several rats, washout data was collected during a longer period (maximal 
53 days) to investigate if the hemodynamic variables returned to baseline. In total, 21 
SHR and 11 WKY rats were included in this study. One SHR and 2 WKY rats died during the 
washout period. Flow cables were connected to the flow probes by 7:00 am and discon-
nected after 5:00 pm. Rats were dosed at 10:00 am and all data were continued to be 
collected until 5:00 pm. Thereafter, only MAP and HR data were captured until the flow 
probes were reconnected the next morning. For each variable, hourly averages of the 
observations were calculated using the continuously recorded CO, MAP and HR measure-
ments. Subsequently, only one observation every 4 hours was included in the dataset for 
model development to reduce run times.
In Study 2, baseline measurements were recorded for 5 days. Thereafter, fingolimod (0, 
0.1, 0.3, 1, 3 and 10 mg/kg p.o.) or siponimod (3 and 10 mg/kg p.o.) was administered 
once daily for 8 weeks. Subsequently, washout data was collected during 3 weeks. In ad-
dition, after 6 weeks of washout from the repeated-dosing study the PK of fingolimod and 
its active metabolite fingolimod-P were investigated following a single oral administration 
of fingolimod (0.1, 0.3, 1, 3 and 10 mg/kg) in SHR. Blood samples were collected at pre-
dosing and at 2, 4, 8, and 24 hrs post-dosing. 
In Study 3, siponimod blood concentrations were measured following intravenous (iv) 
and oral administration of 1 mg/kg of siponimod, in male, Lewis rats. Rats for the oral 
experiment were fasted from approximately 8 h prior to and 2 h post drug administration. 
For each route 3 rats were used. After intravenous administration, blood samples were 
taken at 0.25, 1, 2, 4, 8, 24, 48h and after oral administration at 0.5, 1, 2, 4, 8, 24, 48, 72 
h post administration.
Compounds
In Studies 1 and 2, fingolimod (synthesized at Novartis, Basel, Switzerland, PKF117-812-
AA) and siponimod (synthesized at Novartis, Basel, Switzerland, NVP-BAF312-NX) were 
dissolved in water or 1% carboxymethylcellulose and formulated for administration at 5 
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ml/kg by oral gavage. In Study 3, siponimod (NVP-BAF312-AA) was dissolved in PEG200/
glucose/water (pH-adjusted to 3-4) for administration at 1 ml/kg i.v. and 4 ml/kg p.o..
Data analysis 
Pharmacokinetics of fingolimod-P
Recently, a PK model was developed to characterize the PK of fingolimod and fingolimod-P 
in male Lewis and Sprague Dawley rats in blood (Snelder et al., submitted (b)). This model 
was valid in the evaluated dose range of 0.1 to 3 mg/kg (Snelder et al., submitted (b)). 
As this excludes the 10 mg/kg dose, which was administered in the current studies, the 
predictive value of the model to describe the PK data from the 10 mg/kg dose group in 
Study 2 was assessed. Therefore, the PK model was optimized using the fingolimod-P PK 
measurements from this dose group by changing the parameters one by one using the 
NWPRI prior option in NONMEM® (Gisleskog et al., 2002). Generally, this option serves to 
obtain stable parameter estimates, even with insufficient data, by constraining the values 
of these parameter estimates using prior knowledge from the previously developed PK 
model. When optimizing the parameter Vmabs, which represents the maximum rate of 
absorption of pre-systemically formed fingolimod-P for the 10 mg/kg dose group only, 
the data from this dose group were adequately described and the model-predicted PK 
profiles could be used for pharmacokinetic pharmacodynamic (PKPD) model development 
as specified in the section “Results”.
Systems pharmacology model for the interrelationships between 
hemodynamic variables
The interrelationships between MAP, TPR, CO, HR and SV are expressed by the formulas 
1) MAP=CO*TPR and 2) CO=HR*SV (Levick, 2003). Recently, a systems cardiovascular 
pharmacology model was developed to describe drug effects on the inter-relationship 
between MAP, CO, HR, SV and TPR (Snelder et al., 2013a; Snelder et al., submitted (a)). 
This “CVS model” consists of three differential equations, for HR, SV and TPR respectively, 
which are linked by negative feedback through MAP (Figure 1, Equation 1). The circadian 
rhythm, which was observed in all 5 parameters of the CVS, is described by two cosine 
functions, one influencing the production rate of HR (Kin_HR) and one influencing the pro-
duction rate of TPR (Kin_TPR.). 
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first-order dissipation rate constants of HR, SV and TPR, respectively. In addition, amp 
represents the amplitude of the circadian rhythms, t the time and hor the horizontal displacement 
over time.  
 
The CVS model was applied to characterize the time course of the effect of fingolimod-P on the 
hemodynamic variables. All system-specific parameters were fixed to values reported by Snelder 
et al. (Snelder et al., submitted (a)). However, the parameters of the circadian rhythm were 
optimized as the circadian rhythm varied between studies. The handling effect, i.e. the influence 
of a short manual restraint and oral dose administration, was excluded from the model as only 1 















































Figure 1: CVS model to characterize drug effects on the interrelationship between MAP, CO, HR, SV and TPR. 
(Copied from Snelder (Snelder et al. with permission, submitted).
Cardiac output (CO) equals the product of HR and SV (CO=HR*SV) and MAP equals the product of CO and TPR 
(MAP=CO*TPR). SV influenced by indirect feedback through MAP (SVT) and by HR through a direct inverse log-linear 
relationship, where HR_SV represents the magnitude of this direct effect. Effects on HR, SV and TPR are described by 
three linked turnover equations. In these equations Kin_HR, Kin_SV and Kin_TPR represent the zero-order produc-
tion rate constants and kout_HR, kout_SV and kout_TPR represent the first-order dissipation rate constants. When 
MAP increases as a result of a stimulating effect on HR, SV or TPR, the values of HR, SV and TPR will decrease as a 
result of the action of the different feedback mechanisms regulating the CVS. In this model the magnitude of feed-
back on HR, SV and TPR is represented by FB. System-specific parameters are indicated in black and drug-specific 
parameters are indicated in dark grey.
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In these equations, SV* represents the SV influenced by the negative feedback of MAP, 
Kin_SV represents the zero-order production rate constant and kout_HR, kout_SV and kout_TPR repre-
sent the first-order dissipation rate constants of HR, SV and TPR, respectively. In addition, 
amp represents the amplitude of the circadian rhythms, t the time and hor the horizontal 
displacement over time. 
The CVS model was applied to characterize the time course of the effect of fingolimod-P 
on the hemodynamic variables. All system-specific parameters were fixed to values re-
ported by Snelder et al. (Snelder et al., submitted (a)). However, the parameters of the 
circadian rhythm were optimized as the circadian rhythm varied between studies. The 
handling effect, i.e. the influence of a short manual restraint and oral dose administra-
tion, was excluded from the model as only 1 observation every 4 hours was included in 
the dataset for model development and the handling effect is only relevant on a much 
shorter time scale. Previously, inter-individual variability was identified on the baseline 
values of MAP, CO and HR (BSL_MAP, BSL_CO and BSL_HR). In contrast, in this analysis 
the observed baseline values, calculated as the mean of all observations before active 
treatment, were used to reduce runtimes. The residual errors of MAP, CO and HR were 
optimized on the available data. In addition, an exploratory graphical analysis revealed 
that, in the vehicle-treated groups, within the time frame of these studies, HR decreases 
over time in both SHR and WKY rats and that TPR decreases over time in WKY rats only. 
Therefore, exponentially decreasing functions, linear, power and Emax models were evalu-
ated to describe the change over time of Kin_HR and Kin_TPR (Equation 2).
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In this equation, k, SL, POW, Emax and ET50 represent the first-order rate constants for decrease, 
the slope of the linear relationship, the power parameter in the power relationship, the maximum 
effect and the time at which half of the maximum effect is achieved in the Emax relationship, 
respectively. 
Target activation and transduction model for fingolimod-P 
Data on the blood concentrations of fingolimod-P and the changes in various hemodynamic 
variables were analyzed using the CVS model without changing the system-specific parameters. 
In a first step, a model-based hypothesis testing procedure (Snelder et al., submitted (a)) was 
followed to obtain insights in the site of action of fingolimod-P and the hemodynamics of its 
cardiovascular effects.  
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Target activation and transduction model for fingolimod-P
Data on the blood concentrations of fingolimod-P and the changes in various hemody-
namic variables were analyzed using the CVS model without changing the system-specific 
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parameters. In a first step, a model-based hypothesis testing procedure (Snelder et al., 
submitted (a)) was followed to obtain insights in the site of action of fingolimod-P and the 
hemodynamics of its cardiovascular effects. 
1) Different hypotheses of the site of action (i.e. HR, SV and TPR) and direction of the 
effect (i.e., inhibiting or stimulating) were formulated, resulting in 6 possible combina-
tions of effects. 
2) For each hypothesis, the model was fitted to the MAP, CO, HR, SV and TPR measure-
ments.
3) It was evaluated which hypothesis resulted in the best description of the data as judged 
by the agreement between the observed and predicted direction and magnitude of 
effect and the lowest minimum value of the objective function (MVOF) as specified in 
the section “Model selection and evaluation”. 
The hypothesis that fingolimod-P has a stimulating effect on TPR resulted in the best 
description of the data. Briefly, the effects on MAP, CO, TPR and SV were adequately pre-
dicted, albeit that the magnitude of the effect on SV was under-predicted (Table 2). In ad-
dition, although the nature of the response on HR, i.e. an increase or decrease in HR, was 
predicted adequately, the transient nature of this effect was not captured indicating that 
fingolimod-P might have an additional effect on HR. Overall, it was found that the effect 
of fingolimod-P on all variables of the CVS could be described adequately while assuming 
multiple sites of action, i.e. TPR and HR (Snelder et al., 2013b). In total, three different 
Table 2: Investigation of the site of action of fingolimod-P
Site of action Direction of effect Result
HR Stimulating Adequate prediction of the effect on MAP and SV; Inadequate prediction of the direction of the effect on TPR, CO and HR
HR Inhibiting
Adequate prediction of the effect on TPR and CO; Inadequate 
prediction of the direction of the effect on MAP and SV; Transient 
nature of the effect on HR not captured
TPR Stimulating
Adequate prediction of the effect on MAP, TPR and CO; 
Reasonable prediction of the effect on SV (magnitude of effect 
underestimated); Transient nature of the effect on HR not 
captured
TPR Inhibiting Inadequate prediction of the direction of the effect on MAP, CO, HR, SV and TPR
SV Stimulating
Adequate prediction of the effect on MAP; Inadequate prediction 
of the direction of the effect on CO, TPR and SV; Transient nature 
of the effect on HR not captured
SV Inhibiting
Adequate prediction of the effect on SV and CO; Reasonable 
prediction of the effect on TPR (magnitude of effect 
underestimated); Inadequate prediction of the direction of the 
effect on MAP and HR
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effects were quantified: 1) a fast stimulating effect on TPR, 2) a slow sustained stimulating 
effect on TPR which is only relevant in hypertensive rats following doses higher than 1 mg/
kg and 3) a transient inhibiting effect on HR, which could be described by a standard feed-
back model (type I) (Gabrielsson and Weiner, 2000). In this first step, the changes in the 
hemodynamic variables were described by empirical models. This provided information 
on the most plausible site of action of fingolimod-P, but it also demonstrated that the CVS 
model can be applied to quantify the hemodynamics of the effect of fingolimod-P on five 
different variables, i.e. MAP, CO, HR, SV and TPR, while assuming only two sites of action. 
The obtained information on the site of action of fingolimod-P was in line with indepen-
dent information on the mechanism of action underlying the effect of fingolimod-P as 
Figure 2: Target binding and activation model to describe the cardiovascular effects of fingolimod-P and siponimod 
integrated with the CVS model. 
Effect of S1P agonists on HR: The effect of S1P agonists on HR is thought to be mediated through the S1P1 receptor 
(S1P1R). Fingolimod-P and siponimod bind with high affinity to the S1P1R. The effect of siponimod was considered 
negligible and, therefore, not included in this figure. Fingolimod and siponimod first act as full S1PR agonists caus-
ing a decrease in HR, and thereafter function as an S1PR antagonist, following the internalization and degradation 
of bound S1P1Rs. 
Effect of S1P agonists on TPR: The effect of S1P agonists on TPR is thought to be mediated through the S1P3 recep-
tor (S1P3R). Fingolimod-P and siponimod bind with high and low affinity to the S1P3R, respectively. The effect of 
siponimod was considered negligible and, therefore, not included in this figure. The effect of fingolimod-P on TPR is 
a combination of a fast stimulating effect and a slowly occurring stimulating effect (sensitization).
142
Chapter 6 Cardiovascular effects of fingolimod and siponimod
discussed in detail in the section “Discussion”. Therefore, in a next step, receptor theory 
concepts for the characterization of target binding and target activation processes were 
incorporated in the model (Figure 2), to enable the prediction of the effects of follow-up 
compounds on the basis of information from in vitro assays (Danhof et al, 2007; Ploeger et 
al., 2009). The different components of the proposed target binding and activation model 
are detailed below.
Effect of fingolimod-P on heart rate
As fingolimod-P is an agonist for the S1P receptor, a competitive interaction between 
the endogenous agonist, S1P, and fingolimod-P was taken into account. This is especially 
important for the effect on HR since this effect is transient, which may be a result of 
internalization of the S1P receptor through binding of fingolimod-P (agonistic effects) and, 
thereby, reducing the bound S1P concentration resulting in an opposite effect (functional 
antagonism), i.e. an increase in HR.
It is assumed that the effect on HR is driven by the concentration of receptors activated 
(RAC) by S1P or fingolimod-P (excluding the number of internalized receptors). At baseline 
the activated concentration of receptors (RAC_0) is given by Equation 3. 
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In these equations, RT_0 represents the apparent concentration of receptors at baseline, which 
has been set to 1 to enable calculation of the fractional receptor occupancy. In addition, FRAC_0 
represents the fraction of activated receptors at baseline. 
 
In the presence of fingolimod-P the activated receptor concentration is given by the equation for 
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2012)(Equation 4). 
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In these equations, RT_0 represents the apparent concentration of receptors at baseline, 
which has been set to 1 to enable calculation of the fractional receptor occupancy. In 
addition, FRAC_0 represents the fraction of activated receptors at baseline.
In the presence of fingolimod-P the activated receptor concentration is given by the equa-
tion for reversible competitive interaction between two agonists (Ariëns and Simonis, 
1964; Romero et al., 2012)(Equation 4).
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I  t ese equations, RT refl cts he conce tration f t tal receptors, Kd represents the 
receptor equilibrium dissociation constant for the effect of fingolimod-P on HR, CB equals 
the fingolimod-P blood concentration as predicted by the PK model and S1P represents 
the ratio between the unknown S1P concentration and its dissociation constant for bind-
ing to the S1P receptor. As the S1P concentration is unknown, this ratio is combined into 
one parameter that was estimated.
A turnover equation was used to describe the internalization of the S1P receptor (Romero 
et al., 2012)(Equation 5). Turnover models are also called indirect response models and 
can be used to describe hysteresis, i.e. the delay between a perturbation and a response 
(Dayneka, 1993). 
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In these equations, IR represents the internalized receptor concentration, which is driven 
by the difference between FRAC and FRAC_0, IR50 represents the value of the difference be-
tween FRAC and FRAC_0 that elicits a half maximal reduction in Kin_R and DEGR represents 
the rate of receptor degradation. At baseline (FRAC=FRAC_0 and RT =RT_0=1), IR equals 1. An 
increase in FRAC caused by the binding of fingolimod-P to the receptor is associated with 
a decrease in IR and, consequently, with a reduction in the synthesis of RT representing 
internalization. In addition, an increase in FRAC is associated with a sustained increase in 
Kout_R representing receptor degradation. 
Effect of fingolimod-P on TPR
The receptor activation underlying the effect of fingolimod-P on TPR was described using 
the same equations as were used for the effect on HR (Equations 3 and 4). In addition, 
an exploratory graphical analysis provided evidence of sensitization as reflected in an 
increase in the values of TPR and MAP. Here, a complex pattern was observed. Specifically 
the values of both variables increased rapidly after the first administration of fingolimod in 
both SHR and WKY rat. Subsequently, a more gradual increase over time in TPR and MAP 
was observed during the whole active treatment period. This gradual increase was more 
apparent in SHR as compared to WKY rats. For some of the rats the effect on TPR and MAP 
did not return to baseline after the termination of treatment. Therefore, models including 
an irreversible receptor sensitization were evaluated for the effect of fingolimod-P on TPR 
according to Equation 7.
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In this equation, SENS represents the first-order rate of the receptor sensitization. The change 
over time of kout_TPR is driven by the difference between FRAC and FRAC_0. The baseline value of 
kout_TPR is fixed to the value from the CVS model. At baseline FRAC equals FRAC_0, and therefore, 
kout_TPR does not change over time. An increase in FRAC caused by the binding of fingolimod-P to 
the receptor is associated with a decrease in kout_TPR, and consequently with a sustained increase 
in TPR. As it was observed that the change over time was dependent on the baseline mean 
arterial blood pressure (BMAP), BMAP was evaluated as a continuous covariate on SENS using 
linear, power, Emax and sigmoid Emax relationships (Equation 8). In the linear and power 







In this equation, SENS repr sents the first-o der ate of the rec ptor sensitization. The 
change over time of kout_TPR is driven by the difference between FRAC and FRAC_0. The baseline 
value of kout_TPR is fixed to the value from the CVS model. At baseline FRAC equals FRAC_0, and 
therefore, kout_TPR does not change over time. An increase in FRAC caused by the binding of 
fingolimod-P to the receptor is associated with a decrease in kout_TPR, and consequently with 
a sustained increase in TPR. As it was observed that the change over time was depe dent 
on the baseline mean arterial blood pressure (BMAP), BMAP was evaluated as a continu-
ous covariate on SENS using linear, power, Emax and sigmoid Emax relationships (Equation 8). 
In the linear and power relationships, the effect of BMAP on SENS was evaluated relative 
to the population median of BMAP.
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In these equations, TVSENS represents the value of SENS for a typical subject, SENSSL,
SENSpow, SENSEmax, SENSEC50 and SENSNH represent the slope of the linear relationship, the 
power coefficient in the power relationship, the maximum effect and the BMAP at which half of 
the maximum effect is achieved in the Emax relationship, respectively. 
 
Overall, the activated concentration of TPR and HR receptors (RAC_TPR and RAC_HR) was assumed 
to influence the production rates of TPR and HR according to Equation 9 (Figure 2).  
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The developed model was externally evaluated using data from Study 2. As the amplitude 
of the circadian rhythm and the change in Kin_HR and Kin_TPR over time may vary between 
experiments due to different stress levels and differences in age and body weight, respec-
tively, first the parameters of the circadian rhythms and the change of Kin_HR and Kin_TPR 
over time were estimated on the data from the vehicle groups. Subsequently, the effect 
of fingolim d-P on MAP and HR was predicted using the developed odel and the predic-
tions were compared with the actual data.
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Prediction of the effect of siponimod
The CVS model, integrated with the developed receptor binding, down-regulation and 
sensitization model, was used to predict the effect of siponimod on MAP and HR, on the 
basis of information from in vitro assays. First the PK of siponimod was characterized 
using data from Study 3. One-, two- and three-compartmental models were evaluated to 
describe the disposition of siponimod. Furthermore, it was investigated if the absorption 
from the gastrointestinal-tract (dose compartment) to the blood (central compartment) 
could be described with first- or zero-order processes. In addition, an exploratory graphi-
cal analysis of the raw data indicated that there are two peaks in the absorption phase. 
Therefore, it was evaluated if the description of the data could be improved by including 
two dose compartments in the model from which siponimod was absorbed into the blood. 
Subsequently, the developed PK model for siponimod and the CVS model combined with 
the developed receptor binding and transduction model for fingolimod-P were used to 
predict the effect of siponimod on MAP and HR. The Kd’s of fingolimod-P for the effects 
on HR and TPR were adjusted for siponimod by correcting them for the molecular weights 
(MW) (MW fingolimod-P: 387.46 g/mol; MW siponimod: 516.61 g/mol), the unbound 
fractions (fingolimod-P: 1-1.6%; siponimod: 0.03%) and the ratio of the potencies derived 
from in vitro binding assays. It was assumed that fingolimod-P influences HR through 
binding to the S1P1 receptor (Koyrakh et al., 2005). The potencies of fingolimod-P and 
siponimod for binding to the S1P1 receptor as derived from a GTPγS assay were 2 and 
0.2 nM (Lukas et al., 2013), respectively. The efficacy was the same for both compounds, 
i.e. 0.91-0.92 (Brinkman et al., 2002; Gergely et al., 2012). Overall, the estimated Kd for 
the effect on HR of fingolimod-P (total blood concentrations) was multiplied with 4.44 
((0.2*516.61/0.0003)/(2*387.46/0.01)) to obtain the Kd for siponimod (total blood con-
centrations). In addition, Sykes et al indicated that β-arrestin recruitment could play a role 
in the persistent internalization of the S1P1 receptor, which might explain the observed 
tolerance in the effect on HR (Sykes et al., submitted). Since the potencies derived from 
β-arrestin recruitment assays differ between fingolimod-P and siponimod, i.e. the EC50’s 
for β-arrestin recruitment are 0.4 nM for fingolimod-P and 2.5 nM siponimod (Sykes et 
al., submitted), it was investigated whether the estimated IR50 and/or kout_R should be cor-
rected for this by multiplying the IR50 by 6.25 (2.5/0.4) and/or the kout_R by 0.16 (0.4/2.5). 
Furthermore, it was assumed that fingolimod-P influences TPR through binding to the 
S1P3 receptor (Peters and Alewijnse, 2007; Coussin et al., 2002; Fryer et al., 2012). The 
potencies of fingolimod-P and siponimod for binding to the S1P3 receptor were 3.98 nM 
(Brinkmann et al., 2002) and >1000 nM (Gergely et al., 2012), respectively. Due to its mar-
ginal affinity to the S1P3 receptor compared to fingolimod-P, it is unlikely that siponimod 
changes TPR through S1P3 binding.  Hence the effect of siponimod on TPR was omitted 




The data from Studies 1 and 2 were simultaneously analyzed using the non-linear mixed-
effects modeling approach implemented in NONMEM (version 7.2.0; Icon Development 
Solutions, Ellicott City, Maryland, USA). The models were compiled using Digital Fortran 
(version 6.6C3, Compaq Computer Corporation, Houston, Texas) and executed on a PC 
equipped with an AMD Athlon 64 processor 3200+ under Windows XP. The results from 
the NONMEM analysis were subsequently analyzed using the statistical software package 
S-Plus for Windows (version 8.0 Professional, Insightful Corp., Seattle, USA). Modeling 
techniques were detailed by Snelder et al. (Snelder et al., 2013a; Snelder et al., submitted 
(a)). In addition, the NWPRI subroutine in NONMEM was used to optimize the PK model 
for the 10 mg/kg dose. This allowed a penalty function based on a frequency prior to be 
specified and added to the -2log likelihood function (Gisleskog et al., 2002). It computes 
a function based on a frequency prior that has a multivariate normal form for THETA and 
an inverse Wishart form for OMEGA.
Model selection and evaluation
Models were developed and selected based on the ability to answer the research ques-
tion and pre-defined statistical criteria. For nested models, a decrease of 10.8 points (cor-
responding to p<0.001 in a c2-distribution) in the MVOF, which is defined as minus 2 log 
likelihood, after adding an additional parameter was considered statistically significant. In 
addition, standard errors of a parameter estimate should be less than 50% of the estimated 
parameter value and correlations between parameter estimates should lie between -0.95 
and 0.95. Overall, the simplest model that met the objectives of this investigation and the 
pre-defined statistical criteria was preferred in the process of model development. Model 
evaluation was detailed by Snelder et al. (Snelder et al., 2013a).
Results
Pharmacokinetics of fingolimod-P
In the previously developed PK model for fingolimod-P in rats the bioavailability was 
found to decrease with increasing dose according to a log-dose equation (Snelder et al., 
submitted (b)). According to this equation the bioavailability of the 10 mg/kg dose would 
be very low, i.e. 14%. When using this PK model, and assuming the bioavailability of the 
10 mg/kg dose equals 14%, the PK of fingolimod-P in Study 2 was predicted adequately for 
the doses of 0.1-3 mg/kg. However, fingolimod-P blood concentrations following a dose 
of 10 mg/kg were under-predicted (results not shown). Assuming that the bioavailability 
does not decrease further for doses higher than 3 mg/kg or, more specifically, assuming 
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that bioavailability of the 10 mg/kg dose equals the value of the 3 mg/kg dose, signifi-
cantly improved the goodness of fit. In addition, after optimizing Vmabs (for the 10 mg/
kg dose group only), the data from the 10 mg/kg dose group were adequately described 
(results not shown). The estimated Vmabs (254 [confidence interval (CI): 162–346] ng/h) 
was significantly higher than the estimated Vmabs from the previously developed PK model 
(105 [CI: 70.7–139] ng/h (Snelder et al., submitted (b)). 
Systems pharmacology model for the interrelationships between 
hemodynamic variables
The CVS model as expressed by Equation 1 and graphically represented in Figure 1 was 
applied to characterize the hemodynamics of the effect of fingolimod-P on the CVS. All 
system-specific parameters were fixed to values reported by Snelder et al. (Snelder et al., 
submitted (a)). However, the parameters of the circadian rhythm were optimized. The am-
plitude (0.0726 [CI: 0.0663–0.0789]) was significantly lower than the amplitude from the 
previous investigation (0.0918 [CI: 0.825–1.01] (Snelder et al., submitted (a)). The change 
in Kin_HR and Kin_TPR over time was best described by an Emax model as expressed by Equation 
2 with Emax fixed to 1. In SHR, only Kin_HR was found to change over time, whereas in WKY 
rats Kin_HR and Kin_TPR changed over time with the same ET50. 
Target activation and transduction model for fingolimod-P
The model as expressed by equations 1 - 9 was used to analyze the data from Study 1. The 
response on HR was characterized by a rapid decrease, which attenuated within 1-2 days. 
This transient effect was described by a fast inhibiting effect on Kin_HR (receptor binding), 
which was followed by stimulation of HR due to tolerance development (presumably re-
ceptor internalization and degradation). In addition, the change in TPR was described by a 
combination of a fast (receptor binding) and slow sustained (receptor sensitization) effect 
on TPR. The fast effect resulted in a rapid increase in TPR during active treatment. Due 
to the different feedback mechanisms between TPR, HR and SV (Snelder et al., submitted 
(a)) the effect of fingolimod-P on TPR was expected to translate into differential effects 
on MAP, CO, HR, SV. This was indeed observed in the data and adequately described by 
model. The slow effect was best described by permanent modulation of kout_TPR, resulting 
in a gradual increase in TPR during active treatment. As a result of the modulation of 
kout_TPR, TPR did not return to baseline after stopping treatment. Because of the negative 
feedback, MAP was increased and CO, HR and SV were decreased after stopping treat-
ment. Consequently, the sustained increase in HR, which was mediated through the effect 
of fingolimod-P on HR, was partially reversed. SENS was found to increase with BMAP 
according to a sigmoid Emax relationship as expressed by Equation 8 and SENS was 126.3% 





Figure 3: Prediction of the effect of fingolimod-P on MAP, CO, HR, SV and TPR in SHR (A) and WKY rats (B) after 
oral administration of fingolimod at a dose of 10 mg/kg once daily at 10:00 for 14 days using data from Study 1, 
experiment 2.
The dots represent the observations (symbols varied per rat) and the continuous lines represent the individual pre-
dictions. Start and stop of active treatment are indicated by the vertical grey lines. For clarity, only one observation 
per day was plotted (hourly average of 16:00-17:00).
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Figure 4: Prediction of the effect of fingolimod-P on MAP and HR in SHR (A and B) and WKY rats (C and D) after oral 
administration of fingolimod at a dose of 0, 0.1, 0.3, 1, 3 or 10 mg/kg once daily for 8 weeks using data from Study 





The grey dots represent the observations after administration of fingolimod. The continuous lines represent the 
predicted median and the grey area represents the 90% prediction interval. The observations and predictions were 
corrected for the circadian rhythm and drug-independent change over time as characterized in the vehicle group. 
For clarity, only six (hourly average, one every 4 hours) and one (hourly average of 16:00-17:00) observations per 
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105.31 mmHg). Within SHR, SENS of a rat with a BMAP of 162.14 mmHg (95th percentile 
of the BMAP distribution) was 21.5 % higher as compared to a rat with a BMAP 139.11 
mmHg (5th percentile of the BMAP distribution). The baseline values, BSL_HR, BSL_MAP 
and BSL_CO, were fixed to the individually observed values as specified in the section 
“System-specific model”.
In general, the model adequately described the effect of fingolimod-P on MAP, CO, HR, 
SV and TPR in SHR (Figures 3A and A (appendix)). However, the effect of fingolimod-P on 
MAP of one rat was over-predicted (Figure 3A). Nonetheless, an external model evalua-
tion using the data from Study 2 demonstrated that the model adequately predicts the 
Table 3: Parameter values for the final PKPD model for the effect of fingolimod on the CVS
Parameters Value RSE (%) LLCI ULCI
KdHR* (ng/mL) 3740 24.4 1950 5530
IR50_fr***
 (mL/ng) 1080 19.4 668 1490
kout_R (1/h) 0.0720 14.7 0.0512 0.0928
DEGR (1/h) 0.00286 28.0 0.00129 0.00443
KdTPR* (ng/mL) 500 40.2 106 894
SENSEMAX (1/h) 0.00267 44.2 0.000357 0.00498
SENSEC50 (mmHG) 122 25.6 60.8 183
SENSNH 4.87 44.8 0.597 9.14
S1P 1.17 19.2 0.729 1.61
horHR (h) 11.1 2.05 10.7 11.5
ampHR 0.0726 4.52 0.0662 0.0790
horTPR (h) 22.8 1.61 22.1 23.5
ampTPR Fixed to ampHR
ET50_SHR 16300 15 11500 21100
ET50_WKY rats 7360 18.1 4750 9970
Residual variability     
Prop. Res.ErrorHR (CV%) 7.4 6.70 7.98
Prop. Res.ErrorMAP (CV%) 5.7 4.88 6.41
Prop. Res.ErrorCO (CV%) 8.2  6.60 9.55
RSE: Relative Standard Error
LLCI: Lower limit of 95 % confidence interval
ULCI: Upper limit of 95 % confidence interval
CV: Coefficient of variation
Blood-plasma ratio: 0.95
Molecular weight: 387.46 g/mol
Unbound fraction: 1.3%
*KdHR based free plasma concentrations: 3740*0.013*1000/(387.46*0.95)=132 nM




effect of fingolimod-P on MAP and HR (Figure 4A). In addition, the effect of fingolimod-P 
on CO, HR, SV and TPR in WKY rats was also adequately described (Figure 3B). The effect 
on MAP was slightly under-predicted for 4 out of 7 WKY rats (Figure 3B). On the other 
hand, an external model evaluation using the data from Study 2 demonstrated that the 
model adequately predicts the effect of fingolimod-P on MAP and HR in WKY rats for 
doses of 0.1-10 mg/kg (Figure 4B). All parameters could be estimated with good precision 
(Table 3). Residual errors were small and comparable to the values from the previously 
developed CVS model (Snelder et al., submitted (a)). In addition, all correlations between 
structural parameters were less than 0.95. 
Prediction of the effect of siponimod
The PK of siponimod in the rats from Study 3 was described adequately by a two-com-
partmental model with first-order elimination (results not shown). The absorption, which 
was characterized by two peaks, was described by first-order absorption from two dose 
compartments. The absorption from the second dose compartment was delayed with a 
lag-time (Alag2). All parameters could be estimated with good precision, except for the 
absorption rates from the two dose compartments (ka1 and ka2) (Table 4). 67.7 % of the 
dose was absorbed via the first dose compartment.
The effect of siponimod on MAP and HR in SHR and WKY rats was predicted adequately 
(Figure 5) using the target activation and transduction model that was developed for 
fingolimod-P and replacing KdHR and kout_R (Figure 2). More specifically, the Kd for binding 
of fingolimod-P to the S1P1 receptor was replaced with the Kd for binding of siponimod 
to the S1P1 receptor. In addition, the kout_R for fingolimod-P induced receptor internaliza-
tion was replaced with the kout_R  for siponimod induced receptor internalization from in 
vitro assays. Overall, the effect of siponimod on HR was characterized by a small transient 
decrease in HR followed by a small increase in HR. The effect of siponimod on MAP was 
negligible.
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a
Figure 5: Prediction of the effect of siponimod on MAP (A) and HR (B) in SHR and WKY rats after oral administration 
of siponimod at a dose of 3 or 15 mg/kg once daily for 8 weeks using data from Study 2.
The grey dots represent the observations after administration of siponimod (3 or 15 mg po). The continuous lines 
represent the predicted median and the grey area represents the 90% prediction interval. The observations and 
predictions were corrected for the circadian rhythm and drug-independent change over time as characterized in 
the vehicle group. For clarity, only six (hourly average, one every 4 hours) and one (hourly average of 16:00-17:00) 
observations per day were plotted for days 0-3 and 5-75, respectively. Start and stop of treatment are indicated by 




In humans, S1P receptor agonists, which are effective in the treatment of multiple sclerosis 
(Cohen et al., 2010; Gergely et al., 2012), are associated with cardiovascular effects. The 
immunosuppressant effects, as well as the cardiovascular effects, of these compounds are 
believed to be mediated through the S1P receptor, which complicates the search for novel 
S1P receptor agonists that are devoid of cardiovascular effects. A quantitative understand-
ing of the hemodynamics of these effects is important to select new compounds with an 
improved safety profile. Moreover, it may provide insights in how to pharmacologically 
prevent and reverse these effects for new S1P receptor agonists (Kovarik et al., 2008), 
or to design dose titration schemes to attenuate these effects (Legangneux et al., 2013).
Recently, a CVS model was developed to characterize drug effects on the CVS (Snelder 
et al., 2013a; Snelder et al., submitted (a)). As a systems pharmacology model it char-
acterizes the interactions between different components of a complex system (Kohl et 
al., 2010) and can be applied to characterize drug effects. A potential application of this 
model is the prediction of the cardiovascular effects of novel compounds. To facilitate 
the prediction of cardiovascular effects in vivo using parameters derived from in vitro 
Table 4: Parameter values for the final PK model for siponimod
Parameter Value RSE (%) LLCI ULCI
Structural parameters     
ke (1/h) 0.389 11.3 0.303 0.475
Vc (L) 1.50 16.5 1.01 1.99
ka1 (1/h) 0.112 55.4 -0.00952 0.234
k23 (1/h) 0.676 40.2 0.143 1.21
k32 (1/h) 0.845 24.4 0.441 1.25
k24 (1/h) 0.0673 24.2 0.0354 0.0992
k42 (1/h) 0.0846 19.6 0.0521 0.117
Fr* 0.738 44.6 0.0932 1.38
ka2 (1/h) 0.431 100 -0.414 1.28
Alag2 7.13 28.2 3.19 11.1
Inter-Individual variability    
Fr (additive) (CV%) 123.3 43.0 39.6 211.5
Residual variability     
Prop. Res.ErrorHR (CV%) 21.8  17.77 25.23
RSE: Relative Standard Error
LLCI: Lower limit of 95 % confidence interval
ULCI: Upper limit of 95 % confidence interval
CV: Coefficient of variation
*: F1 (Relative bioavailability dose compartment  1) = EXP(Fr)/(1+EXP(Fr))
    F5 (Relative bioavailability dose compartment  2) = 1- EXP(Fr)/(1+EXP(Fr))
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Figure 6: Illustration of the change over time in the pharmacokinetics of fingolimod or siponimod (A), receptor 
binding kinetics (B), receptor activation (C) and response (D) in SHR after administration of 7 daily doses of fingo-
limod (10 mg/kg; black lines) or siponimod (15 mg/kg; grey lines) as predicted by the CVS model integrated with 
expression for receptor binding kinetics.
For fingolimod the estimated KdTPR is in the same range as the total blood concentrations, whereas the KdHR is above 
estimated total blood concentrations resulting in a larger change in receptor occupancy and a larger relative effect 
at the S1P3 receptor (S1P3R) than at the S1P1 receptor (S1P1R). For siponimod the assumed KdHR is higher than the 
KdHR for fingolimod, whereas the concentrations are in the same range. Therefore, the relative effect of siponimod 
on HR is smaller than the effect of fingolimod. The overall responses on MAP, HR, CO, SV and TPR result from the 
combined effects on HR and TPR. Receptor sensitization was omitted. The predicted maximum decrease in HR is 
approximately 42 beats/min after administration of fingolimod (10 mg/kg), of which ~15 and 27 beats/min result 
from the effects on HR and TPR respectively, and 10 beats/min after administration of siponimod (15 mg/kg). The 
nadir is reached at approximately 8 and 3 hours after the first dose for fingolimod and siponimod, respectively
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experiments this requires the interfacing of the CVS model with a target receptor bind-
ing and activation model. In this investigation the systems cardiovascular pharmacology 
CVS model was successfully applied to characterize and predict the hemodynamics of the 
cardiovascular effects of S1P receptor agonists in rats, using fingolimod-P and siponimod 
as paradigm compounds. 
First the effect of fingolimod-P on the CVS was characterized. The CVS model was combined 
with a receptor binding, down-regulation and sensitization model to describe the effect of 
fingolimod-P on HR and TPR (Figure 2). More specifically, the transient effect on HR was 
described by a fast inhibiting effect depending on the degree of receptor binding, which 
was followed by stimulation of HR due to tolerance development presumably as a result 
of receptor internalization and degradation. Furthermore, the effect of fingolimod-P on 
TPR was described by a combination of a fast and a slow sustained effect. As a next step, 
the effect of siponimod on MAP and HR was predicted. The effect of siponimod on MAP 
was negligible and the effect on HR was characterized by a small transient decrease in HR 
followed by a small increase in HR. In general, these effects were adequately predicted in 
SHR and WKY rats (Figure 5), which indicates that the developed model may be applied 
to predict the effect of other S1P agonists on the CVS in rat. The simulated changes over 
time in all components leading to the overall response on MAP, CO, HR, SV and TPR are 
illustrated in Figure 6 following once daily administration of fingolimod or siponimod at 
doses of 10 and 15 mg/kg, respectively. 
The identified drug effects of fingolimod-P and siponimod are in line with the available 
information on the mechanisms underlying the cardiovascular effects of fingolimod-P and 
siponimod, which increases the confidence in the applied systems pharmacology model-
ing approach and the predictive power of the model. Briefly, the current understanding 
on the mechanisms underlying the cardiovascular effects of fingolimod-P and siponimod 
are as follows. Fingolimod, and more specifically, fingolimod-P binds to 4 of the 5 subtypes 
of the S1P receptor (S1P1 and S1P3-5) with high affinity (0.3-3.1 nM) (Mandala et al., 2002; 
Brinkmann, 2007; Brinkmann et al., 2004), whereas siponimod binds to only 2 of the 5 
subtypes (S1P1 and S1P5) with high affinity, while the affinity for the S1P3 receptor is low 
(Gergely et al., 2012). S1P1 is thought to be the relevant receptor subtype involved in the 
modulation of HR (Horga et al., 2010; Gergely et al., 2012). The atrial muscarinic-gated 
potassium channel IKACH is activated (Koyrakh et al., 2005), which results in a negative 
chronotropic effect. Therefore, fingolimod-P first acts as a full agonist at the S1P1 receptor 
(Horga et al., 2010; Mullershausen et al., 2009). The transient nature of the effect on HR 
is related to receptor internalization and degradation (Horga et al., 2010; Mullershausen 
et al., 2009). As a result fingolimod-P acts a functional antagonist. The exact mechanism 
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underlying the effect of fingolimod-P on TPR, and thus MAP, is under debate. Three differ-
ent mechanisms have been proposed. 
i) Fingolimod-P influences TPR through binding to the S1P3 receptor (Peters and Alewi-
jnse, 2007; Coussin et al., 2002). 
ii) Fingolimod-P influences TPR via a shift in the balanced S1P-S1P1/S1P2/S1P3-signaling 
resulting from finglolimod-P induced S1P1 receptor internalization (Bigaud et al., 
2013).
iii) Fingolimod (not fingolimod-P) induces TPR via inhibition of S1PHK1 (Spijkers et al., 
2012). 
In humans, the first hypothesis is thought to be unlikely as the blood concentrations of S1P 
as well as the affinities of S1P for the S1P3 receptor are considerably higher compared to 
fingolimod-P (Sykes et al., submitted; Bigaud et al., 2013). However, for several reasons it 
is possible that this hypothesis is valid in rat. For instance, 1) the exact free S1P concentra-
tion in different tissues is unknown (Bigaud et al., 2013), 2) large inter-species differences 
may exist in S1P concentration (Gräler et al., 2004) and 3) receptor binding kinetics may 
vary considerably between rat and human. The second hypothesis represents the current 
understanding on the small slow, increase in MAP following therapeutic dosing regimen 
in humans. As siponimod leads to internalization of the S1P1 receptors this assumption 
implies that siponimod would have an effect on MAP, whereas such an effect has not 
been reported in man and was not observed in rats. It cannot be excluded, however, that 
this was not observed in rats due to a limited experimental design, e.g. a low number 
of rats or too low siponimod doses. Finally, the third hypothesis seems implausible as 
inhibiting S1P synthesis would influence the whole S1P biology. Overall, it seems most 
likely that the fast effect of fingolimod-P on TPR, which was observed in rats, is mediated 
through the S1P3 receptor. Furthermore, the slow effect on TPR may be a result of recep-
tor sensitization. More precisely, the major trigger for smooth muscle cell contraction 
is a rise in intracellular calcium concentration. Whereas the calcium-dependent phase 
of smooth muscle cell contraction is rapid and relatively transient, calcium sensitization 
produced by agonist stimulation results in a sustained contraction of vascular smooth 
muscle cells (Watterson et al., 2005), and thus, in a sustained increase in TPR. However, 
other mechanisms underlying the slow effect on TPR, including a shift in the balanced 
S1P- S1P1/S1P2/S1P3-signaling as proposed by Bigaud et al. (Bigaud et al., 2013), may not 
be excluded as it is not possible to distinguish between different hypotheses following a 
data driven modeling approach when the expected effect is comparable.
In general, the effect of fingolimod-P on MAP, CO, HR, SV and TPR in SHR and WKY rats was 
adequately described by the model (Figure 3, 4 and A (appendix)). However, the effect on 
MAP in WKY rats was slightly under-predicted for 4 out of 7 WKY rats. This could indicate 
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that the feedback, which was fixed to the value from the CVS model, was too strong for 
WKY rats. In the CVS model, the efficiency of the feedback was found to decrease with 
higher BSL_MAP values, indicating a decrease in the efficiency of blood pressure regula-
tion in hypertensive subjects. Since the characterization of the feedback relationship was 
based on data from a limited number of rats, i.e. 10 SHR and 2 WKY rats, the accuracy 
of the estimation of feedback might be low for WKY rats. In addition, it should be noted 
that in Study 1 the effect of fingolimod-P on the CVS was investigated for a dose of 10 
mg/kg only. As the external model evaluation demonstrated that the data from Study 2 
could be adequately predicted for all doses in both SHR and WKY rats, the small under-
prediction of the effect of fingolimod-P on MAP in WKY rats in Study 1 was accepted. The 
inter-individual variability in the response was large and originated mostly from variability 
in baselines and receptor sensitization. Therefore, in the final model the variability in 
baselines was accounted for by using the observed baseline values of MAP, CO and HR 
(BSL_MAP, BSL_CO and BSL_HR), rather than the model predictions. Quantification of the 
covariate effect of BMAP on SENS largely explained the observed variability in sensitization. 
However, after accounting for these inter-individual differences, the effect of fingolimod-P 
on MAP in 1 SHR was over-predicted indicating that not all variability between rats was 
explained (Figure 3A). As, in general, the data from Study 1 were adequately described 
by the model, and an external model evaluation demonstrated that the data from Study 
2 could be adequately predicted, the random structure of the model was not further 
optimized. KdTPR and KdHR were estimated to be 17.7 [CI: 3.74–31.6] and 132 [CI: 68.9–195] 
nM based on free plasma concentrations, respectively (Table 3). In addition, S1P, which 
represents the ratio of the S1P concentration and the Kd of S1P for binding to the S1P 
receptor, was estimated to be 1.17 [CI: 0.729-1.61] (Table 3). This indicates that the free 
S1P plasma concentration, which is probably the best predictor for the effect of S1P on 
the CVS, is in the same order of magnitude as the Kd. 
Finally, it should be noted that the identified receptor (target) binding and activation pa-
rameters are estimated on the basis of hemodynamic data. Therefore, a comparison with 
parameters derived from in vitro binding assays using the rat S1P receptor is required in 
order to investigate whether the receptor binding and activation are reflected adequately. 
However, to date no quantitative information has been published on the receptor binding 
kinetics of S1P agonists in rats. Therefore, these estimates should only be interpreted 
in the context of this model. For the same reason, the modeling results do not provide 
definite conclusions on the plausibility of the different hypothesized mechanisms underly-
ing the effect of fingolimod-P on TPR, and thus MAP. 
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In conclusion, a previously developed system-specific model to characterize drug effects 
on the CVS was combined with a receptor binding model with drug-specific parameters, 
and down-regulation and sensitization models with class-specific parameters. This model 
was applied to quantify the cardiovascular effects of fingolimod-P in rat and provided a 
quantitative understanding of the hemodynamics of the cardiovascular effects following 
the administration of fingolimod-P. In addition, the effect of siponimod on the CVS was 
predicted adequately by multiplying the estimated in vivo dissociation constants of fingo-
limod-P for binding to the S1P receptors with the ratio of the potencies of fingolimod-P 
and siponimod derived from in vitro binding assays. Therefore, it is anticipated that the 
developed model can be applied to predict the effect of other S1P receptor agonists on 
the CVS in rat. Ultimately, this quantitative pharmacology model may be used to predict 
the clinical response of fingolimod-P and follow-up compounds on the CVS based on 
preclinical data. Before our model can be applied for that purpose, the model should be 
scaled to human and validated on human MAP, CO and HR measurements (Snelder et 
al., 2013a). In addition, inter-species differences in plasma protein binding, blood-plasma 
distribution (Snelder et al., submitted (b)) and receptor function and expression should 
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BMAP  Observed baseline value of mean arterial pressure (covariate)
BSL_CO Baseline value of cardiac output
BSL_HR Baseline value of heart rate
BSL_MAP Baseline value of mean arterial pressure (parameter)
BSL_SV Baseline value of stroke volume
BSL_TPR Baseline value of total peripheral resistance
C drug concentration in plasma
CO Cardiac output
CVS Cardiovascular system
Emax  Maximum effect
EC50 Concentration resulting in a half-maximal effect






Kin_HR  Zero-order production rate constant of heart rate
Kin_SV Zero-order production rate constant of stroke volume
Kin_TPR Zero-order production rate constant of total peripheral resistance
kout_HR First-order dissipation rate constant of heart rate
kout_SV First-order dissipation rate constant of stroke volume
kout_TPR First-order dissipation rate constant of total peripheral resistance
LVFT Left ventricular filling time
MAP Mean arterial pressure
MC Methylcellulose
MoA Mechanisms of action
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S1P1R sphingosine 1-phosphate receptor, subtype 1
S1P3R sphingosine 1-phosphate receptor, subtype 1
T Time
TPR  Total peripheral resistance








Figure A: Prediction of the effect of fingolimod-P on MAP (A), CO (B), HR (C), SV (D) and TPR (E) in SHR after once 
daily administration of fingolimod (dose: vehicle, 0.1, 0.3, 1, 3 or 10 mg/kg p.o.) using data from Study 1, experi-
ment 1.
The dots represent the observations (symbols varied per rat) and the continuous lines represent the individual pre-
dictions. Start and stop of active treatment are indicated by the vertical grey lines. For clarity, only one observation 
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A systems pharmacology approach to 
the prediction of cardiovascular side 






Cardiovascular safety issues related to changes in blood pressure, arise frequently in drug 
development. In this thesis, a systems pharmacology model is described which allows 
predicting hemodynamic changes in man on the basis of information from pre-clinical 
studies. The proposed model is based on well-established principles of the regulation of 
blood-pressure. It is well-known that mean arterial pressure (MAP) equals the product of 
cardiac output (CO) and total peripheral resistance (TPR) and that CO equals the product 
of HR and stroke volume (SV). However, the effects of drugs on this interrelationship have 
not been analyzed in a mechanism-based and quantitative manner. A pertinent feature 
of mechanism-based pharmacokinetic-pharmacodynamic (PKPD) models is the distinc-
tion between drug and biological-system specific properties for the characterization of in 
vivo drug effects (Danhof et al., 2007; Ploeger et al., 2009). In this regard, drug-specific 
parameters describe the interaction between the drug and the biological system in terms 
of target affinity and target activation, whereas system-specific parameters describe the 
dynamics of the biological system. This separation enables prediction and extrapolation 
of treatment effects to biological systems other than the systems that have been studied 
(e.g. the translation from laboratory animals to humans) (Danhof et al., 2007). Typically, 
mechanism-based and mechanistic PKPD models are based on an analysis of the causal 
path between drug exposure and response. More recently the concept of systems phar-
macology has been introduced. With systems pharmacology models the complexity is 
increased by focusing on networks and the interactions between different components of 
the network. A systems pharmacology modeling approach is uniquely suited to quantify 
drug effects on the interrelationship between MAP, CO, HR, SV and TPR (Chapter 1).
The objectives of the investigations described in this thesis were 1) to establish a systems 
pharmacology model to characterize the effects of drugs with different mechanisms of 
action (MoA’s) on the interrelationship between MAP, CO, HR, SV and TPR in a quantitative 
manner and 2) to apply the model to the quantification of the cardiovascular effects of 
the sphingosine 1-phosphate (S1P) receptor modulator fingolimod. In this chapter, the 
results of the investigations described in this thesis are reviewed and the perspectives and 
conclusions are presented.
Development of a systems pharmacology model to characterize the 
CVS
In Chapter 3, a systems pharmacology model was proposed to characterize the CVS in 
hypertensive rats. This system pharmacology model is based on the interrelationship 
between MAP, CO and TPR. The effects of a prototype set of cardiovascular compounds 
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with different mechanisms of action were characterized in chronically instrumented spon-
taneously hypertensive rats (SHR). Beforehand it was hypothesized that two aspects of 
the experimental design were pivotal to successfully quantify the parameters of the basic 
CVS model: i) the selection of the prototype set of compounds affecting the functioning of 
the CVS and ii) measuring both MAP and CO during the on- and offset phases of the drug 
effects. By selecting a range of cardiovascular drugs with well described, but different 
target sites and with different profiles of the time courses of the effects, all parameters 
of the systems pharmacology model could be estimated with good precision. Moreover, 
system-specific parameters could be distinguished from drug-specific parameters indicat-
ing that the developed model is drug-independent. The measurement of CO, was pivotal 
to identify all parameters of the basic systems pharmacology model as this provide the 
information to distinguish between changes in CO and TPR. To be able to measure drug ef-
fects on MAP and CO, rats were surgically instrumented with both an ascending aortic flow 
BP & HR




Figure 1: Experimental animal instrumentation. Rats were surgically instrumented with both an ascending aortic 
flow probe (A) and a femoral arterial catheter/radiotransmitter (B). CO was measured by connecting the flow probe 
to the flow meter via a cable and electrical swivel (C), which allowed the animal to remain fully ambulatory.  MAP, 
HR, SV, CO, and TPR were derived for all beats averaged over consecutive 2-min intervals.
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probe and a femoral arterial catheter/radiotransmitter (Figure 1). Overall, the rigorous 
experimental design provided the data to describe the interrelationship between MAP, 
CO and TPR in a quantitative and mechanism-based manner. The basic CVS model can be 
applied to elucidate the site of action of new compounds which affect MAP through a still 
unknown MoA.
A limitation of this model is that measuring CO has not been integrated into daily practice 
due to the challenges associated with the implantation of aortic flow probes. Therefore, 
in Chapter 4 the basic CVS model was extended by parsing CO into HR and SV (Figure 
Figure 2: Comparison between the basic CVS model to characterize drug effects on the interrelationship between 
MAP, CO and TPR and the extended CVS model to characterize drug effects on the interrelationship between MAP, 
CO, HR, SV and TPR
Basic CVS model (Chapter 3): MAP equals the product of CO and TPR (MAP=CO*TPR). Effects on CO and TPR are 
described by two linked turnover equations. When MAP increases as a result of a stimulating effect on CO or TPR, 
the values of CO and TPR will decrease as a result of the action of the different feedback mechanisms regulating the 
CVS. The magnitude of feedback on CO and TPR is represented by FB1 and FB2.
Extended CVS model (Chapter 4): MAP equals the product of CO and TPR (MAP=CO*TPR) and CO equals the prod-
uct of HR and SV (CO=HR*SV)). SV is influenced by indirect feedback through MAP (SVT) and by HR through a direct 
inverse log-linear relationship, where HR_SV represents the magnitude of this direct effect. Effects on HR, SV and 
TPR are described by three linked turnover equations. When MAP increases as a result of a stimulating effect on HR, 
SV or TPR, the values of HR, SV and TPR will decrease as a result of the action of the different feedback mechanisms 
regulating the CVS. The magnitude of feedback on HR, SV and TPR is represented by FB. Kin_CO, Kin_HR, Kin_SV 
and Kin_TPR represent the zero-order production rate constants and kout_CO, kout_HR, kout_SV and kout_TPR 
represent the first-order dissipation rate constants
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2) with the aim to 1) characterize drug effects on the interrelationship between HR and 
MAP, which are both important variables in the safety evaluation of novel drugs and 2) 
investigate if the MoA of new compounds can be elucidated using HR and MAP measure-
ments only.
The behavior of the extended CVS model was evaluated by simulating the changes in 
MAP, CO, HR, SV and TPR after triggering the model by inhibiting HR, SV or TPR with a 
hypothetical compound after a single oral dose (Figure 3). The characteristic profiles of 
the time-course of the drug effect on MAP, CO, HR, SV and TPR are referred to as signa-
ture profiles. For the different variables distinctly different profiles were observed. From 
these simulations it can be concluded that, even if CO is not measured, it is likely that 
the extended CVS model can be used to elucidate the site of action of novel compounds 
with a single MoA (i.e., one site of action). In summary, when the nature (i.e. an increase 
or decrease) of the drug induced change in HR and MAP is the same, it is likely that the 
primary effect is on HR. When HR and MAP change in opposite directions, i.e. an increase 
in HR and a decrease in MAP or vice versa, the primary effect of the drug is expected to 
be on SV or TPR. Effects on SV and TPR can be distinguished by the delay between the 
perturbation and the effect on MAP, i.e. a long delay indicates that the primary effect is 
on SV and a short delay indicates that the primary effect is on TPR. Next to MAP, HR is an 
important parameter in the safety evaluation of novel drugs for a wide variety of disorders 
(Sudano et al., 2012; Gasparyan et al., 2012; Cardinale et al., 2013; Guth, 2007). Although 
MAP and HR are usually measured simultaneously, it is common practice to quantify drug 
effects on these hemodynamic parameters independently resulting in two separate dose/
concentration-effect relationships. However, this approach disregards the interrelation-
ship between MAP and HR. Therefore, an additional advantage of extending the basic 
CVS model by parsing CO into HR and SV is that drug effects on MAP, CO, HR, SV and TPR 
can be characterized simultaneously yielding a single unique set of parameter estimates. 
Furthermore, the basic CVS model was extended to a more detailed level by quantifying 
differences in blood pressure regulation between normotensive and hypertensive rats. 
As there are pronounced differences in MAP regulation between hypertensive and nor-
motensive rats (Pinto et al., 1998) the magnitude of the effect of cardiovascular drugs on 
the different hemodynamic endpoints varies considerably between strains. Therefore, the 
basic CVS model is not directly applicable to data from normotensive rats. This is a major 
drawback especially for drug safety evaluations, which are usually conducted in normo-
tensive rats. As the ultimate aim of the proposed quantitative pharmacology model is to 
predict clinical responses to novel pharmacologic agents, it is pivotal that the CVS model 
is applicable to both normotensive and hypertensive rats. The baseline parameters were 
found to differ per strain with a higher baseline value of MAP and a lower baseline value 
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of CO for hypertensive as compared to normotensive rats, whereas the baseline value 
for HR did not significantly differ between the strains. The baseline values of SV and TPR 
were derived from these parameters, resulting in a lower baseline value of SV and a higher 
baseline value of TPR for hypertensive as compared to normotensive rats. In addition, 
feedback was found to decrease with the individual value of the baseline of MAP. Overall, 
the feedback was about 2-fold higher in normotensive rats as compared to hypertensive 
rats indicating impaired blood pressure regulation in hypertensive rats. In conclusion, 
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Figure 3: System properties of the CVS
The system properties of the CVS were investigated by simulating the response on MAP, CO, HR and TPR after inhib-
iting HR (A), SV (B) or TPR (C). Inhibiting HR, SV or TPR always results in a decrease in MAP, which demonstrates that 
feedback cannot be stronger than the primary effect. In addition, the delay in response on MAP was longer when 
the drug effect was on SV as compared to TPR.
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HR, SV and TPR, was obtained in hypertensive and normotensive rats. The extended CVS 
model can be used to quantify the dynamic changes in the CVS and elucidate the MoA 
for novel compounds using HR and MAP measurements only. The model can also be ap-
plied to test hypotheses, e.g., hypotheses on multiple sites of action can be evaluated by 
including drug-effects on multiple parameters in the model. An ultimate application of the 
extended CVS model would be to facilitate the anticipation of the clinical response based 
on preclinical data for newly developed compounds. Before the extended CVS model can 
be applied for that purpose, the system-specific parameters of the model should be scaled 
to human and validated on human MAP, HR and CO measurements as detailed in the sec-
tion “Towards characterization and prediction of cardiovascular drug effects in humans”.
Application of the systems pharmacology model to S1P receptor 
agonists
In humans, S1P receptor modulators, which are effective in the treatment of multiple 
sclerosis (Cohen et al., 2010; Gergely et al., 2012), are associated with cardiovascular side 
effects. More specifically, at the therapeutic dose of 0.5 mg, a transient decrease in HR (8 
beats per minute with attenuation after 6 hours) and a small increase in MAP (1-2 mmHg 
after 2 months) were observed after administration of fingolimod (Kappos et al., 2010). In 
addition, at the supra-therapeutic doses of 1.25 and 5 mg, HR was reduced within 6 hours 
by a mean of 13.8 and 16.6 beats per minute, respectively, returning towards the baseline 
value with continued treatment. At these doses, MAP was mildly increased by 5-6 mmHg 
following continuous treatment (Kappos et al., 2006).
The immunosuppressant effects, as well as the cardiovascular side effects, of these com-
pounds are believed to be mediated through the S1P receptor, which complicates the 
search for novel S1P receptor modulators, which are devoid of cardiovascular side effects. 
A quantitative understanding of the hemodynamics of these effects is important as it may 
constitute a basis for the selection of new compounds with an improved safety profile. 
Moreover, it may provide insights in the possibility to prevent and reverse these effects for 
new S1P receptor modulators by co-administration of other drugs (Kovarik et al., 2008), 
or to design dose titration schemes to attenuate these effects (Legangneux et al., 2013). 
The extended CVS model is uniquely suited to provide a quantitative understanding of 
these effects as the structure of the model and the values of the parameters describing 
the model are independent of the drugs that were used to create it and, therefore, the 
model can be used to quantify the dynamic changes in the CVS for other compounds and 
thus for fingolimod. A potential application of this model is the prediction of the cardio-
vascular effects of novel compounds. This requires interfacing the CVS model with a target 
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binding-activation model. Moreover, the proposed systems pharmacology model may 
allow prediction of cardiovascular effects of S1P receptor modulators in humans based 
on preclinical evaluations. A complicating factor in the translational pharmacology of fin-
golimod and, in general S1P receptor modulators, is that they exert their pharmacological 
effect through their respective phosphate metabolites, which are formed by the enzyme 
sphingosine kinase (S1PHK). At first, the pharmacokinetics (PK) of fingolimod and its active 
metabolite fingolimod-phosphate (fingolimod-P) were characterized in rats and humans. 
Since large inter-species differences exist in the S1PHK enzyme tissue distribution and en-
zyme activity, it is anticipated that the PK of S1PHK substrates in rats may not be scalable 
to humans using a standard allometric scaling approach. In Chapter 5, a semi-mechanistic 
PK model for the inter-conversion of S1PHK substrates and their respective phosphates in 
rats and humans was proposed. A specific aim was to determine whether species specific 
differences in the ex vivo rate of phosphorylation in blood platelets are representative for 
the differences in the phosphorylation in general and might therefore constitute a basis 
for pharmacokinetic scaling. To explore this, data on the time course of fingolimod and 
fingolimod-P blood concentrations in rats following intravenous administration of fingoli-
mod and fingolimod-P as well as following oral administration of fingolimod were analyzed 
in conjunction with data on the ex vivo inter-conversion and blood-plasma distribution in 
rat blood. Separately, data from two healthy volunteer studies, in which fingolimod was 
administered orally in doses of 0.5, 1.25 and 5 mg once daily, were simultaneously ana-
lyzed with data on the ex vivo inter-conversion and blood-plasma distribution in human 
blood. Overall, the PK of fingolimod and fingolimod-P in rats and humans was adequately 
characterized by a semi-mechanistic model in which phosphorylation of fingolimod oc-
curred pre-systemically during first-pass in the liver and in the platelets (Figure 4). In 
addition, dephosphorylation occurred in the plasma. Integrating data from the ex vivo 
and in vivo studies enabled prediction of fingolimod and fingolimod-P concentrations in 
plasma rather than blood. This is important because plasma concentrations are more 
relevant for predicting drug effects as, according to the free drug hypothesis, only drug 
present in plasma is able to bind to its target. Moreover, inter-species differences in the 
rate of phosphorylation could be quantified. In humans, phosphorylation of fingolimod 
in the platelets was 4 times slower compared to rats, whereas the de-phosphorylation 
rates were comparable in both species. In conclusion, using fingolimod as a paradigm 
compound, large interspecies differences in the rate of phosphorylation between rats 
and humans were demonstrated, which cannot be accounted for by allometric scaling. 
Although, this only partly explained the 12-fold over-prediction of fingolimod-P exposure 
in humans when applying an allometric scaling approach on the developed rat model, 
the developed semi-mechanistic PK model constitutes a basis for the prediction of the 
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concentrations of S1PHK substrates and their phosphorylated metabolites in plasma. 
However, differences in pre-systemic phosphorylation should also be taken into account. 
In Chapter 6, the extended CVS model and semi-mechanistic PK model for fingolimod 
and fingolimod-P in rats were applied to characterize the cardiovascular effects following 
the administration of fingolimod in normotensive and hypertensive rats. Briefly, data on 
the concentrations of fingolimimod-P and the changes in various hemodynamic variables 
were analyzed on the basis of the extended CVS model. In a first step, a model-based 
Figure 4: Pharmacokinetic models to describe the time course of the fingolimod and fingolimod-P blood concentra-
tion in rats and humans. 
The grey area describes the inter-conversion and blood/plasma distribution in isolated blood. Kxy represent the 
first-order distribution and elimination rate constants. Arrows with an equal number of slashes indicate that these 
rates are the same. In addition, the dashed lines represent saturable processes.  
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hypothesis testing procedure was followed using the extended CVS model without chang-
ing the system-specific parameters.
1) Different hypotheses of the site of action (i.e. HR, SV and TPR) and direction of the 
effect (i.e., inhibiting or stimulating) were formulated, resulting in 6 possible combina-
tions of effects. 
2) For each hypothesis, the model was fitted to the MAP, CO, HR, SV and TPR measure-
ments.
3) It was evaluated which hypothesis resulted in the best description of the data. 
It was found that effect of fingolimod-P on the CVS could be described while assuming 
multiple sites of action, i.e. TPR and HR (Snelder et al., 2013). Overall three different ef-
fects were quantified: 1) a fast stimulating effect on TPR, 2) a slow sustained stimulating 
effect on TPR which is only relevant in hypertensive rats following doses higher than 1 mg/
kg and 3) a transient inhibiting effect on HR. In this first step, drug effects were described 
by empirical models. This provided information on the most plausible sites of action 
of fingolimod-P, but it also demonstrated that extended CVS model can be applied to 
quantify the hemodynamics of the effect of fingolimod-P on five different parameters, i.e. 
MAP, CO, HR, SV and TPR, while assuming only two different sites of action. In a next step, 
the obtained information on the site of action of fingolimod-P was compared with the 
available information on the mechanism of action of fingolimod-P. Briefly, at the time of 
the analysis the following was known about the MoA underlying the effect of fingolimod-P 
on the CVS. 
i. Fingolimod-P influences HR through to binding to the S1P1 receptor. The arterial 
muscarinic-gated potassium channel IKACH is activated (Koyrakh et al., 2005), which 
results in a negative chronotropic effect.   
ii. Fingolimod-P induces internalization and degradation of the S1P1 receptor (Horga 
et al., 2010; Mullershausen et al., 2009). As a result fingolimod-P acts a functional 
antagonist.
iii. Fingolimod-P influences TPR through binding to the S1P3 receptor (Peters and Alewi-
jnse, 2007; Coussin et al. 2002). The S1P3 receptor is expressed in vascular smooth 
muscle cells and regulates the contractility of these cells. As a result fingolimod-P 
increases peripheral resistance and thus blood pressure.
iv. The major trigger for smooth muscle cell contraction is a rise in intracellular calcium 
concentration. Whereas the calcium-dependent phase smooth muscle cell contraction 
is rapid and relatively transient, calcium sensitization produced by agonist stimulation 
results in as sustained contraction of vascular smooth muscle cells (Watterson et al., 
2005), and thus, in a sustained increase in TPR.
Since this information is in line with the elucidated site of action of fingolimod-P the em-
pirical drug-effect models were replaced by models based on receptor theory concepts 
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for the characterization of target binding and target activation processes, which improved 
the properties for extrapolation to humans and the prediction of the effects of follow-
up compounds (Danhof et al., 2007; Ploeger et al., 2009). As fingolimod-P is an agonist 
for the S1P receptor competitive interaction between the endogenous agonist, S1P, and 
fingolimod-P was taken into account for both the effects on HR and TPR. The developed 
model existed of expressions to describe 1) competitive receptor binding kinetics to 
the S1P1 receptor (fast effect on HR), 2) S1P1 receptor internalization and degradation 
(transient nature of the fast effect on HR), 3) competitive receptor binding kinetics to the 
S1P3 receptor (fast effect on TPR), and 4) S1P3 receptor sensitization (slow effect on TPR) 
(Figure 5). By characterizing drug effects on HR and TPR, the effects of fingolimod-P on 
MAP, CO, HR, SV and TPR were adequately described in hypertensive and normotensive 
rats. The dissociation constants for the effects on TPR (KdTPR; binding to the S1P3 receptor) 
and HR (KdHR; binding to the S1P1 receptor) were estimated to be 17.7 [confidence interval 
(CI): 3.74–31.6] and 132 [CI: 68.9–195] nM based on free plasma concentrations, respec-
tively. The KdTPR is in the same order of magnitude as the in vitro binding dissociation 
constant for binding of fingolimod-P to the human S1P3 receptor reported by Mandale 
et al. of 3.15±1.7 nM (Mandala et al., 2002; calculated using the Cheng-Prusoff equa-
tion (Cheng and Prusoff, 1973)). However, the estimated KdHR differs from the reported in 
vitro dissociation constants for the binding of fingolimod-P to the human S1P1 receptor of 
0.17±0.14 nM (Mandala et al., 2002; calculated using the Cheng-Prusoff equation (Cheng 
and Prusoff, 1973)). It should be noted that, in vivo, the S1P1 receptor is internalized and 
degraded. This could confound the estimation of the dissociation constant. Moreover, it 
should be noted that the reported dissociation constants reflect binding to human S1P1 
and S1P3 receptors. Dissociation constants for binding to rat S1P1 and S1P3 receptors are 
not reported and it is known that large interspecies differences may exist. 
Since the developed model was based on receptor theory concepts for the characterization 
of target binding the model could readily be applied to predict the effect of siponimod, 
a S1P receptor agonist with different receptor subtype selectivity, on the CVS by correct-
ing the estimated dissociation for fingolimod-P for the molecular weights, the unbound 
fractions and the ratio of the potencies derived from in vitro binding assays. Overall, the 
effect of siponimod on MAP and HR in rats was adequately predicted by the model (using 
its in vitro receptor binding constants), which indicates that the developed model can 
be applied to predict the effect of other S1P modulators on the CVS in rats. Ultimately, 
the proposed system pharmacology model may allow prediction of cardiovascular effects 
of S1P receptor modulators in humans based on preclinical evaluations of drug effects. 
However, this requires several steps, which are described in the next section.
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Perspectives - Towards characterization and prediction of 
cardiovascular drug effects in humans
An ultimate application of the developed systems pharmacology model is to predict car-
diovascular effects in man on the basis of information from pre-clinical studies for newly 
developed compounds and, more specifically, for S1P receptor agonists, i.e. follow-up 
compounds of fingolimod. In this section, first, the inter-species translation of the system-
specific CVS model is discussed. Thereafter, the inter-species translation of the effect of 
S1P receptor agonists is addressed.
Figure 5: Cardiovascular model to describe drug effects on the interrelationship between mean arterial pressure 
(MAP), cardiac output (CO), heart rate (HR), stroke volume (SV) and total peripheral resistance (TPR) after admin-
istration of fingolimod. 
Extended CVS model: Cardiac output (CO) equals the product of HR and SV (CO=HR*SV) and MAP equals the prod-
uct of CO and TPR (MAP=CO*TPR). SV influenced by indirect feedback through MAP (SVT) and by HR through a direct 
inverse log-linear relationship, where HR_SV represents the magnitude of this direct effect. Effects on HR, SV and 
TPR are described by three linked turnover equations. In these equations Kin_HR, Kin_SV and Kin_TPR represent the 
zero-order production rate constants and kout_HR, kout_SV and kout_TPR represent the first-order dissipation rate 
constants. When MAP increases as a result of a stimulating effect on HR, SV or TPR, the values of HR, SV and TPR 
will decrease as a result of the action of the different feedback mechanisms regulating the CVS. In this model the 
magnitude of feedback on HR, SV and TPR is represented by FB.
Effect of fingolimod-P: The primary effect of fingolimod-P is on TPR. The effect on TPR is a combination of a fast 
stimulating effect and a slowly occurring stimulating effect (sensitization). The effect on HR is initially an inhibiting 
effect. However, as a result of the receptor internalization this effect rapidly attenuates.
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Translation of the system-specific CVS model
The extended CVS model consisted of three turnover equations, for HR, SV and TPR re-
spectively, which were linked by negative feedback through MAP (Equation 1). 
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In these equations, SV* represents the SV influenced by the negative feedback of MAP, Kin_HR,
Kin_SV  and Kin_TPR represents the zero-order production rate constants and kout_HR, kout_SV and 
kout_TPR represent the first-order dissipation rate constants of HR, SV and TPR, respectively. In 
addition, FB0_MAP, IBSL_ MAP and TVBSL_MAP_SHR represent the exponent of the power 
relationship, the individual baseline values of MAP and typical value of BSL_MAP in SHR, 
respectively. The basic expectations in pharmacodynamics are that physiological turnover rate 
 (1)
In these equations, SV* represents the SV influenced by the negative feedback of MAP, 
Kin_HR, Kin_SV  and Kin_TPR represents the zero-order production rate constants and kout_HR, 
kout_SV and kout_TPR represent the first-order dissipation rate constants of HR, SV and TPR, 
respectively. In addition, FB0_MAP, IBSL_ MAP and TVBSL_MAP_SHR represent the expo-
nent of the power relationship, the individual b s line values of MAP and typical value 
of BSL_MAP in SHR, respectively. The basic expectations in pharmacodynamics are that 
physiological turnover rate constants of most general structures and functions should be 
predictable among species based on allometric principles (Mager et al., 2009; West et al., 
1999). Therefore, to extrapolate the extended CVS model to the human situation allome-
tric scaling principles were applied t  scale the first order rate onstan s kout_HR, kout_SV and 
kout_TPR
 for humans. As allometric models often use an exponent value of 0.75 for clearance 
and 1 for volume of distribution, the corresponding first order rate constants will have an 
allometric exponent of -0.25 (Equation 2; Stevens et al., 2012).
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In this equation, BSL_MAP, BSL_HR, BSL_SV and BSL_TPR represent the bas line value  
of MAP, HR, SV and TPR, respectively. This means that the zero-order human production 
rate constants are intrinsically scaled. Furthermore, Schmidt-Nielsen described how the 
baseline values of MAP, HR and CO (BSL_CO) should be scaled, i.e BSL_MAP, BSL_HR and 
BSL_CO should be scaled with an allometric exponent of 0, -0.25 and 0.75, respectively 
(Schmit-Nielsen, 1995). Since MAP=CO*TPR and CO=HR*SV the allometric exponents for 
scaling BSL_SV and BSL_TPR follow directly from the allometric exponents for BSL_MAP, 
BSL_HR and BSL_CO and are 1 and -0.75, respectively. Concerning the extrapolation of the 
feedback parameter, FB was found to be dependent on BSL_MAP, which is this same in all 
species. Therefore, FB was assumed to be the same in all species too. 
To evaluate the hypothesis that the extended CVS model can be extrapolated to the 
human situation by applying allometric scaling principles to scale the first order rate con-
stants kout_HR, kout_SV and kout_TPR
 from rats to humans, ideally, the experiments, which were 
performed to characterize the extended CVS model in rats should be repeated in humans, 
i.e. the effects of eight drugs with diverse MoA’s (amiloride, amlodipine, atropine, enala-
pril, fasudil, hydrochlorothiazide, prazosin and propranolol) on MAP, HR and CO should be 
measured in humans. However, performing such a study in humans is outside the scope 
of this research. As for none of these compounds data on the time course of the effect 
on all three parameters, i.e. MAP, HR and CO, were published a literature search was 
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performed to obtain data on the time course of the effect of MAP, HR and/or CO following 
the administration of cardiovascular drugs. Francheteau et al. published data on the effect 
of nicardipine on MAP and CO following two types of nicardipine infusion (Francheteau 
et al., 1993); data were digitized using TechDig® version 2.0). Although no HR data was 
published on the time course of the effect of nicardipine on HR, these data were selected 
to evaluate if the extended CVS model can be extrapolated to human.
To scale the extended CVS model from rat to human the following assumptions were 
made (Scenario 1_CVS_model).
i. The dissipation rates can be allometrically scaled with an allometric exponent of -0.25. 
The body weights of rats and humans were assumed to be 0.3 and 72 kg, respectively. 
ii. In rats, feedback (FB) was found to decrease with the baseline MAP according to Equa-
tion 1. It was assumed that this is equation is applicable in humans too.
iii. The observed baselines can be used. These were slightly different from the allometri-
cally scaled baselines, which may be due to inter-individual variability.
iv. The drug specific parameters can be fixed to values from Francheteau et al. (Franche-
teau et al., 1993; Table 1). 
Following these assumptions the extent of the effects of nicardipine on CO and MAP were 
under-predicted (Figure 6, dashed lines). This could indicate that the feedback is slightly 
lower in man as compared to rats. In addition, the time course of the effects on MAP and 
CO was not captured as the observed time lag was much shorter than the predicted time 
lag indicating that men respond faster than rats. Several hypotheses can be postulated 
as to why the time course and the extent of the cardiovascular effects are not predicted 
adequately. First of all, the dissipation rates of HR, SV and TPR do not represent actual 
degradation rates as for proteins and enzymes. Instead they represent parameters for 
the delay in response at an organ level and represent several lumped processes as partly 
reflected by the Guyton model (Guyton et al., 1972). Another hypothesis is that the dif-
ferences between rats and humans may not be related solely to differences in size. The 
most obvious difference between rats and humans is that rats crawl, whereas men walk. 
This could influence both the delay in response and the feedback. To evaluate this last 
hypothesis, the extended CVS model was extrapolated from rats to humans according to 
the following assumptions (Scenario 2_CVS_model).
i. The dissipation rates should be multiplied with an unknown factor (this factor was 
estimated). 
ii. In rats, FB was found to decrease with the baseline MAP according to Equation 1. It 
was assumed that this is equation is applicable in humans.
iii. The observed baselines can be used. These were slightly different from the allometri-
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iv. The drug specific parameters can be fixed to values from Francheteau et al. (Franche-
teau et al., 1993; Table 1). 
Following these assumptions the time course and extent of the effect of nicardipine on 
CO was described adequately, whereas the time course and extent of the effect of nica-
rdipine on MAP were not captured (Figure 6, dotted lines). The multiplication factor was 
estimated to be 23.4 (Table 1). Although MAP is assumed to be a non-scalable parameter, 
albeit in the same order of magnitude, the observed BSL_MAP in humans (75 mmHg) is 
actually lower than in rats (102 mmHg). This means that, when applying Equation 1 to 
calculate FB, an extrapolation was made beyond the observed BSL_MAP range. Therefore, 
the second assumption to extrapolate the extended CVS model from rats to humans was 
changed (Scenario 3_CVS_model).
i. The dissipation rates should be multiplied with an unknown factor (this factor was 
estimated). 
ii. In rats, FB was found to decrease with the baseline MAP according to Equation 1. It 
was assumed that this is equation is not valid in subjects with a BSL_MAP lower than 
102 mmHg (BSL_MAP in normotensive rats). To test this hypothesis FB was estimated.
iii. The observed baselines can be used. These were slightly different from the allometri-
cally scaled baselines, which may be due to inter-individual variability.
iv. The drug specific parameters can be fixed to values from Francheteau et al. (Franche-
teau et al., 1993; Table 1).   
Following these assumptions the time course and extent of the effect of nicardipine on 
CO and MAP were described adequately (Figure 6, continuous lines). The estimated FB 
(0.00817 [CI: 0.00740-0.00894] 1/mmHg) (Table 1) was slightly lower than the calculated 
FB from Equation 1 (0.0122 [CI: 0.0108-0.0136] 1/mmHg). Notably, the estimated FB 
does not differ significantly from the value from normotensive rats (0.00664 [CI: 0.00586-
0.00742] 1/mmHg). This indicates that it is likely that FB does depend on BSL_MAP, but 
not according to a hyperbolic function as FB may reach a maximum. In addition, the 
multiplication factor was 46.7 indicating that the response in humans is very fast, i.e. the 
half-life’s of the effect on HR, SV and TPR are 0.00128, 0.118 and 0.00415 h, respectively. 
In conclusion, the extended CVS model can be extrapolated from rat to human, but the 
extrapolation is not solely depended on size and other factors, such as the fact that men 
are standing whereas rats are crawling, seem to play an important role. By multiplying the 
dissipation rates with a certain factor (a high value which results in a very short delay in 
response in humans), and estimating the feedback, the effect of nicardipine on MAP and 
CO could be described adequately. As the extrapolation of the extended CVS model was 
based on data from one compound (nicardipine) it is not certain if the obtained system 
parameters are drug-independent. Therefore, further research is required to obtain a 
truly system specific CVS model in humans. Ideally, a study should be performed were the 
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time course of the effect of different cardiovascular compounds with different MoA’s on 
MAP, HR and CO is measured.
Translation of the class/drug-specific target binding and activation model 
for S1P agonists
In a next step, it was investigated if the human CVS model, with the parameter estimates 
fixed, can be applied to the characterization and prediction of the cardiovascular effects of 
S1P agonists in humans (data on file). To this end, it is discussed how the rat target binding 
and activation model for fingolimod-P and siponimod may be scaled to man (Supplement). 
Figure 6: Observed (Francheteau et al., 1993) and predicted curves of the extended CVS model to mean plasma 
concentrations of nicardipine (○), cardiac output data (◊) and mean arterial pressure data (□) following two types 
of nicardipine infusion. 
Left panel: constant rate infusion; Right panel: variable rate infusion
Scenario 1_CVS_model: Dissipation rates were allometrically scaled with an allometric exponent of -0.25 (dashed 
lines)
Scenario 2_CVS_model: Dissipation rates are multiplied with an estimated factor of 23.4 (dotted lines)
Scenario 3_CVS_model: Dissipation rates are multiplied with an estimated factor of 46.7 and FB is estimated (con-
tinuous lines)
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General summary, discussion and applications
The objectives of the investigations described in this thesis were 1) to establish a systems 
pharmacology model to characterize the effects of drugs with different MoA’s on the 
interrelationship between MAP, CO, HR, SV and TPR in a quantitative manner and 2) to 
apply the model to the quantification of the cardiovascular effects of the S1P receptor 
modulator fingolimod. A systems pharmacology modeling approach was applied, which 
allows predicting hemodynamic changes in man on the basis of information from pre-
clinical studies. In this section, the development and translation of the system-specific 
CVS model is summarized and discussed first. Thereafter, the development of the target 
binding and activation model for S1P agonists is discussed. Finally, a strategy is presented 
to obtain a quantitative understanding of the in vitro to rat to human translation of the 
cardiovascular effects of S1P agonists. 
First, a system-specific CVS model was developed to characterize drug effects on the 
interrelationship between MAP, CO, HR, SV and TPR in rats. This model can be applied 
to quantify the hemodynamics of novel cardiovascular compounds. Moreover, it can be 
applied to elucidate the site of action of novel compounds. In a first step towards the de-
velopment of a translational system-specific CVS model, the parameters of the rat model 
were scaled to humans following an unconventional (not based on the allometric scaling 
principles), but physiologically plausible, scaling approach. The fact that parameters of 
the rat CVS model were not scaled according to the allometric scaling principles does not 
imply that cardiovascular effects cannot be scaled from rat to human. Instead, this implies 
that differences in cardiovascular responses between rats and humans do not solely de-
pended on size, but other factors are also of importance, such as the fact that humans are 
standing whereas rats are crawling and this should be accounted for. As the translation 
of the CVS model was based on data from one compound (nicardipine) it is not certain 
if the obtained system parameters are drug-independent. Therefore, further research is 
required to obtain a truly system specific and drug independent CVS model in man. Once 
the human CVS model has been validated, it can be applied to the characterization and 
prediction of cardiovascular effects of novel compounds in humans.
In a next step, the rat CVS model, with the system-specific parameter estimates fixed, was 
integrated with a target binding and activation model to quantify the cardiovascular effects 
S1P agonists in rats, using fingolimod-P as a paradigm compound. This model provided a 
quantitative understanding of the mechanisms underlying the cardiovascular effects of 
fingolimod-P. In addition, the effect of siponimod on the CVS was predicted adequately by 
multiplying the estimated in vivo dissociation constants of fingolimod-P for binding to the 
S1P receptors with the ratio of the potencies of fingolimod-P and siponimod derived from 
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in vitro binding assays. Therefore, it is anticipated that the developed model can be ap-
plied to predict the effect of other S1P receptor agonists on the CVS in rats. Subsequently, 
hypotheses were generated on the rat to human translation of the cardiovascular effects 
of S1P agonists. Overall, the human CVS model, integrated with the target binding and 
activation model for S1P agonists from rat, was successfully applied to characterize the 
magnitude and dynamics of the effect of fingolimod-P and siponimod on HR (data on file). 
However, this required several assumptions on the parameter values (Supplement). 
To date, no ‘gold’ standard approach exists for the inter-species translation of cardio-
vascular effects. In practice, the selected translational approach is often driven by the 
available data. Here, an approach is presented to obtain a mechanistic and quantitative 
understanding of the in vitro to rat to human translation of the cardiovascular effects of 
S1P agonists (Figure 7). First, a relationship between in vitro binding constants derived 
from saturation binding experiments using the rat S1P receptor and the apparent in vivo 
rat dissociation constants should be established. Possible differences between these 
parameters may result from processes that occur solely in vivo such as signal transduc-
tion. For fingolimod, it was demonstrated that valuable information on the mechanisms 
underlying its cardiovascular effects can be derived from rat experiments. More precisely, 
the model structure to characterize the interrelationship between the cardiovascular ef-
fects of S1P agonists can be derived from rat experiments and applied to the prediction of 
Figure 7: Schematic map for the translation of cardiovascular effects of S1P agonists.
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cardiovascular effects in humans (Supplement), indicating that the physiological processes 
are qualitatively comparable between rats and humans. Subsequently, relationships be-
tween the in vitro dissociation constant for rats and humans and between the in vitro and 
apparent in vivo dissociation constants in humans should be established. This requires 
information on 1) the effects of multiple S1P receptor agonists on MAP, HR and CO in rats 
and humans and on 2) the corresponding dissociation constants for binding to the rat and 
human S1P receptors. When these relationships are established, it is foreseen that the 
magnitude and hemodynamics of the cardiovascular effects of novel S1P agonists, i.e. S1P 
agonists that were not included in model development, can be predicted directly using 
parameters estimates obtained from in vitro experiments and no further experiments in 
rats are required. If the proposed approach results in an adequate translational model for 
the cardiovascular effects of S1P agonists, this would demonstrate that preclinical experi-
ments are predictive for clinical effects, but a quantitative understanding of the processes 
in the causal chain between drug administration and the change in response over time, 
including the pharmacokinetics of a drug, target site distribution and receptor binding 
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Algemene inleiding en doel van het onderzoek
Nieuwe geneesmiddelen hebben vaak cardiovasculaire bijwerkingen die gerelateerd zijn 
aan veranderingen in bloeddruk. Een voorbeeld van een geneesmiddel met ongewenste 
effecten op de bloedruk is finglimod, dat het onlangs geregistreerd is voor de behan-
deling van multiple sclerose (MS). Dit middel werkt op de zogenaamde sphingosine-1-
fosfaatreceptor (S1P) welke naast de gewenste verbetering van de MS symptomen ook 
voor een (kleine) verhoging van de bloeddruk en een (kortstondige) verlaging van de 
hartslag zorgt. Deze stof is in dit onderzoek als voorbeeld stof gebruikt om de ongewenste 
effecten op de bloeddruk te begrijpen. Dit proefschrift beschrijft de ontwikkeling van een 
systeemfarmacologiemodel dat gebruikt kan worden om de verandering in bloeddruk (en 
andere hemodynamische variabelen) in mensen te voorspellen, op basis van informatie 
verkregen uit preklinisch, reageerbuis (in vitro) en dierexperimenteel onderzoek. Dit 
model is gebaseerd op de algemeen bekende principes van de bloeddrukregulatie. Dat 
wil zeggen, het gemiddelde van de arteriële bloeddruk (‘mean arterial pressure (MAP)’) 
is gelijk aan het product van het hartminuutvolume (‘cardiac output (CO)’) en de perifere 
weerstand (‘total peripheral resistance (TPR)’). Vervolgens, is CO gelijk aan het product 
van de hartslag (‘heart rate (HR)’) en het slagvolume (‘stroke volume (SV)’). Hoewel deze 
relaties algemeen bekend zijn, zijn de effecten van geneesmiddelen op deze relaties nog 
niet op een mechanistische en kwantitatieve manier onderzocht. 
Het onderzoek is ook gebaseerd op de principes van farmacokinetisch-farmacodynamisch 
modeleren (‘pharmacokinetic-pharmacodyanmic (PKPD) modelling’). Bij PKPD modeleren 
wordt de relatie tussen de verandering in de geneesmiddelconcentratie (farmacokinetiek) 
en verandering in het geneesmiddeleffect (farmacodynamiek) over tijd gekwantificeerd. 
Mechanistische PKPD modellen karakteriseren, op een kwantitatieve manier, het causale 
verband tussen de toediening van het geneesmiddel en het uiteindelijke effect. Eén van 
de eigenschappen van een mechanistisch PKPD model is de strikte scheiding tussen de 
eigenschappen van het geneesmiddel en die van het biologische systeem. Stofspecifieke 
parameters beschrijven de interactie tussen het geneesmiddel en het biologische systeem 
met binding- en activeringconstanten, terwijl de systeemspecifieke parameters de dyna-
miek van het biologische systeem beschrijven. Dit onderscheid maakt het voorspellen 
van de geneesmiddeleffecten in andere biologische systemen mogelijk (bijvoorbeeld 
de voorspelling van geneesmiddeleffecten in mensen op basis van een mechanistisch 
model dat ontwikkeld is voor ratten). Recent is het concept van de systeemfarmacologie 
geïntroduceerd. Systeemfarmacologiemodellen zijn complexer dan mechanistische PKPD 
modellen, omdat deze zijn gebaseerd op de relaties tussen verschillende componenten 
van een biologisch/farmacologisch systeem of netwerk. Om deze redenen is een systeem-
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farmacologiemodel uitermate geschikt om de effecten van geneesmiddelen op de relatie 
tussen MAP, CO, HR, SV en TPR te kwantificeren (hoofdstuk 1)
De doelen van het onderzoek dat beschreven is in dit proefschrift waren 1) het ontwik-
kelen van een systeemfarmacologiemodel om de effecten van geneesmiddelen met 
verschillende werkingsmechanismen op de relatie tussen MAP, CO, HR, SV en TPR op een 
kwantitatieve manier te karakteriseren en 2) het kwantificeren van de cardiovasculaire 
effecten van de S1P modulator fingolimod met dit model.
Ontwikkeling van een systeemfarmacologiemodel om het 
cardiovasculaire systeem (CVS) te karakteriseren
In hoofdstuk 3 is een systeemfarmacologiemodel ontwikkeld om geneesmiddeleffecten 
op het CVS te karakteriseren in spontaan hypertensieve ratten (SHR). Dit model is geba-
seerd op de wisselwerking tussen MAP, CO en TPR en wordt hier het ‘Basic CVS model’ 
genoemd. De effecten van een groep geneesmiddelen die op verschillende manieren de 
bloeddruk veranderen werden gekarakteriseerd in SHR‘s. Deze ratten waren langdurig ge-
instrumenteerd met sondes die de stroming van het bloed in de aortawortel (CO), HR en 
MAP continue registreren. De veronderstelling was dat twee aspecten van de studieopzet 
essentieel zijn om de parameters van het ‘Basic CVS model’ succesvol te karakteriseren: 
i) de selectie van de groep van geneesmiddelen met een werking op het cardiovasculaire 
systeem en ii) de continue meting van de waarden van zowel MAP als CO, voor, tijdens en 
na toedienen van het geneesmiddel. Door het selecteren van een aantal cardiovasculaire 
geneesmiddelen met bekende, maar verschillende werkingsmechanismes, was het mo-
gelijk alle systeemspecifieke parameters van het ‘Basic CVS model’ met goede precisie te 
schatten. Bovendien kon er een onderscheid gemaakt worden tussen systeemspecifieke 
en stofspecifieke parameters. Dit geeft aan dat het model inderdaad stofonafhankelijk 
is. Het model kan daarom, in principe, ook toegepast worden om de cardiovasculaire 
effecten van nieuwe stoffen (geneesmiddelen die niet voor dit onderzoek gebruikt zijn) 
te voorspellen. Het meten van CO was essentieel om alle parameters van het ‘Basic CVS 
model’ te kunnen identificeren, omdat dit resulteerde in de informatie die nodig is om een 
onderscheid te kunnen maken tussen hemodynamische veranderingen in CO en TPR. De 
conclusie was dat de onderzoeksopzet heeft geresulteerd in de data om the wisselwerking 
tussen MAP, CO en TPR op een kwantitatieve en mechanistisch manier te identificeren. 
Het model kan worden toegepast om het werkingsmechanisme (het aangrijpingspunt) 
van nieuwe geneesmiddelen die de bloedruk veranderen te identificeren.
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Een beperking van dit model is dat in de praktijk CO niet vaak gemeten wordt vanwege 
het complexe en invasieve karakter van de bijbehorende procedure. Om deze reden, is 
het ‘Basic CVS model’ uitgebreid door CO te splitsen in HR en SV (hoofdstuk 4; ‘Extended 
CVS model’) met als doel 1) het karakteriseren van de werking van geneesmiddelen op 
de relatie tussen HR en MAP, welke beide belangrijke variabelen zijn voor de veiligheid 
van nieuwe geneesmiddelen, en 2) te onderzoeken of het werkingsmechanisme en het 
aangrijpingspunt van nieuwe geneesmiddelen vastgesteld kan worden op basis van alleen 
HR en MAP metingen. 
Het gedrag van het ‘Extended CVS model’ is geëvalueerd door de verandering in MAP, 
CO, HR, SV en TPR te simuleren na het inhiberen van HR, SV of TPR met een fictief 
(hypothetisch) geneesmiddel. De karakteristieke profielen van het tijdsverloop van het 
geneesmiddeleffect op MA, CO, HR, SV en TPR worden ook wel ‘signature profiles’ ge-
noemd. Er waren duidelijke verschillen zichtbaar na het inhiberen van HR, SV of TPR. 
Hieruit kan geconcludeerd worden dat, zelfs als CO niet wordt gemeten, het waarschijnlijk 
is dat ‘Extended CVS model’ gebruikt kan worden om het aangrijpingspunt van nieuwe 
geneesmiddelen te identificeren. De volgende wetmatigheden werden waargenomen bij 
de ontwikkeling van het model: i) Als de richting van het geneesmiddeleffect op HR en 
MAP hetzelfde is (een verhoging van HR en MAP of een daling van HR en MAP) is het 
waarschijnlijk dat het geneesmiddel primair HR beïnvloedt. ii) Als de richting van genees-
middeleffect op HR en MAP tegengesteld is (een verhoging van HR en een daling in MAP 
of vice versa) is het waarschijnlijk dat het geneesmiddel een primair effect op SV of TPR 
heeft. Vervolgens kan er een onderscheid gemaakt worden tussen een primair effect op 
SV of TPR, op basis van de vertraging tussen het moment toedienen van het geneesmiddel 
en het optreden van het effect op MAP. Een grotere vertraging duidt op een primair effect 
op SV en een kleine vertraging duidt op een primair effect op TPR. Zowel MAP als HR zijn 
belangrijke variabelen in het onderzoek naar veiligheid van nieuwe geneesmiddelen. 
Ondanks het feit dat in de praktijk vaak de verandering in MAP en HR simultaan gemeten 
wordt, worden er in het algemeen in het geneesmiddelonderzoek twee onafhankelijke re-
laties tussen de blootstelling aan het geneesmiddel en het effect op MAP en HR bepaald. 
Op deze manier wordt er geen rekening gehouden met de relatie tussen MAP en HR. Het 
‘Extended CVS model’ heeft daarom als bijkomend voordeel dat geneesmiddeleffecten op 
MAP en HR simultaan geanalyseerd kunnen worden. Dit resulteert in één set van para-
meters en daarmee één schatting van de dosering/concentratie die nodig is om 50% van 
het maximale effect (‘EC50’) te bereiken. Hierdoor kunnen eenduidige conclusies over de 
cardiovasculaire effecten van nieuwe geneesmiddelen getrokken worden en dit komt de 
selectie van nieuwe geneesmiddelen ten goede. 
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Het ‘Basic CVS model’ is verder uitgebreid door de de invloed van verschillen in bloed-
drukregulatie tussen normotensieve en hypertensieve ratten te kwantificeren. Omdat er 
duidelijke verschillen in bloeddrukregulatie zijn tussen normotensieve en hypertensieve 
ratten, kan de grootte van het geneesmiddeleffect op de verschillende hemodynamische 
eindpunten sterk variëren tussen verschillende rat stammen. Om deze reden zijn de 
uitkomsten die zijn verkregen met het ‘Basic CVS model’ niet direct toepasbaar op normo-
tensieve ratten. Dit is een nadeel, omdat de veiligheid van nieuwe geneesmiddelen initi-
eel vaak in normotensieve ratten onderzocht wordt. Om het systeemfarmacologie model 
uiteindelijk te kunnen toepassen om de cardiovasculaire effecten van nieuwe geneesmid-
delen in gezonde vrijwilligers en in patiënten met hoge bloeddruk te voorspellen, is het 
essentieel dat het model voor zowel normotensieve als hypertensieve ratten toepasbaar 
is. In vergelijking met normotensieve ratten hebben hypertensieve ratten een hogere 
uitgangswaarde voor MAP en lagere uitgangswaarde voor CO, terwijl de uitgangswaarde 
voor HR niet significant verschillend is. Uit de hemodynamische wetten (MAP=COxTPR en 
CO=HRxSV) volgt dan dat hypertensieve ratten een lagere uitgangswaarde voor SV en een 
hogere uitgangswaarde voor TPR hebben dan normotensieve ratten. Bovendien is er op 
individueel niveau een relatie vastgesteld tussen de sterkte van bloeddrukregulatie (‘feed-
back’) en de uitgangswaarde van MAP wat resulteert in een 2-keer sterkere feedback 
van MAP (bloeddrukregulatie) in een typische normotensieve rat in vergelijking met een 
typische hypertensieve rat. Dit duidt op verminderde bloeddrukregulatie in hypertensieve 
ratten. 
Toepassing van het systeemfarmacologiemodel op S1P receptor 
agonisten
Fingolimod is een S1P receptor agonist die wordt gebruikt in de behandeling van multiple 
sclerose. In mensen wordt het gebruik van S1P receptor agonisten geassocieerd met 
cardiovasculaire bijwerkingen. Er kan een kortstondige verlaging van hartslag (gemiddeld 
8 bpm, 6 uur na de eerste toediening) en een kleine verhoging van MAP (gemiddeld 1-2 
mmHg na 2 maanden) optreden na toediening van een therapeutische dosering van 0.5 
mg fingolimod. Bovendien zijn er bij hogere doseringen van 1.25 en 5 mg gemiddelde 
verlagingen in HR van respectievelijk 13.8 en 16.6 bpm waargenomen, waarbij het mini-
mum 6 uur na de eerste toediening bereikt werd. Na langdurige toediening verdween het 
effect en keerde HR terug naar de uitgangswaarde. Bij de hogere doseringen werd een 
milde verhoging in MAP waargenomen van ongeveer 5-6 mmHg. Zowel het immunosup-
pressieve effect, als de cardiovasculaire effecten, van deze stoffen worden veroorzaakt 
door binding aan de S1P receptor. Dit bemoeilijkt de zoektocht naar nieuwe S1P receptor 
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agonisten welke effectief zijn in de behandeling van multiple sclerose, maar geen cardio-
vasculaire bijwerkingen hebben. Een kwantitatief begrip van de hemodynamica van deze 
effecten zou de basis kunnen vormen voor de selectie van nieuwe geneesmiddelen met 
een verbeterd bijwerkingenprofiel. Bovendien zou dit inzicht geven in de mogelijkheden 
om deze effecten voor bestaande en nieuwe S1P agonisten te voorkomen of te vermin-
deren door gelijktijdige toediening van andere geneesmiddelen met een tegengesteld 
effect of door het ontwikkelen van titratieschema’s, waarbij de dosering langzaam wordt 
verhoogd om het lichaam de tijd te geven de (geringe) verandering in de bloeddruk te 
compenseren voordat de volgende, hogere, dosering wordt gegeven. Het ‘Extended CVS 
model’ kan gebruikt worden om een kwantitatief begrip van deze effecten te verkrijgen, 
omdat de modelstructuur en de bijbehorende parameterschattingen onafhankelijk zijn 
van de geneesmiddelen die gebruikt zijn om het model te ontwikkelen. Daarom kan het 
model in principe ook voor nieuwe geneesmiddelen gebruikt worden en zodoende ook 
voor fingolimod. Het effect van fingolimod wordt bewerkstelligd door binding aan de S1P 
receptor. In het algemeen, wordt receptorbinding gekarakteriseerd door de evenwichts-
constante (dissociatieconstante), welke de concentratie weergeeft waarbij 50% van de 
receptoren bezet is. Dissociatieconstanten kunnen met in vitro experimenten bepaald 
worden. Door het ‘Extended CVS model’ met een receptorbinding- en activatiemodel te 
integreren kan het model niet alleen voor fingolimod, maar ook voor nieuwe S1P ago-
nisten gebruikt worden (door de dissociatieconstante van fingolimod te vervangen door 
de dissociatieconstante van de nieuwe S1P agonist). Bovendien kan het model hierdoor 
gebruikt worden om de cardiovasculaire effecten van fingolimod en nieuwe S1P agonisten 
in mensen te voorspellen. 
De translatie van de farmacologie van fingolimod en andere S1P agonisten van ratten naar 
mensen wordt bemoeilijkt door het feit dat niet de stof zelf, maar de fosfaatmetabolieten, 
welke gevormd worden door afbraak (metabolisme) van het geneesmiddel, farmacolo-
gisch actief zijn. De eerste stap in de ontwikkeling van een translationeel model voor 
S1P agonisten was het karakteriseren van de PK van fingolimod en de actieve metaboliet 
fingolimod-fosfaat (‘fingolimod-phosphate (fingolimod-P)’) in ratten en mensen. Omdat er 
tussen ratten en mensen grote verschillen bestaan in weefseldistributie en activiteit van 
het enzym sphingosine kinase (S1PHK) dat de omzetting van fingolimod in fingolimod-P 
katalyseert, kan de PK van fingolimod-P in mensen niet eenvoudig voorspeld worden met 
behulp van schaling op basis van het verschil in het gewicht tussen ratten en mensen 
(allometrische schaling). In hoofdstuk 5 is daarom een semi-mechanistisch PK model ont-
wikkeld voor de inter-conversie van S1PHK substraten en de gevormde fosfaten in ratten 
en mensen. Een specifiek doel was het onderzoeken of de snelheid van de fosforylering 
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in de bloedplaatjes (welke ex vivo bepaald kan worden) een voorspellende waarde heeft 
voor de verschillen in farmacokinetiek tussen ratten en mensen. 
In deze studies is het tijdsverloop van de fingolimod en fingolimod-P bloedconcentraties 
in ratten, na intraveneuze en orale toediening, simultaan geanalyseerd met gegevens 
over de snelheid van de inter-conversie in ex vivo experimenten en ex vivo gegevens over 
de verdeling tussen bloed en plasma. Daarnaast zijn data van twee studies in gezonde 
vrijwilligers, die oraal fingolimod kregen in dosering van 0.5, 1.25 en 5 mg, simultaan 
geanalyseerd met data van ex vivo inter-conversie en bloed-plasma verdelings experimen-
ten in humaan bloed. De farmacokinetiek van fingolimod en fingolimod-P in de rat en 
in de mens kon goed worden beschreven met een semi-mechanistisch PK model met 1) 
een term (parameter) voor de pre-systemische fosforylering van fingolimod tijdens de 
eerste leverpassage, 2) een parameter voor de fosforylering in de bloedplaatjes en 3) een 
parameter voor de deforsforylering in het plasma. Het integreren van ex vivo en in vivo 
data maakt de voorspelling van het de fingolimod en fingolimod-P concentraties in zowel 
plasma als bloed (in plaats van alleen in bloed) mogelijk. Dit is belangrijk omdat volgens 
de ‘free drug hypothesis’ geneesmiddeleffecten gedreven worden door vrije plasmacon-
centraties. Bovendien heeft het integreren van data van ex vivo en in vivo experimenten 
het mogelijk gemaakt verschillen in de fosforyleringssnelheid te kwantificeren. In mensen 
wordt fingolimod in bloedplaatjes vier keer langzamer gefosforyleerd dan in ratten, terwijl 
de defosforyleringsnelheid vergelijkbaar is tussen ratten en mensen.
Er kan geconcludeerd worden dat er grote verschillen bestaan in de fosforyleringssnelheid 
van fingolimod tussen ratten en mensen welke niet verklaard kunnen worden met allome-
trische schaling. Hoewel het verschil in fosforylering in de bloedplaatjes de twaalfvoudige 
overschatting van de fingolimod-P blootstelling in mensen slechts gedeeltelijk verklaart, 
vormt het ontwikkelde PK model een basis voor het voorspellen van het verloop van de 
plasmaconcentraties van S1PHK substraten en de bijbehorend fosfaatmetabolieten. Ver-
schillen in de pre-systemische fosforylering moeten daarbij worden meegenomen.
In hoofdstuk 6, zijn de cardiovasculaire effecten van fingolimod in normotensieve en 
hypertensieve ratten gekarakteriseerd op basis van het ‘Extended CVS model’ in combi-
natie met het semimechanistische farmacokinetische model voor fingolimod. De eerste 
stap, in deze analyse, was de evaluatie van verschillende hypotheses over het werkings-
mechanisme van fingolimod. Daartoe werden simulaties uitgevoerd, zonder daarbij de 
systeemspecifieke parameters van het ‘Extended CVS model’ te veranderen.
201
7
1) Er werden verschillende hypotheses geformuleerd met betrekking tot het aangrijpings-
punt (HR, SV of TPR) en de richting van het effect (positief of negatief). Dit resulteerde 
in 6 mogelijke combinaties van effecten.
2) Voor elke hypothese werden simulaties uitgevoerd voor de effecten op de MAP, CO, 
HR, SV en TPR.
3) Er werd geëvalueerd welke hypothese resulteerde in beste beschrijving van de experi-
mentele data.
De conclusie was dat het effect van fingolimod-P op het CVS alleen beschreven kon 
worden als fingolimod-P op meerdere plaatsen het CVS beïnvloedt. Uiteindelijk zijn er 
3 verschillende effecten geïdentificeerd: 1) een snel optredend positief effect op TPR, 2) 
een langzaam optredend (en blijvend) positief effect op TPR en 3) een kortstondig (en van 
tijdelijke aard) negatief effect op HR. In deze eerste stap werden empirische modellen 
gebruikt om het effect van fingolimod-P te beschrijven. Met deze modellen kon de meest 
waarschijnlijke werkingsplaats geïdentificeerd worden. Bovendien werd aangetoond dat 
het ‘Extended CVS model’ toegepast kan worden om de hemodynamische veranderingen 
in vijf verschillende parameters (MAP, CO, HR, SV en TPR) te beschrijven, onder de aan-
name dat fingolimod-P het CVS op twee plaatsen beïnvloedt. Vervolgens werd de op deze 
manier verkregen informatie over het werkingsmechanisme van fingolimod-P vergeleken 
met informatie uit de literatuur. De volgende samengevatte informatie over het werkings-
mechanisme van fingolimod-P was beschikbaar ten tijde van de analyse.
i. Fingolimod-P beïnvloedt HR via binding aan de S1P1 receptor. Hierdoor wordt het 
kaliumkanaal IKACH geactiveerd wat resulteert in een negatief chronotroop effect.
ii. Fingolimod-P induceert internalisatie en degradatie van de S1P1 receptor, waardoor 
deze niet meer functioneel is. Hierdoor gedraagt fingolimod-P zich als een functionele 
antagonist (een geneesmiddel dat de werking van een lichaamseigen stof opheft).
iii. Fingolimod-P bindt aan de S1P3 receptor en heeft hierdoor een effect op TPR.
iv. Samentrekken van het gladde spierweefsel in de bloedvaten wordt geïnduceerd door 
een verhoging van de intracellulaire calciumconcentratie. De calciumafhankelijke fase 
van samentrekken van het gladde spierweefsel verloopt snel en is van korte duur, 
maar calcium sensitisatie als resultaat van stimulatie door een agonist is van blijvende 
aard en resulteert in een blijvende verhoging van TPR
Deze informatie komt overeen met het op basis van het model geïdentificeerde werkings-
mechanisme van fingolimod-P. In een volgende stap werd daarom het empirische model 
voor het effect van het geneesmiddel vervangen door een model dat is gebaseerd op 
de receptortheorie. In dit model wordt onderscheid gemaakt tussen receptorbinding en 
activatie processen. Hierdoor heeft het model een grotere voorspellende waarde voor het 
effect van fingolimod-P in mensen en voor het effect van andere S1P agonisten in ratten 
en mensen. Omdat fingolimod-P een agonist voor de S1P receptor is, is het van belang om 
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rekening te houden met de competitieve interactie tussen de endogene agonist, S1P, en 
fingolimod-P voor zowel het effect op HR als het effect of TPR. Het ontwikkelde model be-
stond uit vergelijkingen voor de beschrijving van 1) de kinetiek van competitieve binding 
aan de S1P1 receptor (snel effect op HR), 2) de snelheid van S1P1 receptor internalisatie 
en degradatie (kortstondig effect op HR), 3) de competitieve binding aan de S1P3 receptor 
(snel effect op TPR) en 4) de sensibilisatie van de S1P3 receptor (langzaam en blijvend 
effect op TPR).
Door het karakteriseren van de effecten op HR en TPR kon de door fingolimod-P geïndu-
ceerde verandering in MAP, CO, HR, SV en TPR in normotensieve en hypertensieve ratten 
goed beschreven worden. De dissociatieconstanten voor de effecten op TPR (KdTPR) en 
HR (KdHR) werden geschat op respectievelijk 17.7 [betrouwbaarheidsinterval (‘confidence 
interval (CI)’): 3.74 – 31.6] en 132 [CI: 68.9 – 195] nM op basis van de vrije plasmacon-
centratie. De KdTPR is in dezelfde orde van grootte als de in de literatuur gerapporteerde in 
vitro dissociatieconstanten voor binding van fingolimod-P aan de humane S1P3 receptor 
van 3.15 ± 1.7 nM. Echter, de geschatte waarde voor KdHR is ongeveer 1000 keer groter dan 
de in de literatuur gerapporteerde waarde van 0.17 ± 0.14 nM. Hierbij is het belangrijk om 
op te merken dat de S1P1 receptor in vivo geïnternaliseerd en gedegradeerd wordt. Dit kan 
de schatting van dissociatieconstanten beïnvloeden. Bovendien refereren de waardes uit 
de literatuur naar experimenten met de humane S1P1 en S1P3 receptoren en zijn er geen 
dissociatieconstanten voor ratten gerapporteerd. Dit is belangrijk omdat er bekend is dat 
er grote verschillen in receptorbinding tussen ratten en mensen kunnen bestaan. Dit is 
een complicerende factor in de interpretatie van het eerder genoemde duizendvoudig 
verschil tussen de geschatte in vivo KdHR en de gerapporteerde in vitro KdHR. 
Omdat het ontwikkelde model gebaseerd is op concepten uit de receptortheorie kon het 
model gebruikt worden om het effect van siponimod (een nieuwe S1P receptor agonist 
met een ander selectiviteitprofiel) op CVS te voorspellen. Hiertoe werden de voor fingoli-
mod-P geschatte dissociatieconstanten gecorrigeerd voor het moleculairgewicht, de vrije 
fractie en de ratio van de EC50’s uit in vitro bindingsexperimenten. Dit resulteerde in een 
goede voorspelling van het effect van siponimod op MAP en HR in ratten. Dit impliceert 
dat het model in principe gebruikt kan worden om het effect van andere S1P agonisten op 
het CVS in ratten te voorspellen. 
Prospect 
Een uiteindelijke toepassing van het ontwikkelde systeemfarmacologiemodel is het voor-
spellen van de effecten van nieuwe geneesmiddelen, en specifiek S1P agonisten, op het 
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cardiovasculaire systeem in mensen op basis informatie uit preklinische experimenten. In 
de hoofdstuk 7 werd besproken welke stappen hiervoor nodig zijn en welke aannames 
hiervoor gedaan moeten worden. 
Het is de verwachting dat het ‘Extended CVS model’ van ratten naar mensen geëxtrapoleerd 
kan worden, maar deze extrapolatie zal niet alleen gebaseerd zijn op lichaamsgrootte en 
andere factoren. Deze verwachting is gebaseerd op de voorspelling de cardiovasculaire 
effecten van nicardipine (een calciumantagonist) als modelstof. Na het vermenigvuldigen 
van de dissipatiesnelheden (‘kout’) met een bepaalde factor (een hoge waarde wat resul-
teert in een erg kleine vertraging in respons in mensen) en het schatten van de ‘feedback’ 
kon het effect van nicardipine op MAP en CO goed voorspeld worden. Deze extrapolatie 
is gebaseerd op data van slechts één voorbeeld stof, met een werkingsmechanisme dat 
identiek is aan dat van een de stoffen in de trainingset (amlodipine). Daarom is het niet 
zeker of de verkregen systeemparameters stofonafhankelijk zijn. Verder onderzoek is 
nodig om het effect van verschillende cardiovasculaire geneesmiddelen met verschillende 
werkingsmechanismes op MAP, CO en HR te voorspellen.
Als laatste werd onderzocht of het humane CVS model (dat ontwikkeld is voor nicardipine) 
gebruikt kan worden om het effect van S1P agonisten te karakteriseren en te voorspellen. 
In het supplement van dit proefschrift is beschreven welke stappen en aannames hiervoor 
nodig zijn.
Conclusies
Het onderzoek beschreven in dit proefschrift heeft geleid tot een systeemspecifiek model 
dat gebruikt kan worden om de effecten van nieuwe geneesmiddelen (die niet gebruikt 
zijn om het model te ontwikkelen) op de relatie tussen MAP, CO, HR, SV en TPR te kwan-
tificeren. Bovendien kan dit model gebruikt worden om het aangrijpingspunt van nieuwe 
geneesmiddelen te identificeren op basis van alleen MAP en HR metingen. Een ultieme 
toepassing van het ‘Extended CVS model’ is de voorspelling van cardiovasculaire effecten 
in mensen op basis van informatie uit preklinische experimenten. Voordat het ontwik-
kelde model hiervoor gebruikt kan worden, moeten de systeemspecifieke parameters 
naar mensen geschaald worden en moet het model gevalideerd worden met behulp dat 
MAP, HR en CO metingen na toediening van verschillende stoffen met een werking op het 
cardiovasculaire systeem.
Daarnaast heeft het onderzoek geleid tot een systeemfarmacologiemodel dat gebruikt 
kan worden om de cardiovasculaire effecten van fingolimod-P en andere S1P agonisten in 
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ratten te kwantificeren en voorspellen. Dit systeemfarmacologiemodel is een combinatie 
van het ‘Extended CVS model’ en receptorbinding en activatie modellen om het effect van 
fingolimod-P (en andere S1P agonisten) op HR en TPR te kwantificeren. Het ontwikkelde 
model geeft een kwantitatief begrip van het werkingsmechanisme onderliggend aan de 
cardiovasculaire effecten van fingolimod-P. Bovendien kon het model gebruikt worden 
om de cardiovasculaire effecten van een nieuwe stof, siponimod te voorspellen. Hiertoe 
werden de voor fingolimod-P geschatte dissociatieconstanten gecorrigeerd voor het mo-
leculairgewicht, de vrije fractie en de ratio van de EC50’s uit in vitro bindingsexperimenten. 
Op grond hiervan kan worden geconcludeerd dat het model gebruikt kan worden om het 
effect van andere S1P agonisten op het CVS in ratten te voorspellen. De verwachting is 
dat dit model ook gebruikt kan worden om de cardiovasculaire effecten van fingolimod-P 
en andere S1P agonisten in mensen te voorspellen. De aannames, beschreven in het sup-




De afgelopen zes jaar heb ik, naast mijn werk bij LAP&P, met veel plezier aan mijn promo-
tieonderzoek gewerkt. Klaar! Natuurlijk heb ik dit niet alleen gedaan en zijn er een aantal 
mensen die, een bijdrage hebben geleverd aan het tot stand komen van dit proefschrift. 
Ik zou het kort kunnen houden: “Iedereen bedankt!”, maar dat zou geen recht doen aan 
alle hulp en steun, die ik heb gekregen.
Allereerst, wil ik het “Leiden-Novartis Collaboration Team” bedanken. Ik heb het geluk 
gehad om met dit kundige team te mogen werken. In het bijzonder, wil ik Bart, Meindert, 
Don, Olivier, Dean en Randy noemen. Bart, jij hebt mij, eerst vanuit Leiden en later vanuit 
verschillende andere Europese steden, uitgedaagd om steeds één, twee of drie stappen 
verder te gaan en mijn werk naar een hoger niveau te tillen. Bedankt voor alle interes-
sante discussies en de prettige samenwerking. Meindert and Don, you were great tutors 
in many aspects and taught me how to present my work in a scientifically correct, but 
perhaps more important, in an understandable and attractive way. Olivier, thank you very 
much for all your support from within Novartis during this project. There were many chal-
lenges and you helped me to manage them. Dean and Randy, thank you very much for 
providing me with your extreme high quality data and giving me the opportunity to help 
designing the experiments. 
Daarnaast bedank ik al mijn collega’s bij LAP&P voor jullie oprechte interesse in mijn 
onderzoek. In het bijzonder wil ik Henk-Jan bedanken voor de tijd en ruimte die ik heb 
gekregen om aan mijn promotie te kunnen werken en Diana voor haar bijdrage aan het 
datamanagement. Via LAP&P heb ik ook met Bert Peletier mogen werken. Bert, bedankt 
voor onze discussies over de wiskundige aspecten van mijn modellen. Dit heeft zeker 
nieuwe inzichten opgeleverd.
De keuze voor mijn paranimfen was snel gemaakt. Tamara, mijn kamergenoot, we heb-
ben talloze inhoudelijk discussies gehad ….. over agonisten, antagonisten, potencies, 
dissociatieconstanten, in vitro  experimenten etc. etc., maar ook vele discussies over de 
randfactoren van promoveren ..… Bedankt voor je hulp en steun op heel veel verschil-
lende gebieden. Sanne, inmiddels geroutineerd paranimf. Met jou als paranimf weet ik 
zeker dat mijn promotie een feestje wordt. 
Mama, het is nu echt zover. Maaike, jij hebt het voorgedaan. Papa, Sanne en G, mijn 
cardiovasculaire gewetens. En last, but not least, Martin, jij bent er altijd voor mij en hebt 
ervoor gezorgd dat ik niet mijn promotieonderzoek was ….. samen uit eten, samen op 
vakantie en samen heel veel andere leuke dingen doen. Nog even volhouden en je mag 
206
 






Snelder n, Ploeger BA, Luttringer O, Rigel DF, Webb 
RL, Feldman D, Fu F, Beil 
M, Jin L, Stanski DR, Danhof M. Characterization and 
prediction of cardiovascular effects of fingolimod and 
siponimod using a systems pharmacology modeling 
approach. Submitted
Snelder n, Ploeger BA, Luttringer O, Rigel DF, Fu F, 
Beil M, Stanski D, Danhof M. PKPD modeling of drug 
effects on the cardiovascular system in conscious rats 
– parsing cardiac output into heart rate and stroke 
volume. Submitted
Snelder n, Ploeger BA, Luttringer O, Stanski D, 
Danhof M. Translational pharmacokinetic modeling of 
fingolimod (FTY720) as a paradigm compound subject 
to sphingosine kinase-mediated phosphorylation. 
Submitted
van Rijn-Bikker PC, Snelder n, Ackaert O, van Hest 
RM, Ploeger BA, van Montfrans GA, Koopmans RP, 
Mathôt RA. Nonlinear mixed effects modeling of the 
diurnal blood pressure profile in a multiracial popula-
tion. Am J Hypertens. 2013 Sep;26(9): 1103-1113.
Snelder n, Ploeger BA, Luttringer O, Rigel DF, Webb 
RL, Feldman D, Fu F, Beil M, Jin L, Stanski DR, Danhof 
M. PKPD modelling of the interrelationship between 
mean arterial BP, cardiac output and total peripheral 
resistance in conscious rats. Br J Pharmacol. 2013 
Aug;169(7):1510-1524. 
van Rijn-Bikker PC, Ackaert O, Snelder n, van 
Hest RM, Ploeger BA, Koopmans RP, Mathôt RA. 
Pharmacokinetic-pharmacodynamic modeling of the 
antihypertensive effect of eprosartan in Black and 
White hypertensive patients. Clin Pharmacokinet. 
2013 Sep;52(9):793-803. 
Reif S, Snelder n, Blode H. Characterisation of 
the pharmacokinetics of ethinylestradiol and 
drospirenone in extended-cycle regimens: population 
pharmacokinetic analysis from a randomised Phase 
III study. J Fam Plann Reprod Health Care. 2013 Apr; 
39(2):e1
Benson N, Snelder n, Ploeger B, Napier C, Sale H, 
Birdsall NJ, Butt RP, van der Graaf PH. Estimation 
of binding rate constants using a simultaneous 
mixed-effects method: application to monoamine 
transporter reuptake inhibitor reboxetine. Br J 
Pharmacol. 2010 May; 160(2):389-398. 
Maas HJ, Snelder n, Danhof M, Della Pasqua O. 
Prediction of attack frequency in migraine treatment. 




Nelleke Snelder werd op 28 augustus 1980 geboren te Rotterdam. Na het behalen van 
het diploma VWO in 1998 aan het Caland Lyceum te Rotterdam begon zij in datzelfde jaar 
aan de studie Technische Wiskunde aan de Technische Universiteit Delft. In 1999 maakte 
zij de overstap naar de studie Life Science & Technology aan de Universiteit Leiden en 
Technische Universiteit Delft. In de master fase heeft ze haar hoofdstage gedaan bij de 
afdeling Farmacologie van de Universiteit Leiden onder begeleiding van Dr. H. Maas en Dr. 
O. E. Della Pasqua. In 2004 behaalde zij haar Master en startte zij als consultant bij LAP&P 
Consultants BV in Leiden. Naast het consultancy werk, begon zij haar promotieonder-
zoek in 2008 onder begeleiding van Prof. Dr. M. Danhof (promotor) en Dr. B.A. Ploeger 
(co-promotor). In 2013 werd zij uitgenodigd om haar werk te presenteren in de Lewis 
Sheiner Student Session van het PAGE congres in Glasgow. In 2014  werd zij uitgenodigd 
haar werk te presenteren op het 7th Noordwijkerhout Symposium on Pharmacokinetics, 
Pharmacodynamics and Systems Pharmacology.  Op dit moment is zij werkzaam als senior 
consultant bij LAP&P Consultants BV in Leiden.


